UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, ~~2022~~2023

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____________ to _____________

Qualigen Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-37428

26-3474527

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

2042 Corte Del Nogal, Carlsbad, California 92011

(Address of principal executive offices) (Zip Code)

(760) 918-9165

(Registrant’s telephone number, including area code)

n/a

(Former name or former address, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol		Name of each exchange on which registered
Common Stock, par value $.001 per share		QLGN		The Nasdaq Capital Market of The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes ☐ No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☒ Yes ☐ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes ☒ No

As of August ~~15, 2022,~~10, 2023, there were ~~38,795,541~~5,052,463 shares of the registrant’s common stock, par value $0.001 per share, outstanding.

TABLE OF CONTENTS

		Page
PART I.	Financial Information	3

Item 1.	Condensed Consolidated Financial Statements (Unaudited)	3
	Condensed Consolidated Balance Sheets as of June 30, ~~2022~~2023 and December 31, ~~2021~~2022	3
	Condensed Consolidated Statements of Operations and Other Comprehensive Loss for the Three and Six Months Ended June 30, ~~2022~~2023 and ~~2021~~2022	4
	Condensed Consolidated Statements of Changes in Stockholders’ Equity for the Three and Six Months Ended June 30, ~~2022~~2023 and ~~2021~~2022	5
	Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, ~~2022~~2023 and ~~2021~~2022	6
	Notes to Condensed Consolidated Financial Statements	7

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	2932
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	4043
Item 4.	Controls and Procedures	4043

PART II.	Other Information	4245

Item 1.	Legal Proceedings	4245
Item 1A.	Risk Factors	4245
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	4346
Item 3.	Defaults Upon Senior Securities	4346
Item 4.	Mine Safety Disclosures	4346
Item 5.	Other Information	4346
Item 6.	Exhibits	4447

ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

QUALIGEN THERAPEUTICS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

	June 30,			December 31,
	2022			2021			June 30, 2023			December 31, 2022
ASSETS
Current assets
Cash	$	9,746,257		$	17,538,272		$	1,341,659		$	7,034,434
Accounts receivable, net		719,883			822,351			679,380			538,587
Inventory, net		1,310,213			1,055,878			1,563,399			1,586,297
Prepaid expenses and other current assets		1,928,383			1,379,896			1,278,077			1,661,220
Total current assets		13,704,736			20,796,397			4,862,515			10,820,538
Restricted cash		5,719			—			5,434			5,690
Right-of-use assets		1,535,764			1,645,568			1,305,970			1,422,538
Property and equipment, net		329,630			204,216			498,647			345,087
Intangible assets, net		5,858,446			171,190			5,833,070			5,845,702
Goodwill		4,896,223			—			625,602			625,602
Other assets		18,333			18,334			18,334			18,334
Total Assets	$	26,348,851		$	22,835,705		$	13,149,572		$	19,083,491

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities
Accounts payable	$	918,327		$	886,224		$	1,756,183		$	857,311
Accrued vacation								332,617			467,948
Accrued expenses and other current liabilities		1,414,535			1,793,901			1,980,555			1,511,856
R&D grant liability		1,098,733			—			151,620			780,682
Deferred revenue, current portion		109,833			135,063			94,474			116,161
Operating lease liability, current portion		177,439			134,091			257,155			240,645
Short term debt-related party		939,919			—			965,155			950,722
Warrant liabilities		987,300			1,686,200			133,500			788,100
Warrant liabilities - related party								2,010,180			2,834,547
Convertible debt - related party								812,419			60,197
Total current liabilities		5,646,086			4,635,479			8,493,858			8,608,169
Operating lease liability, net of current portion		1,425,808			1,542,564			1,168,653			1,301,919
Deferred revenue, net of current portion		70,814			92,928			28,648			49,056
Deferred tax liability		736,000			—			150,369			357,757
Total liabilities		7,878,708			6,270,971			9,841,528			10,316,901
Commitments and Contingencies (Note 12)								-			-
Stockholders’ equity
Qualigen Therapeutics, Inc. stockholders’ equity:
Common stock, $0.001 par value; 225,000,000 shares authorized; 38,795,541 and 35,290,178 shares issued and outstanding as of June 30, 2022 and December 31, 2021, respectively		38,795			35,290
Common stock, $0.001 par value; 225,000,000 shares authorized; 5,052,463 and 4,210,737 shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively								42,952			42,110
Additional paid-in capital		107,557,744			101,274,073			112,554,830			110,528,050
Accumulated other comprehensive income		65,540			—			131,891			50,721
Accumulated deficit		(93,187,820	)		(84,744,629	)		(110,695,598	)		(103,385,172	)
Total Qualigen Therapeutics, Inc. stockholders’ equity		14,474,259			16,564,734			2,034,075			7,235,709
Noncontrolling interest		3,995,884			—			1,273,969			1,530,881
Total Stockholders’ Equity		18,470,143			16,564,734			3,308,044			8,766,590
Total Liabilities & Stockholders’ Equity	$	26,348,851		$	22,835,705		$	13,149,572		$	19,083,491

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

QUALIGEN THERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND OTHER COMPREHENSIVE LOSS

(Unaudited)

	2022			2021			2022			2021
	For the Three Months Ended June 30,						For the Six Months Ended June 30,						For the Three Months Ended June 30,						For the Six Months Ended June 30,
	2022			2021			2022			2021			2023			2022			2023			2022
REVENUES
Net product sales	$	1,430,534		$	1,117,935		$	2,152,563		$	2,538,776		$	1,627,031		$	1,430,534		$	3,234,201		$	2,152,563
License revenue		—			—			—			478,654
Total revenues		1,430,534			1,117,935			2,152,563			3,017,430			1,627,031			1,430,534			3,234,201			2,152,563

EXPENSES
Cost of product sales		1,099,677			916,624			1,928,524			2,119,103			1,016,542			1,099,677			2,281,368			1,928,524
General and administrative		2,660,857			2,952,100			5,559,608			5,826,038			2,665,849			2,660,857			4,380,283			5,559,608
Research and development		1,506,227			4,508,466			3,370,972			8,007,840			1,326,544			1,506,227			3,448,095			3,370,972
Sales and marketing		305,103			135,543			443,426			272,129			169,223			305,103			368,337			443,426
Total expenses		5,571,864			8,512,733			11,302,530			16,225,110			5,178,158			5,571,864			10,478,083			11,302,530

LOSS FROM OPERATIONS		(4,141,330	)		(7,394,798	)		(9,149,967	)		(13,207,680	)		(3,551,127	)		(4,141,330	)		(7,243,882	)		(9,149,967	)

OTHER INCOME (EXPENSE), NET
OTHER EXPENSE (INCOME), NET
Gain on change in fair value of warrant liabilities		14,800			1,982,256			698,042			2,535,064			(440,294	)		(14,800	)		(1,478,967	)		(698,042	)
Interest income, net		4,824			12,718			11,132			30,061
Other income (expense), net		(376	)		2,352			(341	)		2,894
Total other income, net		19,248			1,997,326			708,833			2,568,019
Interest expense (income), net														377,416			(4,824	)		921,652			(11,132	)
Loss on voluntary conversion of convertible debt														—			—			1,077,287			—
Loss on disposal of equipment held for lease														63,302			—			63,302			—
Other income, net														(5,680	)		376			(10,559	)		341
Loss on fixed asset disposal														—			—			300			—
Total other expense (income), net														(5,256	)		(19,248	)		573,015			(708,833	)

LOSS BEFORE PROVISION FOR INCOME TAXES		(4,122,082	)		(5,397,472	)		(8,441,134	)		(10,639,661	)
LOSS BEFORE (BENEFIT) PROVISION FOR INCOME TAXES														(3,545,871	)		(4,122,082	)		(7,816,897	)		(8,441,134	)

PROVISION FOR INCOME TAXES		5,438			605			6,173			1,135
(BENEFIT) PROVISION FOR INCOME TAXES														(38,182	)		5,438			(201,959	)		6,173

NET LOSS		(4,127,520	)		(5,398,077	)		(8,447,307	)		(10,640,796	)		(3,507,689	)		(4,127,520	)		(7,614,938	)		(8,447,307	)

Net loss attributable to noncontrolling interest		(4,116	)		—			(4,116	)		—			(43,484	)		(4,116	)		(304,512	)		(4,116	)

Net loss attributable to Qualigen Therapeutics, Inc.	$	(4,123,404	)	$	(5,398,077	)	$	(8,443,191	)	$	(10,640,796	)	$	(3,464,205	)	$	(4,123,404	)	$	(7,310,426	)	$	(8,443,191	)

Net loss per common share, basic and diluted	$	(0.11	)	$	(0.19	)	$	(0.23	)	$	(0.37	)	$	(0.69	)	$	(1.12	)	$	(1.46	)	$	(2.35	)
Net loss per common share, basic													$	(0.69	)	$	(1.12	)	$	(1.46	)	$	(2.35	)
Weighted—average number of shares outstanding, basic and diluted		36,680,156			28,850,451			35,990,933			28,510,014			5,052,463			3,668,016			5,006,050			3,599,093
Weighted—average number of shares outstanding, basic														5,052,463			3,668,016			5,006,050			3,599,093

Other comprehensive loss, net of tax
Net loss	$	(4,127,520	)	$	(5,398,077	)	$	(8,447,307	)	$	(10,640,796	)	$	(3,507,689	)	$	(4,127,520	)	$	(7,614,938	)	$	(8,447,307	)
Foreign currency translation adjustment		65,540			—			65,540			—			(56,747	)		65,540			119,473			65,540
Other comprehensive loss		(4,061,980	)		(5,398,077	)		(8,381,767	)		(10,640,796	)		(3,564,436	)		(4,061,980	)		(7,495,465	)		(8,381,767	)
Comprehensive loss attributable to noncontrolling interest		(4,116	)		—			(4,116	)		—			(43,484	)		(4,116	)		(304,512	)		(4,116	)
Comprehensive loss attributable to Qualigen Therapeutics, Inc.	$	(4,057,864	)	$	(5,398,077	)	$	(8,377,651	)	$	(10,640,796	)	$	(3,520,952	)	$	(4,057,864	)	$	(7,190,953	)	$	(8,377,651	)

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

QUALIGEN THERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY

(Unaudited)

Total
Accumulated Qualigen Therapeutics,
Common Stock Additional Other Inc. Total
Shares Amount
$ Paid-In
Capital Comprehensive Income
Accumulated
Deficit
Stockholders’
Equity Noncontrolling Interest
Stockholders’
Equity

Balance at December 31, 2021 - 35,290,178 $ 35,290 $ 101,274,073 $ — $ (84,744,629 ) $ 16,564,734 $ — $ 16,564,734
Stock issued upon exercise of warrants 5,363 5 4,711 — — 4,716 — 4,716
Stock-based compensation - — — 1,267,166 — — 1,267,166 — 1,267,166
Net loss — — — — (4,319,787 ) (4,319,787 ) — (4,319,787 )
Balance at March 31, 2022 - 35,295,541 $ 35,295 $ 102,545,950 $ — $ (89,064,416 ) $ 13,516,829 $ — $ 13,516,829
Common stock issued for business acquisition 3,500,000 3,500 1,841,000 — — 1,844,500 — $ 1,844,500
Prefunded warrants issued for business acquisition — — 1,746,816 — — 1,746,816 — 1,746,816
Foreign currency translation adjustment — — — 65,540 — 65,540 — 65,540
Fair value of noncontrolling interest related to business acquisition — — — — — — 4,000,000 4,000,000
Fair value of warrant modification for business acquisition — — 696 — — 696 — 696
Stock-based compensation - — — 1,423,282 — — 1,423,282 — 1,423,282
Net loss — — — — (4,123,404 ) (4,123,404 ) (4,116 ) (4,127,520 )
Balance at June 30, 2022 - 38,795,541 $ 38,795 $ 107,557,744 $ 65,540 $ (93,187,820 ) $ 14,474,259 $ 3,995,884 $ 18,470,143


													Total
													Qualigen
					Additional		Accumulated Other						Therapeutics, Inc.						Total
	Common Stock				Paid-In		Comprehensive			Accumulated			Stockholders’			Noncontrolling			Stockholders’
	Shares		Amount		Capital		Income			Deficit			Equity			Interest			Equity
Balance at December 31, 2022		4,210,737	$	42,110	$	110,528,050	$	50,721		$	(103,385,172	)	$	7,235,709		$	1,530,881		$	8,766,590
Voluntary conversion of convertible debt into common stock		841,726		842		1,111,740		—			—			1,112,582			—			1,112,582
Stock-based compensation		—		—		247,657		—			—			247,657			4,569			252,226
Foreign currency translation adjustment		—		—		—		119,723			—			119,723			56,497			176,220
Net loss		—		—		—		—			(3,846,221	)		(3,846,221	)		(261,028	)		(4,107,249	)
Balance at March 31, 2023		5,052,463	$	42,952	$	111,887,447	$	170,444		$	(107,231,393	)	$	4,869,450		$	1,330,919		$	6,200,369
Stock-based compensation		—		—		667,383		—			—			667,383			4,728			672,111
Foreign currency translation adjustment		—		—		—		(38,553	)		—			(38,553	)		(18,194	)		(56,747	)
Net loss		—		—		—		—			(3,464,205	)		(3,464,205	)		(43,484	)		(3,507,689	)
Balance at June 30, 2023		5,052,463	$	42,952	$	112,554,830	$	131,891		$	(110,695,598	)	$	2,034,075		$	1,273,969		$	3,308,044

Total
Series Alpha Convertible Accumulated Qualigen Therapeutics,
Preferred Stock Common Stock Additional Other Inc. Total
Shares Amount
$ Shares Amount
$ Paid-In
Capital Comprehensive Income Accumulated Deficit Stockholders’
Equity Noncontrolling
Interest
Stockholders’
Equity

Balance at December 31, 2020 $ 180 $ 1 27,296,061 $ 27,296 $ 85,114,755 $ — $ (66,847,492 ) $ 18,294,560 $ — $ 18,294,560
Stock issued upon cash exercise of warrants — — 1,319,625 1,320 1,813,353
—
— 1,814,673
—
1,814,673
Stock issued upon net-exercise of warrants — — 192,373 192 (192 )
—
— —
—
—
Stock issued for professional services — — 25,000 25 101,725 — — 101,750
—
101,750
Stock-based compensation — — — — 1,262,123
—
— 1,262,123
—
1,262,123
Net loss — — — — — (5,242,719 ) (5,242,719 ) (5,242,719 )
Balance at March 31, 2021 180 $ 1 28,833,059 $ 28,833 $ 88,291,764 $ — $ (72,090,211 ) $ 16,230,387 $ — $ 16,230,387
Stock issued upon cash exercise of warrants — — 69,129 69 142,513
—
— 142,582 — 142,582
Stock-based compensation — — — — 1,286,926
—
— 1,286,926 —
1,286,926
Net loss — — — — — — (5,398,077 ) (5,398,077 )
—
(5,398,077 )
Balance at June 30, 2021 180 $ 1 28,902,188 $ 28,902 $ 89,721,203 $ — $ (77,488,288 ) $ 12,261,818 $ — $ 12,261,818

					Additional		Other					Therapeutics, Inc.						Total
	Common Stock				Paid-In		Comprehensive		Accumulated			Stockholders’			Noncontrolling			Stockholders’
	Shares		Amount $		Capital		Income		Deficit			Equity			Interest			Equity
Balance at December 31, 2021		3,529,018	$	35,290	$	101,274,073	$	—	$	(84,744,629	)	$	16,564,734		$	—		$	16,564,734
Stock issued upon exercise of warrants		536		5		4,711		—		—			4,716			—			4,716
Stock-based compensation		—		—		1,267,166		—		—			1,267,166			—			1,267,166
Net Loss		—		—		—		—		(4,319,787	)		(4,319,787	)		—			(4,319,787	)
Balance at March 31, 2022		3,529,554	$	35,295	$	102,545,950	$	—	$	(89,064,416	)	$	13,516,829		$	—		$	13,516,829
Common stock issued for business acquisition		350,000		3,500		1,841,000		—		—			1,844,500			—			1,844,500
Prefunded warrants issued for business acquisition		—		—		1,746,816		—		—			1,746,816			—			1,746,816
Foreign currency translation adjustment		—		—		—		65,540		—			65,540			—			65,540
Estimated fair value of noncontrolling interest related to business acquisition		—		—		—		—		—			—			4,000,000			4,000,000
Fair value of warrant modification for business acquisition		—		—		696		—		—			696			—			696
Stock-based compensation		—		—		1,423,282		—		—			1,423,282			—			1,423,282
Net loss		—		—		—		—		(4,123,404	)		(4,123,404	)		(4,116	)		(4,127,520	)
Balance at June 30, 2022		3,879,554	$	38,795	$	107,557,744	$	65,540	$	(93,187,820	)	$	14,474,259		$	3,995,884		$	18,470,143

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

QUALIGEN THERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

	2022			2021
	For the Six Months Ended June 30,						For the Six Months Ended June 30,
	2022			2021			2023			2022
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$	(8,447,307	)	$	(10,640,796	)	$	(7,614,938	)	$	(8,447,307	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		66,258			53,736			122,523			66,258
Amortization of right-of-use assets		109,803			109,719			116,567			109,803
Accounts receivable reserves and allowances		(75,295	)		3,645			(133,278	)		(75,295	)
Inventory reserves		(16,405	)		40,644			(22,992	)		(16,405	)
Stock-based compensation		2,690,447			2,549,049			906,145			2,690,447
Change in fair value of warrant liabilities		(698,042	)		(2,535,064	)		(1,478,967	)		(698,042	)
Loss on voluntary conversion of convertible debt								1,077,287			—
Accretion of discount on convertible debt								787,517			—
Loss on disposal of fixed assets and equipment held for lease								63,602			—

Changes in operating assets and liabilities:
Accounts receivable		250,201			(154,799	)		(8,614	)		250,201
Inventory and equipment held for lease		(237,930	)		(89,617	)		(37,390	)		(237,930	)
Prepaid expenses and other assets		(548,487	)		746,787			382,893			(548,487	)
Accounts payable		27,941			283,706			899,753			27,941
Accrued expenses and other current liabilities		(828,229	)		1,176,970			357,508			(828,229	)
R&D grant liability								(613,793	)		—
Operating lease liability		(73,408	)		(122,780	)		(116,756	)		(73,408	)
Deferred revenue		(47,345	)		(206,257	)		(42,095	)		(47,345	)
Deferred tax liability								(207,388	)		—
Net cash used in operating activities		(7,827,798	)		(8,785,057	)		(5,562,416	)		(7,827,798	)

CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment		(63,483	)		(107,798	)		(246,418	)		(63,483	)
Payments for patents and licenses		—			(6,893	)
Net cash acquired in business combination		135,354			—			—			135,354
Net cash provided by (used in) investing activities		71,871			(114,691	)
Net cash (used in)/provided by investing activities								(246,418	)		71,871

CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from warrant exercises		3,859			294,319			—			3,859
Principal payments on notes payable		—			(138,739	)
Net cash provided by financing activities		3,859			155,580			—			3,859

Net change in cash and restricted cash		(7,752,068	)		(8,744,168	)		(5,808,834	)		(7,752,068	)
Effect of exchange rate changes on cash and restricted cash		(34,228	)		—			115,803			(34,228	)
Cash and restricted cash - beginning of period		17,538,272			23,976,570			7,040,124			17,538,272
Cash and restricted cash - end of period	$	9,751,976		$	15,232,402		$	1,347,093		$	9,751,976

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
Cash paid during the year for:
Interest	$	—		$	1,683		$	—		$	—
Taxes	$	3,501		$	2,200		$	6,293		$	3,501

NONCASH FINANCING AND INVESTING ACTIVITIES:
Issuance of common stock for professional services	$	—		$	101,750
Net transfers to inventory from equipment held for lease	$	—		$	1,304
Fair value of shares issued for cashless warrant exercises	$	—		$	722,970
Net transfers to equipment held for lease from inventory							$	83,271		$	—
Fair value of warrant liabilities on date of exercise	$	858		$	1,662,936		$	—		$	858

ACQUISITION:
Fair value of assets acquired	$	(5,896,278	)	$	—
Fair value of liabilities assumed, net of goodwill		2,439,620			—
Fair value of Alpha Capital/Qualigen warrants repriced due to acquisition		696			—
Fair value of Qualigen prefunded warrant issued in exchange for NanoSynex stock		1,746,816			—
Fair value of Qualigen common stock issued in exchange for NanoSynex stock		1,844,500			—
Net cash acquired in business acquisition (Note 3)	$	135,354		$	—

Cash and restricted cash included in the accompanying balance sheet was as follows:
Cash	$	9,746,257		$	15,232,402
Restricted cash		5,719			—
Total cash and restricted cash	$	9,751,976		$	15,232,402
Voluntary conversion of convertible debt into common stock							$	1,112,582		$	—

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

QUALIGEN THERAPEUTICS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

NOTE 1 — ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES

Organization

Qualigen, Inc., ~~now~~ a subsidiary of Qualigen Therapeutics, Inc., was incorporated in Minnesota in 1996 to design, develop, manufacture and sell point-of-care quantitative immunoassay diagnostic products for use in physician offices and other point-of-care settings worldwide, and was reincorporated in Delaware in 1999. Qualigen Therapeutics, Inc. (the “Company”) operates in one business segment. In May 2020, Qualigen, Inc. completed a reverse recapitalization transaction with Ritter Pharmaceuticals, Inc. (“Ritter”) and Ritter was renamed Qualigen Therapeutics, Inc. All shares of Qualigen, Inc.’s capital stock were exchanged for Qualigen Therapeutics, Inc.’s capital stock in the merger. Ritter/Qualigen Therapeutics common stock, which was previously traded on the Nasdaq Capital Market under the ticker symbol “RTTR,” commenced trading on the Nasdaq Capital Market, on a post-reverse-stock-split adjusted basis, under the trading symbol “QLGN” on May 26, 2020.

On May 26, 2022, the Company acquired 2,232,861shares of Series A-1 Preferred Stock of NanoSynex, ~~Ltd,~~Ltd. (“NanoSynex”) from Alpha Capital Anstalt (“Alpha Capital”), a related party, in exchange for ~~3,500,000~~350,000 reverse split adjusted shares of the Company’s common stock and a prefunded warrant to purchase ~~3,314,641~~331,464 reverse split adjusted shares of the Company’s common stock at an exercise price of $0.001per share.These warrants were subsequently exercised on September 13, 2022. Concurrently with this transaction, the Company also purchased 381,786shares of Series B preferred stock from NanoSynex for a total purchase price of $600,000. The transactions resulted in the Company acquiring a 52.8% interest in ~~NanoSynex. The Company envisions future synergies from the integration of its own proprietary results-proven FastPack diagnostics platform with the innovative~~ NanoSynex ~~technology.~~(the “NanoSynex Acquisition”). NanoSynex is a micro-biologics diagnostics company domiciled in Israel.On July 20, 2023, the Company entered into an Amendment and Settlement Agreement with NanoSynex Ltd. (the “NanoSynex Amendment”), which amended the Master Funding Agreement for the Operational and Technology Funding of NanoSynex Ltd., dated May 26, 2022, by and between the Company and NanoSynex (the “NanoSynex Funding Agreement”), a majority owned subsidiary of the Company, to, among other things, provide for the further funding of NanoSynex, as contemplated by the NanoSynex Funding Agreement (see Note 16 - Subsequent Events: Amendment and Settlement Agreement with NanoSynex Ltd. ).

Basis of Presentation

The ~~unaudited~~accompanying condensed consolidated financial statements of the Company have been prepared in ~~accordance~~conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”), Regulation S-X and ~~the~~ rules and regulations of the Securities and Exchange Commission (“SEC”) applicable to interim reports of companies filing as a smaller reporting company. These financial statements should be read in conjunction with the audited financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 filed with the Securities Exchange Commission on March 31, 2022, as amended on April 29, 2022 (the “2021 Annual Report”). In the opinion of management, the accompanying condensed consolidated interim financial statements include all adjustments necessary in order to make the financial statements not misleading. The results of operations for interim periods are not necessarily indicative of the results to be expected for the full year or any other future period. Certain notes to the financial statements that would substantially duplicate the disclosures contained in the audited financial statements for the most recent fiscal year as reported in the Company’s 2021 Annual Report have been omitted. The accompanying condensed consolidated balance sheet at December 31, 2021 has been derived from the audited balance sheet at December 31, 2021 contained in the 2021 Annual Report.

Principles of Consolidation

The accompanying condensed consolidated financial statements include the accounts of the Company and its majority owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP. The Company views its operations and manages its business in one operating segment. In general, the functional currency of the Company and its subsidiaries is the U.S. dollar, however for NanoSynex, the functional currency is the local currency, New Israeli Shekels (NIS). As such, assets and liabilities for NanoSynex are translated into U.S. dollars and the effects of foreign currency translation adjustments are reflected as a component of accumulated other comprehensive income within the Company’s consolidated statements of changes in stockholders’ equity.

Accounting Estimates

Management uses estimates and assumptions in preparing its ~~unaudited~~ condensed consolidated financial statements in accordance with U.S. GAAP. Those estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported revenues and expenses. The most significant estimates relate to the estimated fair value of in-process research and development, goodwill, warrant liabilities, stock-based compensation, amortization and depreciation, inventory reserves, allowances for doubtful accounts and returns, and warranty costs. Actual results could vary from the estimates that were used.

Reverse Stock Split

On November 23, 2022, the Company effected a 1-for-10, as determined by the Company’s board of directors, reverse stock split of its outstanding shares of common stock (the “Reverse Stock Split”). The Reverse Stock Split reduced the Company’s shares of outstanding common stock, stock options, and warrants to purchase shares of our common stock. Fractional shares of common stock that would have otherwise resulted from the Reverse Stock Split were rounded down to the nearest whole share and cash in lieu of fractional shares was paid to stockholders. All share and per share data for all periods presented in the accompanying financial statements and the related disclosures have been adjusted retrospectively to reflect the Reverse Stock Split. The number of authorized shares of common stock and the par value per share remains unchanged.

Cash ~~cash equivalents and restricted cash~~

The Company considers all highly liquid investments purchased with an initial maturity of 90 days or less and money market funds to be cash equivalents. Restricted cash includes cash that is restricted due to Israeli banking regulations.

The Company maintains the majority of its cash in ~~bank deposits which~~government money market mutual funds and in accounts at banking institutions in the U.S. that are of high quality. Cash held in these accounts often exceed ~~federally insured limits~~the FDIC insurance limits. If such banking institutions were to fail, the Company could lose all or a portion of amounts held in excess of such insurance limitations. In March 2023, Silicon Valley Bank and ~~could potentially be subject~~Signature Bank, and more recently in May 2023, First Republic Bank, were closed due to ~~significant concentrations~~liquidity concerns and taken over by the Federal Deposit Insurance Corporation (FDIC). While the Company did not have an account at any of ~~credit risk on cash. The Company reviews~~these banks, in the event of failure of any of the financial ~~stability of~~institutions where the Company maintains its ~~depository institutions on~~cash and cash equivalents, there can be no assurance that the Company would be able to access uninsured funds in a ~~regular basis,~~timely manner or at all. Any inability to access or delay in accessing these funds could adversely affect our business and ~~has not experienced any losses in such accounts.~~financial position.

Inventory, Net

Inventory is recorded at the lower of cost or net realizable value. Cost is determined using the first-in, first-out method. The Company reviews the components of its inventory on a periodic basis for excess or obsolete inventory, and records reserves for inventory components identified as excess or obsolete.

Impairment of Long-Lived Assets

The Company assesses potential impairments to its long-lived assets when there is evidence that events or changes in circumstances indicate that assets may not be recoverable. An impairment loss would be recognized when the sum of the expected future undiscounted cash flows is less than the carrying amount of the assets. The amount of impairment loss, if any, will generally be measured as the difference between the net book value of the assets and their estimated fair values. During the three and six months ended June 30, ~~2022~~2023 and ~~2021,~~2022, 0no such impairment losses have been recorded.

Segment Reporting

Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. To date, the Company has viewed its operations and managed its business as one segment operating primarily within the United States and Israel.

Accounts Receivable, Net

The Company grants credit to domestic physicians, clinics, and distributors. The Company performs ongoing credit evaluations of its customers and generally requires no collateral. Customers can purchase certain products through a financing agreement that the Company has with an outside leasing company. Under the agreement, the leasing company evaluates the credit worthiness of the customer. Upon acceptance of the product by the customer, the leasing company remits payment to the Company at a discount. This financing arrangement is without recourse to the Company.

The Company records an allowance for doubtful accounts and returns equal to the estimated uncollectible amounts or expected returns. The Company’s estimates are based on historical collections and returns and a review of the current status of trade accounts receivable.

Accounts receivable, net is comprised of the following at:

SCHEDULE OF ACCOUNTS RECEIVABLE

	June 30,			December 31,
	2022			2021			June 30, 2023			December 31, 2022
Accounts Receivable	$	780,684		$	958,448		$	733,964		$	726,449
Less Allowances		(60,801	)		(136,097	)
Less Reserves and Allowances								(54,584	)		(187,862	)
Accounts receivable, net	$	719,883		$	822,351		$	679,380		$	538,587

Research and Development

Except for acquired in process research and development (IPR&D), the Company expenses research and development costs as incurred including therapeutics license costs.

R&D Grants

NanoSynex has received R&D grants from Israel Innovation Authority (IIA) and from the European Commission. These grants may provide cash funding to NanoSynex from time to time in advance of the applicable costs being incurred. When such cash funding is received from these grants in advance, the proceeds are recorded as a current or non-current R&D grant liability based on the time from the condensed consolidated balance sheets date to the expected future date of recognition as a reduction to research and development expenses.

Patent Costs

The Company expenses all costs as incurred in connection with patent applications (including direct application fees, and the legal and consulting expenses related to making such applications) and such costs are included in general and administrative expenses in the condensed consolidated statement of operations.

Shipping and Handling Costs

The Company includes shipping and handling fees billed to customers in net sales. Shipping and handling costs associated with inbound and outbound freight are generally recorded in cost of sales which totaled approximately $~~72,000~~ 78,000and $~~28,000~~72,000, respectively, for the three months ended June 30, 2023 and 2022, ~~and 2021,~~ and approximately $~~111,000~~ 144,000and $~~58,000~~111,000, respectively, for the six months ended June 30, ~~2022~~2023 and ~~2021~~.2022. Other shipping and handling costs included in general and administrative, research and development, and sales and marketing expenses ~~totaled approximately~~were $0 and $4,000 for ~~both~~ the three months ended June 30, 2023 and 2022, ~~and 2021,~~respectively, and approximately $~~8,000~~ 4,000and $~~5,000~~ 8,000for the six months ended June 30, 2023 and 2022, ~~and 2021,~~ respectively.

Revenue from Contracts with Customers

~~We apply~~The Company applies the following five-step model in accordance with ASC 606, Revenue from Contracts with Customers, in order to determine revenue: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.

Product Sales

The Company generates revenue from selling FastPack System analyzers, accessories and disposable products used with the FastPack System. Disposable products include reagent packs, which are diagnostic tests for prostate-specific antigen, ~~(“PSA”),~~ testosterone, thyroid disorders, pregnancy, and Vitamin D.

The Company provides disposable products and equipment in exchange for consideration, which occurs when a customer submits a purchase order and the Company provides disposable products and equipment at the agreed upon prices in the invoice. Generally, customers purchase disposable products using separate purchase orders after the equipment (“analyzer”) has been provided to the customer. The initial delivery of the equipment and reagent packs represents a single performance obligation and is completed upon receipt by the customer. The delivery of each subsequent individual reagent pack represents a separate performance obligation because the reagent packs are standardized, are not interrelated in any way, and the customer can benefit from each reagent pack without any other product. There are no significant discounts, rebates, returns or other forms of variable consideration. Customers are generally required to pay within 30 days.

The performance obligation arising from the delivery of the equipment is satisfied upon the delivery of the equipment to the customer. The disposable products are shipped Free on Board (“FOB”) shipping point. For disposable products that are shipped FOB shipping point, the customer has the significant risks and rewards of ownership and legal title to the assets when the disposable products leave the Company’s shipping facilities, thus the customer obtains control and revenue is recognized at that point in time.

The Company has elected the practical expedient and accounting policy election to account for the shipping and handling as activities to fulfill the promise to transfer the disposable products and not as a separate performance obligation.

The Company’s contracts with customers generally have an expected duration of one year or less, and therefore the Company has elected the practical expedient in ASC 606 to not disclose information about its remaining performance obligations. Any incremental costs to obtain contracts are recorded as selling, general and administrative expense as incurred due to the short duration of the Company’s contracts.

~~License Revenue~~

~~The Company enters into out-license agreements with counterparties to develop and/or commercialize its products in exchange for nonrefundable upfront license fees and/or sales-based royalties.~~

If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from nonrefundable upfront fees allocated to the license when the license is transferred to the customer and the customer can benefit from the license. For licenses that are bundled with other performance obligations, management uses judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from nonrefundable upfront fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of progress and related revenue recognition. During the three months ended June 30, 2022 and 2021, the Company recognized no license revenue, and during the six months ended June 30, 2022 and 2021, the Company recognized license revenue of $0 ~~and approximately $479,000, respectively.~~

Contract Asset and Liability Balances

The timing of the Company’s revenue recognition may differ from the timing of payment by the Company’s customers. The Company records a receivable when revenue is recognized prior to payment and there is an unconditional right to payment. Alternatively, when payment precedes the performance of the related services, the Company records deferred revenue until the performance obligations are satisfied.

Multiple performance obligations ~~included~~include contracts that ~~combined~~combine both the Company’s analyzer and a customer’s future reagent purchases under a single contract. In some sales contracts, the Company ~~provided~~provides analyzers at no charge to customers. Title to the analyzer ~~was~~is maintained by the Company and the analyzer ~~was~~is returned by the customer to the Company at the end of the purchase agreement.

During the three months ended June 30, ~~2022~~2023 and ~~2021,~~2022, product sales are stated net of an allowance for estimated returns of approximately $~~10,000~~28,000 and $010,000, respectively. During the six months ended June 30, ~~2022~~2023 and ~~2021,~~2022, product sales are stated net of an allowance for estimated returns of approximately $~~53,000~~33,000 and $053,000, re~~spectively.~~respectively.

Deferred Revenue

Payments received in advance from customers pursuant to certain collaborative research license agreements, deposits against future product sales, multiple element arrangements and extended warranties are recorded as a current or non-current deferred revenue liability based on the time from the condensed consolidated balance sheets date to the future date of revenue recognition.

Operating Leases

Effective April 1, 2020, the Company adopted Accounting Standards Update (“ASU”) No. 2018-11, Leases (Topic 842) Targeted Improvements (“Topic 842”). In accordance with the guidance in Topic 842, the Company recognizes lease liabilities and corresponding right-of-use-assets for all leases with terms of greater than 12 months. Leases with a term of 12 months or less will be accounted for in a manner similar to the guidance for operating leases prior to the adoption of Topic ~~842 (see~~842. (See Note 12 –- Commitments and Contingencies for more information).

Property and Equipment, Net

Property and equipment are stated at cost and are presented net of accumulated depreciation. Depreciation is provided for on a straight-line basis over the estimated useful lives of the related assets as follows:

SCHEDULE OF USEFUL LIVES OF PROPERTY AND EQUIPMENT

Machinery and equipment			5 years
Computer equipment			3 years
Molds and tooling			5 years
Furniture and fixtures			5 years

Leasehold improvements are amortized on a straight-line basis over the shorter of the lease term or their estimated useful lives. The Company occasionally designs and builds its own machinery. The costs of these projects, which includes the cost of construction and other direct costs attributable to the construction, are capitalized as construction in progress. No provision for depreciation is made on construction in progress until the relevant assets are completed and placed in service.

The Company’s policy is to evaluate the remaining lives and recoverability of long-term assets on at least an annual basis or when conditions are present that indicate impairment.

Business Combinations

The Company accounts for business combinations using the acquisition method pursuant to FASB ASC Topic 805. This method requires, among other things, that results of operations of acquired companies are included in Qualigen’s financial results beginning on the respective acquisition ~~dates,~~date, and that assets acquired and liabilities assumed are recognized at fair value as of the acquisition date. Intangible assets acquired in a business combination are recorded at fair value using a discounted cash flow model. The discounted cash flow model requires assumptions about the timing and amount of future net cash flows, the cost of capital and terminal values from the perspective of a market participant. Each of these factors can significantly affect the value of the intangible asset. Any excess of the fair value of consideration transferred (the ~~“Purchase Price”~~“purchase price”) over the fair values of the net assets acquired is recognized as goodwill. The fair value of assets acquired and liabilities assumed in certain cases may be subject to revision based on the final determination of fair value during a period of time not to exceed 12 months from the acquisition date. Legal costs, due diligence costs, business valuation costs and all other acquisition-related costs are expensed when incurred.

Goodwill

Goodwill represents the difference between the purchase price and the fair value of the identifiable tangible and intangible net assets acquired, when accounted for using the purchase method of accounting. Goodwill has an indefinite useful life and is not amortized but is reviewed for impairment annually and whenever events or changes in circumstances indicate that the carrying value of the goodwill may not be recoverable.

In testing for impairment, the fair value of the reporting unit is compared to the carrying value. If the net assets assigned to the reporting unit exceed the fair value of the reporting unit, an impairment loss equal to the difference ~~would be~~is recorded. As a result of the annual goodwill impairment analysis, the Company recognized a $4,239,000 non-cash goodwill and fixed asset impairment charge in the valuation of its business acquisition of NanoSynex for the fiscal year ended December 31, 2022. There were no impairment losses during the three and six months ended June 30, 2023 and 2022.

Intangible Assets

In Process R&D

Acquired in process R&D (IPR&D) represents the fair value assigned to the research and development assets that have not reached technological feasibility. The value assigned to IPR&D is determined by estimating the costs to develop the acquired technology into commercially viable products, estimating the resulting revenue from the projects, and discounting the net cash flow to present value. The revenue and cost projections used to value acquired IPR&D are, as applicable, reduced based on the probability of success of developing the new product. Additionally, projections consider relevant market sizes and growth factors, expected trends in technology and the nature and expected timing of new product introductions. The rates utilized to discount the net cash flow to its present value are commensurate with the stage of development of the project and uncertainties in the economic estimates used in the projections. Upon the acquisition of acquired IPR&D, an assessment is completed as to whether the acquisition constitutes an acquisition ~~of the purchase~~ of a single asset or a group of assets. Multiple factors are considered in this assessment, including the nature of the technology acquired, the presence or absence of separate cash flows, the development process and stage of completion, quantitative significance, and the Company’s rationale for entering into the transaction.

If a business is acquired, as defined under the applicable accounting standards, then the acquired IPR&D is capitalized as an intangible asset. If an asset or group of assets is acquired that do not meet the definition under the applicable accounting standards, then the acquired IPR&D is expensed on its acquisition date. Future costs to develop these assets are recorded to research and development expense in the Company’s condensed consolidated statements of operations and other comprehensive income (loss) as they are incurred.

IPR&D is evaluated for impairment annually using the same methodology as described above for calculating fair value. If the carrying value of the acquired IPR&D exceeds the fair value, then the intangible asset is written down to its fair value, with the resulting adjustment recorded as a charge to operations. Changes in estimates and assumptions used in determining the fair value of acquired IPR&D could result in an impairment.

Other Intangible Assets, Net

Other intangible assets consist of patent-related costs and costs for license agreements. Management reviews the carrying value of other intangible assets that are being amortized on an annual basis or sooner when there is evidence that events or changes in circumstances may indicate that impairment exists. The Company considers relevant cash flow and profitability information, including estimated future operating results, trends and other available information, in assessing whether the carrying value of intangible assets being amortized can be recovered.

If the Company determines that the carrying value of other intangible assets will not be recovered from the undiscounted future cash flows expected to result from the use and eventual disposition of the underlying assets, the Company considers the carrying value of such intangible assets as impaired and reduces them by a charge to operations in the amount of the impairment.

Costs related to acquiring patents and licenses are capitalized and amortized over their estimated useful lives, which is generally 5 to 17 years, using the straight-line method. Amortization of patents and licenses commences once final approval of the patent or license has been obtained. Patent and license costs are charged to operations if it is determined that the patent or license will not be obtained.

Derivative Financial Instruments and Warrant Liabilities

The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates all of its financial instruments, including issued stock purchase warrants, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the condensed consolidated statements of operations and other comprehensive income (loss). Depending on the features of the derivative financial instrument, the Company uses either the Black-Scholes option-pricing model or a Monte-Carlo simulation to value the derivative instruments at inception and subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period ~~(see~~(See Note ~~10 –~~9- Warrant Liabilities).

Fair Value Measurements

The Company determines the fair value measurements of applicable assets and liabilities based on a three-tier fair value hierarchy established by accounting guidance and prioritizes the inputs used in measuring fair value. The Company discloses and recognizes the fair value of its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to valuations based upon unobservable inputs that are significant to the valuation (Level 3 measurements). The guidance establishes three levels of the fair value hierarchy as follows:

	●	Level 1 - Inputs that reflect unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date;
	●	Level 2 - Inputs other than quoted prices that are observable for the assets or liability either directly or indirectly, including inputs in markets that are not considered to be active; and
	●	Level 3 - Inputs that are unobservable.

Fair Value of Financial Instruments

Cash, accounts receivable, prepaids, accounts payable, and accrued liabilities are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments.

Comprehensive Loss

Comprehensive loss consists of net income and foreign currency translation adjustments. Comprehensive gains (losses) have been reflected in the statements of operations and comprehensive loss and as a separate component in the statements of stockholders’ equity for all periods presented.

Stock-Based Compensation

Stock-based compensation cost for equity awards granted to employees and non-employees is measured at the grant date based on the calculated fair value of the award using the Black-Scholes option-pricing model, and is recognized as an expense, under the straight-line method, over the requisite service period (generally the vesting period of the equity grant). If the Company determines that other methods are more reasonable, or other methods for calculating these assumptions are prescribed by regulators, the fair value calculated for the Company’s stock options could change significantly. Higher volatility, lower risk-free interest rates, and longer expected lives would result in an increase to stock-based compensation expense to employees and non-employees determined at the date of grant.

Income Taxes

Deferred income taxes are recognized for temporary differences in the basis of assets and liabilities for financial statement and income tax reporting that arise due to net operating loss carry forwards, research and development credit carry forwards and from using different methods and periods to calculate depreciation and amortization, allowance for doubtful accounts, accrued vacation, research and development expenses, and state taxes. A provision has been made for income taxes due on taxable income and for the deferred taxes on the temporary differences.

Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. Realization of the deferred income tax asset is dependent on generating sufficient taxable income in future years.

Sales and Excise Taxes

Sales and other taxes collected from customers and subsequently remitted to government authorities are recorded as accounts receivable with corresponding tax payable. These balances are removed from the condensed consolidated balance sheet as cash is collected from customers and remitted to the tax authority.

Warranty Costs

The Company’s warranty policy generally provides for one year of coverage against defects and nonperformance within published specifications for sold analyzers and for the term of the contract for equipment held for lease. The Company accrues for estimated warranty costs in the period in which the revenue is recognized based on historical data and the Company’s best estimates of analyzer failure rates and costs to repair.

Accrued warranty liabilities were approximately $~~101,000~~140,000 and $~~60,000~~138,000, respectively, as of June 30, ~~2022~~2023 and December 31, ~~2021~~2022 and are included in accrued expenses and other current liabilities on the accompanying condensed consolidated balance sheets. Warranty costs were approximately $~~22,000~~63,000 and $~~20,000~~22,000 for the three months ended June 30, ~~2022~~2023 and ~~2021,~~2022, respectively, and approximately $~~41,000~~104,000 and $41,000 for the six months ended June 30, ~~2022~~2023 and ~~2021,~~2022, respectively, and are included in cost of product sales in the condensed consolidated statements of operations and other comprehensive loss.

Foreign Currency Translation

The functional currency for the Company is the U.S. dollar. The functional currency for NanoSynex, the Company’s newly acquired majority owned subsidiary, is the New Israeli Shekel (NIS). The financial statements of NanoSynex are translated into U.S. dollars using exchange rates in effect at each period end for assets and liabilities; using exchange rates in effect during the period for results of operations; and using historical exchange rates for certain equity accounts. The adjustment resulting from translating the financial statements of NanoSynex is reflected as a separate component of other comprehensive income (loss).

Other comprehensive loss related to the effects of foreign currency translation adjustments attributable to NanoSynex was ($56,747) and $65,540 at for the three months ending June 30, ~~2022.~~2023 and 2022, respectively, and $119,473 and $65,540 for the six months ending June 30, 2023 and 2022, respectively.

~~Recent Accounting Pronouncements~~War in Ukraine

In ~~June 2016, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2016-13,~~ ~~Measurement of Credit Losses on Financial Instruments~~, which supersedes current guidance by requiring recognition of credit losses when it is probable that a loss has been incurred. The new standard requires the establishment of an allowance for estimated credit losses on financial assets including trade and other receivables at each reporting date. The new standard will result in earlier recognition of allowances for losses on trade and other receivables and other contractual rights to receive cash. In November 2019, the FASB issued ASU No. 2019-10, ~~Financial Instruments – Credit Losses (Topic 326), Derivatives and Hedging (Topic 815)~~ ~~and~~ ~~Leases (Topic 842)~~~~, which extends the effective date of Topic 326 for certain companies until fiscal years beginning after December 15, 2022. The new standard will be effective for~~February 2022, Russia invaded Ukraine. While the Company has no direct exposure in Russia and Ukraine, the ~~first quarter~~Company continues to monitor any broader impact to the global economy, including with respect to inflation, supply chains and fuel prices. The full impact of the conflict on the Company’s business and financial results remains uncertain and will depend on the severity and duration of the conflict and its impact on regional and global economic conditions.

Inflation and Global Economic Conditions

During the year ended 2022 and continuing into the current fiscal year, ~~beginning January 1, 2023,~~global commodity and ~~early adoption is permitted.~~labor markets experienced significant inflationary pressures attributable to ongoing economic recovery and supply chain issues. The Company ~~has not completed~~is subject to inflationary pressures with respect to raw materials, labor and transportation. Accordingly, the Company continues to take actions with its ~~review of~~customers and suppliers to mitigate the impact of ~~this standard on its condensed consolidated financial statements. However, based on~~these inflationary pressures in the ~~Company’s history~~future. Actions to mitigate inflationary pressures with suppliers include aggregation of ~~immaterial credit losses~~purchase requirements to achieve optimal volume benefits, negotiation of cost-reductions and identification of more cost competitive suppliers. While these actions are designed to offset the impact of inflationary pressures, the Company cannot provide assurance that it will be successful in fully offsetting increased costs resulting from ~~trade receivables, management does not expect~~inflationary pressure. In addition, the global economy suffers from slowing growth and rising interest rates, and some economists believe that there may be a global recession in the ~~adoption of this standard will have a material effect on~~near future. If the ~~Company’s condensed consolidated financial statements.~~global economy slows, our business would be adversely affected.

Impact of ~~the~~ COVID-19 Pandemic

~~Events surrounding the SARS-CoV-2 virus that emerged in late 2019 and the ensuing global~~The COVID-19 pandemic ~~have~~has had a dramatic impact on businesses globally and ~~our~~on the Company’s business as well. ~~Our~~During the height of the pandemic sales of diagnostic products ~~fell~~decreased significantly ~~during 2020~~ and ~~our~~the Company’s net loss increased significantly, as deferral of patients’ non-emergency visits to physician offices, clinics and small hospitals sharply reduced demand for FastPack tests. ~~Since then~~For 2023 we ~~have experienced some~~continue to experience recovery in demand. The severity and duration of the pandemic and economic repercussions of the virus and government actions taken in response to the pandemic remain uncertain and will ultimately depend on many factors, including the speed of global dissemination and effectiveness of the vaccination and containment efforts throughout the world, the duration and spread of the virus, as well as seasonality, variants or new outbreaks.

In the United States, federal, state, and local government directives and policies have been put in place throughout the course of the pandemic to manage public health concerns and address the economic impacts of the pandemic, including reduced business activity and overall uncertainty presented by this new healthcare challenge. Similar actions have been taken by governments around the world. Our facilities could be required to temporarily curtail production levels or temporarily cease operations based on government mandates or as a result of the pandemic. To mitigate risks, we continue to evaluate the extent to which COVID-19 may impact our business and operations and adjust risk mitigation planning and business continuity activities as needed.

Other accounting standard updates are either not applicable to the Company or are not expected to have a material impact on the Company’s ~~unaudited~~ condensed consolidated financial statements.

NOTE 2 — LIQUIDITY

~~The Company has incurred recurring losses from operations~~As of June 30, 2023, we had approximately $1.3 million in cash and ~~has~~ an accumulated deficit atof $110.7 million. For the six months ended June 30, ~~2022. The Company expects to continue to incur losses subsequent to the condensed consolidated balance sheet date~~2023 and year ended December 31, 2022, we used cash of ~~June 30, 2022. In December 2021, the Company raised~~ $~~8.82~~5.6 million ~~through a Securities Purchase Agreement with several institutional investors.~~and $13.2 million, respectively, in operations.

~~Based on~~On July 20, 2023, the Company entered into a stock purchase agreement (the “Purchase Agreement”) with Chembio Diagnostics, Inc. (“Chembio”), Biosynex, S.A. and Qualigen, Inc., a wholly-owned subsidiary of the Company (see Note 16 - Subsequent Events). Pursuant to the Purchase Agreement, the Company agreed to sell to the Buyer all of the issued and outstanding shares of common stock (collectively, the “Shares”) of Qualigen, Inc., which was the legal entity operating the Company’s ~~current cash position, and assuming currently planned expenditures and level of operations,~~FastPack™ diagnostics business (the “Transaction”). The Transaction closed on July 20, 2023. Following the ~~Company believes it has sufficient capital to fund operations for the 12-month period subsequent to the issuance~~consummation of the ~~accompanying unaudited condensed financial statements. We will need substantial additional funding to continue~~Transaction, our ~~operations, particularly for QN-302 clinical trials, to continue preclinical development~~Qualigen, Inc. subsidiary became a wholly-owned subsidiary of ~~QN-247 and RAS-F, and to continue funding the NanoSynex operations. (see Note 3 - Acquisition)~~Chembio.

AsThe aggregate net purchase price paid to the Company for the Shares was $5.2 million in cash, based on a ~~pre-clinical development-stage therapeutics biotechnology company, we expect~~base purchase price of $5.8 million, subject to certain post-closing adjustments, upward or downward, as applicable, for: (i) cash held by Qualigen, Inc. as of the closing of the Transaction; (ii) net working capital of Qualigen, Inc. as of the closing of the Transaction, (iii) certain indebtedness of Qualigen, Inc. as of the closing of the Transaction, and (iv) certain Transaction expenses as of the closing of the Transaction. Of the $5.2 million in cash, $450,000 is being held in escrow to satisfy certain Company indemnification obligations (the “Indemnity Escrow”). Any amounts remaining in the Indemnity Escrow that have not been offset or reserved for claims will be released to the Company within five business days following the date that is 18 months after the closing.

The Company’s cash balances as of the date that these financial statements were issued along with the proceeds from the above sale to Chembio, without additional financing, are expected to fund operations into the first quarter of 2024. The Company expects to continue to have net losses and negative cash flow from operations, which over time will challenge ~~our~~its liquidity. These factors raise substantial doubt about the Company’s ability to continue as a going concern for the one-year period following the date that these financial statements were issued.

There is no assurance that profitable operations will ever be achieved, or, if achieved, could be sustained on a continuing basis. In order to fully execute ~~our~~its business plan, wethe Company will require significant additional financing for planned research and development activities, capital expenditures, clinical testing for its QN-302 clinical trials, preclinical development of RAS and ~~pre-clinical testing~~QN-247, and funding for NanoSynex operations, as well as commercialization activities.

Historically, the Company’s principal sources of cash have included proceeds from the issuance of common and preferred equity and proceeds from the issuance of debt. In December 2021, the Company raised $8.8 million from the issuance of common stock to several institutional investors, and in December 2022 the Company raised $3.0 million from the sale of an 8% Senior Convertible Debenture (the “Debenture”) to a related party (see Note 10 - Convertible Debt - Related Party). There can be no assurance that further financing can be obtained on favorable terms, or at all. If we are unable to obtain funding, we could be required to delay, reduce or eliminate research and development programs, product portfolio expansion or future commercialization efforts, which could adversely affect our business prospects.

On July 20, 2023, the Company entered into an Amendment and Settlement Agreement with NanoSynex Ltd. (the “NanoSynex Amendment”), which amended the Master Funding Agreement for the Operational and Technology Funding of NanoSynex Ltd., dated May 26, 2022, by and between the Company and NanoSynex (the “NanoSynex Funding Agreement”), a majority owned subsidiary of the Company, to, among other things, provide for the further funding of NanoSynex, as contemplated by the NanoSynex Funding Agreement (see Note 16 - Subsequent Events: Amendment and Settlement Agreement with NanoSynex Ltd. ).

Pursuant to the terms of the NanoSynex Amendment, the Company agreed to advance to NanoSynex an aggregate amount of $1,610,000 as follows: (i) $380,000 within five business days of the execution of the NanoSynex Amendment, (ii) $560,000 on or before November 30, 2023, against which NanoSynex will issue a promissory note to the Company with a face value in the amount of such funding, and (iii) $670,000 on or before March 31, 2024, against which NanoSynex will issue a promissory note to the Company with a face value in the amount of such funding. The NanoSynex Amendment further provides that the initial payment of $380,000 will be satisfied by the Company’s surrender of the 281,000 Preferred B Shares of NanoSynex currently held by the Company, resulting in the Company’s ownership in NanoSynex being reduced from approximately 52.8% to approximately 49.97% of the issued and outstanding voting equity of NanoSynex.

In the event we fail to make any future advances, we have agreed to forfeit additional shares in a number that will be equal to a fraction, the numerator of which is the amount of the default (i.e., the amount that we should have, but failed, to advance to NanoSynex pursuant to the terms of the NanoSynex Amendment), and the denominator of which shall be the price per share that we originally paid in consideration for our Preferred A-1 shares of NanoSynex to the previous holder thereof, being $1.5716 per share.

13 14

To the extent that ~~we raise~~the Company raises additional capital through the sale of equity or convertible debt securities, the ownership interests of ~~our~~its common stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If ~~we raise~~the Company raises additional funds through government or other third-party funding, commercialization, marketing and distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, weit may have to relinquish valuable rights to ~~our~~its technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to ~~us.~~the Company. Additional funding may not be available to the Company on acceptable terms, or at all. In addition, any future financing (depending on the terms and conditions) may be subject to the approval of Alpha Capital, the holder of the Debenture, or trigger certain adjustments to the Debenture or warrants held by Alpha Capital.

~~As a condition to the NanoSynex closing,~~The accompanying financial statements have been prepared assuming that the Company ~~agreed~~will continue as a going concern. The financial statements do not include any adjustments that would be necessary should the Company be unable to ~~provide NanoSynex with up~~continue as a going concern, and therefore, be required to $~~10.4~~ ~~million~~liquidate its assets and discharge its liabilities in other than the normal course of ~~future funding based on NanoSynex’s achievement of certain future development milestones~~business and ~~subject to other terms and conditions described~~at amounts that may differ from those reflected in the Master Agreement for the Operational and Technological Funding of NanoSynex (the “Funding Agreement”) entered into with NanoSynex. These funding commitments are in the form of convertible promissory notes to be issued to the Company with a face value equal to the amount paid by the Company to NanoSynex upon satisfaction of the applicable performance milestone, bearing interest at the rate of 9% per annum on the principal balance from time to time outstanding under the particular promissory note, convertible at the option of the Company into additional shares of NanoSynex in order for the Company to maintain at least a 50.1% controlling ownership interest in NanoSynex, should NanoSynex issue additional shares. The principal of the convertible notes are due and payable upon the sooner to occur of: i) five years from the date of issuance of the particular promissory note; ii) the acquisition by any person or entity of all or substantially all of the share capital of NanoSynex, through share purchase, issuance or shares or merger of NanoSynex, or the purchase of all or substantially all of the assets of NanoSynex; or iii) the initial public offering of NanoSynex. The Company provided funding to NanoSynex of $~~1.5~~ ~~million on July 5, 2022 pursuant to this agreement. The Company may terminate the Funding Agreement after October 29, 2022 upon 120 days’ notice.~~accompanying financial statements

NOTE 3 — ~~ACQUISITION~~

~~Business Combination~~

~~The Company acquired a~~ ~~52.8%~~ ~~voting equity interest in NanoSynex on May 26, 2022 (the “Acquisition Date”) through: (1) the purchase of~~ ~~2,232,861~~ ~~shares Preferred A-1 Stock of NanoSynex for~~ ~~3,500,000~~ ~~shares of the Company’s common stock and a prefunded warrant to purchase~~ ~~3,314,641~~ ~~shares of the Company’s common stock at a purchase price of $0.001~~ ~~per share and, (2) the purchase of~~ ~~381,786~~ ~~shares of Series B preferred stock of NanoSynex from NanoSynex in exchange for $600,000~~.

The acquisition of the majority interest of NanoSynex was accounted for as a business combination using the acquisition method, in accordance with FASB ASC Topic 805. A summary of the consideration transferred and recorded fair value of assets acquired and liabilities assumed in the NanoSynex acquisition is as follows:

~~SCHEDULE OF CONSIDERATION TRANSFERRED~~

Consideration transferred, net of cash acquired
Cash paid for NanoSynex preferred stock: $ 600,000

Purchase of NanoSynex common Stock:
Price per share of Qualigen Stock on May 26, 2022 $ 0.527

FMV of 3,500,000 shares of Qualigen stock issued to Alpha Capital Anstalt $ 1,844,500
FMV of 3,314,641 shares of Qualigen stock related to prefunded warrant issued to Alpha Capital Anstalt $ 1,746,816
Total consideration paid for NanoSynex common stock $ 3,591,316

FMV of consideration related to related to repricing of 70,478 shares of Alpha Capital/Qualigen warrants ^* $ 696

NanoSynex cash acquired (735,354 )
Total consideration transferred, net of cash acquired $ 3,456,658
* ~~See disclosure under~~ ~~Noncompensatory Equity Classified Warrants~~ ~~regarding May 26, 2022 transaction in Note 14 – Stockholders Equity.~~
~~SCHEDULE OF ASSETS ACQUIRED AND LIABILITIES~~
Purchase Price Allocation
Accounts receivable $ 75,336
Property and equipment 120,942
In process R&D 5,700,000
Accounts payable (4,588 )
Accrued expenses and other payables (291,093 )
R&D grant liability (1,362,264 )
Short term debt (941,898 )
Deferred tax liability (736,000 )
Noncontrolling interest assumed (4,000,000 )
Identifiable net assets acquired (1,439,565 )
Goodwill 4,896,223
Total consideration transferred, net of cash acquired $ 3,456,658
The purchase accounting adjustments are preliminary and subject to revision within the measurement period provided by ASC Topic 805. Qualigen transaction costs, which were immaterial, have been expensed as incurred and charged to the Company’s consolidated statements of operations and other comprehensive loss. There was no provision for reimbursement of transaction costs from Qualigen to NanoSynex.
Goodwill represents the excess of the purchase price over the fair value of the net assets acquired as of the acquisition date. Goodwill represents the value of the future technology to be developed in excess of the identifiable assets as well as the operational synergies of the combined companies to be recognized. Goodwill has an indefinite useful life and is not amortized.
~~As a condition to the closing, the Company agreed to provide NanoSynex with up to $10.4~~ million of future funding based on NanoSynex’s achievement of certain future development milestones and subject to other terms and conditions described in the Funding Agreement entered into with NanoSynex (see Note 2 - Liquidity for further details regarding the terms and conditions of the Funding Agreement).
~~The Company’s condensed consolidated statement of operations and other comprehensive loss for the three and six months ended June 30, 2022 includes $8,722~~ ~~of net loss associated with the results of operations of NanoSynex from the Acquisition Date to June 30, 2022.~~
The following pro forma information has been prepared as if the NanoSynex acquisition occurred on January 1, 2021. The following unaudited supplemental pro forma consolidated results do not purport to reflect what the combined Company’s results of operations would have been, nor do they project the future results of operations of the combined company. The unaudited supplemental pro forma consolidated results reflect the historical financial information of Qualigen and NanoSynex, adjusted to give effect to the NanoSynex acquisition as if it had occurred on January 1, 2021, as well as to record NanoSynex stock compensation expense and to record the net loss related to the noncontrolling interest, in accordance with generally accepted accounting principles.:
15
~~SCHEDULE OF PRO FORMA INFORMATION~~
Consolidated Pro Forma Financial Results for the Six Months Ending

June 30,
2022

June 30,
2021

Net revenues $ 2,152,563 $ 3,017,430
Net loss $ (8,722,302 ) $ (10,800,317 )
~~NOTE 4~~ — INVENTORY, NET
Inventory, net consisted of the following at June 30, ~~2022~~2023 and December 31, ~~2021:~~2022:

SCHEDULE OF INVENTORY
June 30,
2022 December 31,
2021 June 30, 2023 December 31, 2022
Raw materials $ 808,815 $ 823,315 $ 1,027,455 $ 949,796
Work in process 327,311 188,135 177,591 200,318
Finished goods 174,087 44,428 358,353 436,183
Total inventory $ 1,310,213 $ 1,055,878 $ 1,563,399 $ 1,586,297

NOTE 54 — PREPAID EXPENSES AND OTHER CURRENT ASSETS
Prepaid expenses and other current assets consisted of the following at June 30, ~~2022~~2023 and December 31, ~~2021:~~2022:
SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS
June 30, December 31,
2022 2021 June 30, 2023 December 31, 2022
Prepaid insurance $ 1,810,413 $ 1,197,726 $ 938,106 $ 1,377,323
Prepaid manufacturing expenses 54,741 67,410 51,710 43,820
Other prepaid expenses 63,229 114,760 65,288 227,451
Prepaid research and development expenses 211,337 —
Other current assets 11,636 12,626
Prepaid expenses and other current assets $ 1,928,383 $ 1,379,896 $ 1,278,077 $ 1,661,220

NOTE 65 — PROPERTY AND EQUIPMENT, NET

Property and equipment, net consisted of the following at June 30, ~~2022~~2023 and December 31, ~~2021:~~2022:
SCHEDULE OF PROPERTY AND EQUIPMENT
June 30, December 31,
2022 2021 June 30, 2023 December 31, 2022
Machinery and equipment $ 2,505,367 $ 2,482,841 $ 2,735,507 $ 2,510,148
Computer equipment 500,488 345,117 369,589 395,836
Leasehold improvements 333,271 333,271 336,916 333,271
Molds and tooling 260,002 260,002 260,002 260,002
Furniture and fixtures 143,013 143,013 144,832 144,832
Equipment held for lease, net 148 296
Equipment held for lease 1,405,384 1,399,444
Property and equipment, gross 3,742,289 3,564,540 5,252,230 5,043,533
Accumulated depreciation (3,412,659 ) (3,360,324 ) (4,678,583 ) (4,623,446 )
Fixed asset impairment (75,000 ) (75,000 )
Property and equipment, net $ 329,630 $ 204,216 $ 498,647 $ 345,087

Depreciation expense relating to property and equipment was approximately $~~24,000~~19,000 and $~~17,000~~24,000 for the three months ended June 30, 2023 and 2022, ~~and 2021,~~ respectively, and $~~48,000~~37,000 and $~~32,000~~48,000 for the six months ended June 30, 2023 and 2022, ~~and 2021,~~ respectively.
16

Upon termination of the Sekisui Distribution Agreement on March 31, 2022, the Company had a commitment to purchase leased FastPack rental systems back from Sekisui at Sekisui’s net book value, which was determined to be approximately $154,000. An assignment agreement was executed by the parties on June 26, 2023 to legally transfer title to this equipment from Sekisui to the Company, and this amount is included in accounts payable at June 30, 2023.
NOTE 76 — GOODWILL, IPR&D AND OTHER INTANGIBLES
SCHEDULE OF GOODWILL AND OTHER ~~INTANGIBLE~~INTANGIBLES
June 30, December 31,
2023 2022
Estimated Useful Lives Gross carrying amounts Gross carrying amounts

Goodwill $ 625,602 $ 625,602

Finite-lived intangible assets:
Developed-product-technology rights 8 - 17 years $ 479,103 $ 479,103
Licensing rights 10 years 418,836 418,836
Less: Accumulated amortization (764,869 ) (752,237 )
Total finite-lived intangible assets, net 133,070 145,702
Indefinite-lived intangible assets:
In-process research and development 5,700,000 5,700,000
Total other intangible assets, net $ 5,833,070 $ 5,845,702
The Company periodically reviews goodwill for impairment in accordance with relevant accounting standards. Goodwill is attributable to the NanoSynex Acquisition. Goodwill and intangible assets are recognized at fair value during the period in which an acquisition is completed, from updated estimates during the measurement period, or when they are considered to be impaired. These non-recurring fair value measurements, primarily for goodwill and intangible assets acquired, were based on Level 3 inputs. The Company estimates the fair value of long-lived assets on a non-recurring basis based on a market valuation approach, engaging independent valuation experts to assist in the determination of fair value. In the fourth quarter of fiscal 2022, in conjunction with the annual impairment assessment, the Company determined that the fair value of the reporting unit was less than the carrying value. In addition to continued losses in the reporting unit, the Company considered macroeconomic conditions including a deterioration in the equity markets evidenced by sustained declines in the Company’s stock price, peer companies, and major market indices since the acquisition date. The Company engaged independent valuation experts to assist in determining the fair value of the reporting unit. As a result of this analysis, the Company recorded a $4,239,000 goodwill and fixed asset impairment charge associated with the reporting unit for fiscal year ended December 31, 2022. There were no impairment losses during the three and six months ended June 30, 2023 and 2022.
June 30, December 31,
2022 2021
Estimated Useful Lives Gross carrying
amounts Gross carrying
amounts

Goodwill (Note 3) $ 4,896,223 $ —

Finite-lived intangible assets:
Developed-product-technology rights 8 - 17 years $ 479,103 $ 479,103
Licensing rights 10 years 418,836 418,836
Less: Accumulated amortization (739,493 ) (726,749 )
Total finite-lived intangible assets, net 158,446 171,190
Indefinite-lived intangible assets:
In-process research and development 5,700,000 —
Total intangible assets, net $ 5,858,446 $ 171,190

The carrying value of the patents of approximately $~~150,000~~131,000 and $~~159,000~~140,000 at June 30, ~~2022~~2023 and December 31, ~~2021,~~2022, respectively, are stated net of accumulated amortization of approximately $~~329,000~~348,000 and $~~320,000~~339,000, respectively. Amortization of patents charged to operations for the three months ended June 30, ~~2022~~2023 and ~~2021~~2022 was approximately $~~5,000~~9,000 and $~~4,000~~5,000 respectively, and for the six months ended June 30, ~~2022~~2023 and ~~2021~~2022 was approximately $9,000and $~~7,000~~9,000, ~~respectively. Total future estimated amortization of patent costs for the five succeeding years is approximately $9,000~~ ~~for the remaining six months in the year ending December 31, 2022, approximately $18,000~~ ~~for year 2023, approximately $15,000~~ ~~for year 2024, approximately $14,000~~ ~~for years 2025, 2026 and 2027.~~respectively.

The carrying value of the in-licenses of approximately $~~9,000~~2,000 and $~~12,000~~5,000 at June 30, ~~2022~~2023 and December 31, ~~2021,~~2022, respectively, are stated net of accumulated amortization of approximately $~~410,000~~417,000 and $~~407,000~~414,000, respectively, andand amortization of licenses charged to ~~operations for~~ both the three months ended June 30, ~~2022~~2023 and ~~2021~~2022 was approximately $~~2,000~~3,000. Amortization of licenses charged to operations for both the six months ended June 30, ~~2022~~2023 and ~~2021~~2022 was approximately $3,000.~~Total~~
On July 20, 2023, the Company entered into a Purchase Agreement with Chembio, Biosynex, S.A. (“Biosynex”), and Qualigen, Inc., a wholly-owned subsidiary of the Company. Pursuant to the Purchase Agreement, the Company agreed to sell to Chembio all of the issued and outstanding shares of common stock of Qualigen, Inc. (see Note 16 - Subsequent Events: Stock Purchase Agreement with Chembio Diagnostics, Inc. and Biosynex, S.A.). Therefore, there is no future estimated amortization of patent and license costs ~~is approximately $4,000~~for the ~~remaining six months in the year ending December 31, 2022, and approximately $5,000~~five ~~for the year ending December 31, 2023.~~succeeding years.
16

NOTE 87 — ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES

Accrued expenses and other current liabilities consisted of the following at June 30, ~~2022~~2023 and December 31, ~~2021:~~2022:
SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES
June 30, December 31,
2022 2021 June 30, 2023 December 31, 2022
Board compensation $ 26,500 $ 17,500 $ 84,000 70,000
Equipment held for lease — 154,433
Franchise, sales and use taxes 20,467 14,090 30,407 27,531
Income taxes 4,356 3,620 6,921 4,663
Interest (Convertible debt - related party) 50,101 2,829
License fees 100,026 150,130
Payroll 101,557 682,036 484,048 209,303
Professional fees 139,551 225,308 368,032 238,211
Research and development 299,288 232,712 523,490 322,987
Royalties 13,900 10,152 16,383 13,158
Vacation 457,022 282,910
Warranty liability 101,103 60,281 140,370 137,568
Other 250,791 265,292 176,777 181,043
Accrued liabilities $ 1,414,535 $ 1,793,901
Accrued expenses and other current liabilities $ 1,980,555 $ 1,511,856

NOTE 98 – SHORT TERM DEBT-RELATED PARTY

NanoSynex has four separate Notes Payable (‘the Notes”) outstanding to Alpha Capital, dated between March 26, 2020 and September 2, 2021, aggregating to a total principal outstanding balance of $905,000, and aggregate accrued interest of $~~34,919~~60,155 for a total outstanding balance of $~~939,919~~965,155 as of June 30, ~~2022.~~2023. The Notes all accrue interest at 2.62% per annum, accrued daily, and provide that the full amount of principal and interest under each Note shall be due immediately prior to a Liquidation Event (the Maturity Date) unless due earlier in accordance with the terms of the Notes. “Liquidation Event” means either i) the merger or consolidation of NanoSynex into any other entity, other than one in control or under control of NanoSynex or NanoSynex’s majority shareholder; ii) a transaction or series of transactions resulting in the transfer of all or substantially all of NanoSynex’s assets or issued and outstanding share capital (other than to a company under the control of NanoSynex or NanoSynex’s majority shareholders; or iii) an underwritten public offering by NanoSynex of its ordinary shares. Notwithstanding the above, if NanoSynex receives subsequent debt, convertible debt, or equity funding with gross proceeds of USD $3,000,000 or more, then the unused portion of these Notes shall be due and payable upon the actual receipt of such funding. On July 20, 2023, the Company entered into an Amendment and Settlement Agreement with NanoSynex Ltd. (the “NanoSynex Amendment”), which amended the Master Funding Agreement for the Operational and Technology Funding of NanoSynex Ltd., dated May 26, 2022, by and between the Company and NanoSynex (the “NanoSynex Funding Agreement”), a majority owned subsidiary of the Company, to, among other things, provide for the further funding of NanoSynex, as contemplated by the NanoSynex Funding Agreement (see Note 16 - Subsequent Events: Amendment and Settlement Agreement with NanoSynex Ltd. ).
17

NOTE 109 – WARRANT LIABILITIES

In 2004, the Company issued warrants to various investors and brokers for the purchase of Series C preferred stock in connection with a private placement (the “Series C Warrants”). The Series C Warrants were subsequently extended and, upon closing of the reverse recapitalization transaction with Ritter, exchanged for warrants to purchase common stock of the Company, pursuant to the Series C Warrant terms as adjusted.

In exchange for the Series C Warrants, upon closing of the merger with Ritter, the holders received warrants to purchase ~~an aggregate of~~ ~~4,713,490~~shares of the Company’s common stock at ~~approximately~~ $~~0.72~~7.195 per share, subject to adjustment. As of June 30, ~~2022, the warrants received in exchange for~~2023, the Series C Warrants have remaining terms ranging from ~~1.4~~.40 to ~~1.9~~.99 years. The ~~warrants~~Series C Warrants were determined to be liability-classified pursuant to the guidance in ASC 480 and ASC 815-40, ~~resulting from~~based on the inclusion of a leveraged ratchet provision for subsequent dilutive issuances. On April 25, 2022, the ~~warrants~~Series C Warrants were repriced from $~~0.7195~~7.195 to $~~0.60~~6.00 with an49,318 additional ~~493,187~~ratchet ~~shares~~Warrants issued, and on May 26, 2022, the ~~warrants~~Series C Warrants were repriced from $~~0.60~~6.00 to $~~0.5136~~5.136 with an49,952 additional ~~499,520~~ratchet ~~shares~~Warrants issued. As a result of these repricings, ~~2,476,251~~247,625 warrants were forfeited and ~~3,468,958~~346,896 warrants were ~~reissued~~reissued. On December 22, 2022, the Series C Warrants were repriced again from $5.136 to $1.32 with 1,002,717 additional ratchet Warrants issued.
Additionally, on December 22, 2022, in conjunction with the issuance of the Debenture to Alpha Capital (see Note 10 – Convertible Debt – Related Party), the Company issued to Alpha Capital a warrant to purchase 2,500,000 shares of the Company’s common stock (the “Alpha Warrant”). The exercise price of the Alpha Warrant is $1.65 (equal to 125% of the conversion price of the Debenture on the closing date). The Alpha Warrant may be exercised by Alpha Capital, in whole or in part, at any time on or after June 22, 2023 and before June 22, 2028, subject to certain terms and conditions described in the ~~current $0.5136~~ ~~exercise price.~~Alpha Warrant, including the Company’s receipt of the necessary stockholder approvals.
17

The following table summarizes the activity in ~~the Common Stock Warrants (received in exchange~~liability classified warrants for the ~~Series C Warrants)~~six months ended June 30, 2023:
SCHEDULE OF WARRANTS ACTIVITY
Common Stock Warrants
Shares Weighted–
Average
Exercise
Price Range of Exercise
Price Weighted–
Average
Remaining Life (Years)
Total outstanding – December 31, 2022 3,849,571 $ 1.53 $1.32 - $1.65 3.9
Exercised — — — —
Forfeited — — — —
Expired — — — —
Granted — — — —
Total outstanding – June 30, 2023 3,849,571 $ 1.53 $1.32 - $1.65 3.41
Exercisable 3,849,571 $ 1.53 $1.32 - $1.65 3.41
The following table summarizes the activity in liability classified warrants for the six months ended June 30, 2022:

~~SCHEDULE OF WARRANTS ACTIVITY~~
Common Stock Warrants (received in exchange for the
Series C Warrants) Common Stock Warrants
Shares Weighted–
Average
Exercise
Price Range of Exercise
Price Weighted–
Average
Remaining Life (Years) Shares Weighted– Average
Exercise
Price Range of Exercise
Price Weighted–
Average
Remaining
Life (Years)
Total outstanding – December 31, 2021 2,481,614 $ 0.72 2.00
Total outstanding –December 31, 2021 248,161 $       7.20 2.00
Exercised (5,363 ) 0.72 (536 ) 7.20
Forfeited (2,476,251 ) 0.72 (247,625 ) 7.20
Expired — — — —
Granted 3,468,958 0.51 346,896 5.10
Total outstanding – June 30, 2022 3,468,958 $ 0.51 346,896 $ 5.10
Exercisable 3,468,958 $ 0.51 $ 0.51 1.51 346,896 $ 5.10 $ 5.10 1.51

~~The following table summarizes the activity in the Common Stock Warrants (received in exchange for the Series C Warrants) activity for the six months ended June 30, 2021:~~
Common Stock Warrants (received in exchange for the
Series C Warrants)
Shares Weighted– Average
Exercise
Price Range of Exercise
Price Weighted–
Average
Remaining
Life (Years)
Total outstanding –December 31, 2020 3,378,596 $ 0.72
Exercised (542,737 ) 0.72
Forfeited (36,097 ) 0.72
Expired — —
Granted — —
Total outstanding – June 30, 2021 2,799,762 $ 0.72
Exercisable 2,799,762 $ 0.72 $ 0.72 2.5
18
The following table presents the Company’s fair value hierarchy for its ~~warrant~~ liabilities ~~and exercises (all of which arise under the warrants received in exchange for the Series C Warrants)~~ measured at fair value on a recurring basis ~~using Level 3 inputs~~ as of June 30, ~~2022:~~2023:

SCHEDULE OF FAIR VALUE HIERARCHY FOR WARRANT LIABILITIES
Quoted Quoted
Market Significant Market Significant
Prices for Other Significant Prices for Other Significant
Identical Observable Unobservable Identical Observable Unobservable
Assets Inputs Inputs Assets Inputs Inputs
Common Stock Warrant liabilities (Level 1) (Level 2) (Level 3) Total (Level 1) (Level 2) (Level 3) Total
Balance as of December 31, 2021 $ — $ — $ 1,686,200 $ 1,686,200
Balance as of December 31, 2022 $ — $     — $ 3,622,647 $ 3,622,647
Exercises — — (858 ) (858 ) — — — —
Gain on change in fair value of warrant liabilities — — (698,042 ) (698,042 ) — — (1,478,967 ) (1,478,967 )
Balance as of June 30, 2022 $ — $ — $ 987,300 $ 987,300
Balance as of June 30, 2023 $ — $ — $ 2,143,680 $ 2,143,680

There were no transfers of financial assets or liabilities between category levels for the three and six months ended June 30, ~~2022.~~2023.

The value of the warrant liabilities was based on a valuation received from an independent valuation firm determined using a Monte-Carlo simulation. For volatility, the Company considers comparable public companies as a basis for its expected volatility to calculate the fair value of common stock warrants and transitions to its own volatility as the Company develops sufficient appropriate history as a public company. The risk-free interest rate is based on U.S. Treasury notes with a term approximating the expected term of the common stock warrant. The Company uses an expected dividend yield of zero based on the fact that the Company has never paid cash dividends and does not expect to pay cash dividends in the foreseeable future. Any significant changes in the inputs may result in significantly higher or lower fair value measurements.
18

The following ~~table shows~~are the weighted average and the range of assumptions used in estimating the fair value of warrant liabilities (weighted average calculated based on the number of outstanding warrants on each issuance) as of June 30, ~~2022~~2023 and ~~2021:~~2022:

SCHEDULE OF ASSUMPTIONS OF WARRANT LIABILITIES
June 30, 2022 June 30, 2021 June 30, 2023 June 30, 2022
Range Weighted
Average Range Weighted
Average Range Weighted
Average Range Weighted
Average
Risk-free interest rate 2.80% — 2.87 % 2.82 % 0.34% — 0.46 % 0.103 % 4.05% — 5.31% 4.49 % 2.80% — 2.87% 2.82 %
Expected volatility (peer group) 74% — 96 % 78.6 % 82% — 83 % 82.83 % 66.3% — 134% 110.55 % 74% — 96% 78.6 %
Term of warrants (in years) 1.39 — 1.99 1.51 2.41 — 2.99 2.5 .39 — 4.98 3.41 1.39 — 1.99 1.51
Expected dividend yield 0.00 % 0.00 % 0.00 % 0.00 % 0.00 % 0.00 % 0.00 % 0.00 %

NOTE 10 — CONVERTIBLE DEBT- RELATED PARTY
On December 22, 2022, the Company issued to Alpha Capital, an 8% Senior Convertible Debenture in the aggregate principal amount of $3,300,000 for a purchase price of $3,000,000 pursuant to the terms of a Securities Purchase Agreement, dated December 21, 2022. The Debenture is convertible, at any time, and from time to time, at Alpha Capital’s option, into shares of common stock of the Company (the “Conversion Shares”), at a price equal to $1.32 per share, subject to adjustment as described in the Debenture (the “Conversion Price”) and other terms and conditions described in the Debenture, including the Company’s receipt of the necessary stockholder approvals. Additionally, on December 22, 2022, the Company issued to Alpha Capital a liability classified warrant to purchase 2,500,000 shares of the Company’s common stock (see Note 9 - Warrant Liabilities). The exercise price of the Alpha Warrant is $1.65 (equal to 125% of the Conversion Price of the Debenture on the closing date). The Alpha Warrant may be exercised by Alpha Capital, in whole or in part, at any time on or after June 22, 2023 and before June 22, 2028, subject to certain terms and conditions described in the Alpha Warrant, including the Company’s receipt of the necessary stockholder approvals, which the Company obtained at its 2023 annual meeting of stockholders.
The proceeds from the transaction are being used to advance the Company’s QN-302 Investigative New Drug candidate towards clinical trials and other working capital purposes.
Commencing June 1, 2023 and continuing on the first day of each month thereafter until the earlier of (i) December 22, 2025 and (ii) the full redemption of the Debenture (each such date, a “Monthly Redemption Date”), the Company will redeem $110,000 plus accrued but unpaid interest, liquidated damages and any amounts then owing under the Debenture (the “Monthly Redemption Amount”). The Monthly Redemption Amount will be paid in cash; provided that after the first two monthly redemptions, the Company may elect to pay all or a portion of a Monthly Redemption Amount in shares of common stock of the Company, based on a Conversion Price equal to the lesser of (i) the then Conversion Price of the Debenture and (ii) 85% of the average of the VWAPs (as defined in the Debenture) for the five consecutive trading days ending on the trading day that is immediately prior to the applicable Monthly Redemption Date. The Company may also redeem some or all of the then outstanding principal amount of the Debenture at any time for cash in an amount equal to 105% of the then outstanding principal amount of the Debenture being redeemed plus accrued but unpaid interest, liquidated damages and any amounts then owing under the Debenture. The Company’s election to pay monthly redemptions in Conversion Shares or to effect an optional redemption is subject to the satisfaction of the Equity Conditions (as defined in the Debenture), including the Company’s receipt of the necessary stockholder approvals, which the Company obtained at its 2023 annual meeting of stockholders.
The Debenture accrues interest at the rate of 8% per annum, which does not begin accruing until December 1, 2023, and will be payable on a quarterly basis. Interest may be paid in cash or shares of common stock of the Company or a combination thereof at the option of the Company; provided that interest may only be paid in shares if the Equity Conditions have been satisfied, including the Company’s receipt of the necessary stockholder approvals, which the Company obtained at its 2023 annual meeting of stockholders.
Both the Debenture and the Alpha Warrant provide for adjustments to the Conversion Price and exercise price, respectively, in connection with stock dividends and splits, subsequent equity sales and rights offerings, pro rata distributions, and certain fundamental transactions. Both the Debenture and the Alpha Warrant include a beneficial ownership blocker of 9.99%, which may only be waived by Alpha Capital upon 61 days’ notice to the Company.
The Company filed a registration statement on Form S-3 (No. 333-269088) with the Securities and Exchange Commission on December 30, 2022 registering the resale by Alpha Capital of an aggregate of 5,157,087 shares of the Company’s common stock, which may be issuable to Alpha Capital pursuant to the terms of the Debenture and the Alpha Warrant.
The Company evaluated the Debenture and the Alpha Warrant and determined that the Alpha Warrant is a freestanding financial instrument. The Alpha Warrant is not considered indexed to the Company’s own stock, because the settlement amount would not equal the difference between the fair value of a fixed number of the Company’s equity shares and a fixed strike price and all of the adjustment features in Section 3(b) of the warrant agreement are not down round provisions, as defined in ASU 2017-11. Accordingly, the Alpha Warrant is classified as a liability and recognized at fair value, with subsequent changes in fair value recognized in earnings.
19
The proceeds from the Debenture were allocated to the initial fair value of the Alpha Warrant, with the residual balance allocated to the initial carrying value of the Debenture. The Company has not elected the fair value option for the Debenture. The Debenture was recognized as proceeds received after allocating the proceeds to the Alpha Warrant, and then allocating remaining proceeds to a suite of bifurcated embedded derivative features (conversion option, contingent acceleration upon an Event of Default, and contingent interest upon an Event of Default), with the resulting difference, if any, allocated to the loan host instrument. The suite of derivative features was measured and determined to have no fair value.
The original issue discount of $0.3 million, the initial fair value of the Warrant of $2.8 million, the initial fair value of the suite of bifurcated embedded derivative features of $0, and the fees and costs paid to Alpha Capital and other third parties of $0.1 million comprised the debt discount upon issuance. The debt discount is amortized to interest expense over the expected term of the Debenture using the effective interest method, in accordance with ASC 835-30. The debt host instrument of the Debenture will subsequently be measured at amortized cost using the effective interest method to accrete interest over its term to bring the Debenture’s initial carrying value to the principal balance at maturity.
Between January 9 and 12, 2023, the Company issued 841,726 shares of common stock upon Alpha Capital’s partial conversion of the Debenture at $1.32 per share for a total of $1,111,078 principal. Upon conversion, the Company recognized a loss on conversion of convertible debt of approximately $1.1 million, recorded to other expenses in the condensed consolidated statements of operations. During the three and six months ended June 30, 2023, the Company recorded accrued interest of approximately $383,000 and $945,000, respectively (of which approximately $364,000 and $898,000 was attributable to discount amortization, respectively) in other expenses in the condensed consolidated statements of operations. As of June 30, 2023, the fair value of the Alpha Warrant was approximately $2.0 million, and the fair value of the suite of bifurcated embedded derivative features was $0.
Convertible debt-related party is comprised of the following as of June 30, 2023 and December 31, 2022:
SCHEDULE OF SENIOR SECURED CONVERTIBLE DEBT
June 30, 2023 December 31, 2022
Senior secured convertible debenture $ 2,078,922 $ 3,300,000
Discount on convertible debenture (1,266,503 ) (3,239,803 )
Total convertible debt-related party $ 812,419 $ 60,197
As of June 30, 2023, there were no events of default or violation of any covenants under our financing obligations.
NOTE 11 — ~~LOSS~~EARNINGS (LOSS) PER SHARE

Basic loss per share (“EPS”) is computed by dividing net loss by the weighted-average number of common shares outstanding. Diluted EPS is computed based on the sum of the weighted-average number of common shares and potentially dilutive common shares outstanding during the period. Potentially dilutive common shares consist of shares issuable from stock options and warrants.

19
~~The following table reconciles net loss and the weighted-average shares used in computing basic and diluted EPS in the respective periods:~~
~~SCHEDULE OF EARNINGS PER SHARE BASIC AND DILUTED~~

For the Three Months Ended
June 30, For the Three Months Ended
June 30, For the Six Months Ended
June 30, For the Six Months Ended
June 30,
2022 2021 2022 2021

Net loss used for basic earnings per share $ (4,123,404 ) $ (5,398,077 ) $ (8,443,191 ) $ (10,640,796 )

Basic weighted-average common shares outstanding 36,680,156 28,850,451 35,990,933 28,510,014
Dilutive potential shares issuable from stock options and warrants — �� — — —
Diluted weighted-average common shares outstanding 36,680,156 28,850,451 35,990,933 28,510,014

The following potentially dilutive securities have been excluded from diluted net loss per share as of June 30, ~~2022~~2023 and ~~2021~~2022 because their effect would be ~~antidilutive:~~anti-dilutive:
SCHEDULE OF DILUTIVE SECURITIES EXCLUDED FROM DILUTED NET LOSS PER SHARE
As of June 30, As of June 30, As of June 30,
2022 2021 2023 2022
Shares of common stock subject to outstanding options 4,767,834 4,133,856 445,163 476,783
Shares of common stock subject to outstanding warrants 14,123,380 9,540,187 4,119,934 1,412,338
Shares of common stock subject to conversion of Series Alpha Convertible Preferred Stock — 243,418
Total common stock equivalents 18,891,214 13,917,461 4,565,097 1,889,121

NOTE 12 — COMMITMENTS AND CONTINGENCIES

Leases

The Company leases its facilities under a long-term operating lease agreement. On December 15, 2021, our wholly-owned subsidiary Qualigen, Inc. entered into a Second Amendment to Lease with Bond Ranch LP. This Amendment extended the Company’s triple-net leasehold on the Company’s existing 22,624-square-feet headquarters/manufacturing facility at 2042 Corte del Nogal, Carlsbad, California for the 61-month period of November 1, 2022 to November 30, 2027. Over the 61 months, the base rent payable by Qualigen, Inc. will total $1,950,710; however, the base rent for the first 12 months of the ~~61-month~~61-month period will be only $335,966. Additionally, under the Second Amendment to Lease, Qualigen, Inc. is entitled to a $339,360 tenant improvement allowance.

The tables below show the operating lease right-of-use assets and operating lease liabilities as of June 30, ~~2022,~~2023, including the changes during the periods:

SCHEDULE OF OPERATING LEASE RIGHT OF USE ASSETS AND OPERATING LEASE LIABILITIES
Operating lease right-of-use assets
Net right-of-use assets at December 31, 2021 $ 1,645,568
Less amortization of operating lease right-of-use assets (109,804 )
Operating lease right-of-use assets at June 30, 2022 $ 1,535,764
Operating lease right-of-use assets
Net right-of-use assets at December 31, 2022 $ 1,422,538
Less amortization of operating lease right-of-use assets (116,568 )
Operating lease right-of-use assets at June 30, 2023 $ 1,305,970

Operating lease liabilities
Lease liabilities at December 31, 2021 $ 1,676,655
Less principal payments on operating lease liabilities (73,408 )
Lease liabilities at June 30, 2022 1,603,247
Less non-current portion (1,425,808 )
Current portion at June 30, 2022 $ 177,439
Operating lease liabilities
Lease liabilities at December 31, 2022 $ 1,542,564
Less principal payments on operating lease liabilities (116,756 )
Lease liabilities at June 30, 2023 1,425,808
Less non-current portion (1,168,653 )
Current portion at June 30, 2023 $ 257,155

As of June 30, ~~2022,~~2023, the Company’s operating leases have a weighted-average remaining lease term of ~~5.4~~4.3 years and a weighted-average discount rate of 8.9%.

20
As of June 30, ~~2022,~~2023, future minimum payments during the next five fiscal years and thereafter are as follows:

SCHEDULE OF MATURITIES OF OPERATING LEASE LIABILITIES
Year Ending December 31, Amount Amount
2022 (six months) $ 277,192
2023 368,341
2023 (six months) 184,171
2024 379,392 379,392
2025 390,773 390,773
2026 402,497 402,497
2027 379,165 379,164
Total 2,197,360 1,735,997
Less present value discount (594,113 ) (310,189 )
Operating lease liabilities $ 1,603,247 $ 1,425,808

Total lease expense was approximately $~~119,000~~114,000 and $~~86,000~~119,000 for the three months ended June 30, ~~2022~~2023 and ~~2021,~~2022, respectively, and approximately $~~233,000~~230,000 and $~~172,000~~233,000, respectively, for the six months ended June 30, ~~2022~~2023 and ~~2021.~~2022. Lease expense was recorded in cost of product sales, general and administrative expenses, research and development and sales and marketing expenses.

21
~~Termination of Sekisui Distribution Agreement~~
~~In March 2018,~~On July 20, 2023, the Company ~~extended a strategic partnership~~ entered into ~~in May 2016~~a Purchase Agreement with ~~Sekisui Diagnostics, LLC~~Chembio, Biosynex, S.A. (“~~Sekisui”~~Biosynex”)~~. The Company appointed Sekisui as its diagnostics commercial partner~~, and ~~exclusive worldwide distributor with~~Qualigen, Inc., a wholly-owned subsidiary of the ~~exception of certain customer accounts retained by Qualigen; Sekisui’s distribution arrangement expired on March 31, 2022. Subsequent~~Company. Pursuant to the ~~expiration~~Purchase Agreement, the Company agreed to sell to Chembio all of the ~~agreement,~~issued and outstanding shares of common stock of Qualigen, Inc. The lease commitments described above transferred to Chembio upon the ~~Company has a commitment to purchase leased FastPack rental systems back from Sekisui at Sekisui’s net book value, the amount~~closing of ~~which has not yet been determined.~~this transaction. (see Note 16 - Subsequent Events: Stock Purchase Agreement with Chembio Diagnostics, Inc. and Biosynex, S.A. ).

NanoSynex Funding Commitment

AsOn July 20, 2023, the Company entered into an Amendment and Settlement Agreement with NanoSynex Ltd. (the “NanoSynex Amendment”), which amended the Master Funding Agreement for the Operational and Technology Funding of NanoSynex Ltd., dated May 26, 2022, by and between the Company and NanoSynex (the “NanoSynex Funding Agreement”), a ~~condition~~majority owned subsidiary of the Company, to, among other things, provide for the further funding of NanoSynex, as contemplated by the NanoSynex Funding Agreement (see Note 16 - Subsequent Events: Amendment and Settlement Agreement with NanoSynex Ltd. ).
Pursuant to the ~~closing,~~terms of the NanoSynex Amendment, the Company agreed to ~~provide~~advance to NanoSynex an aggregate amount of $1,610,000 as follows: (i) $380,000 within five business days of the execution of the NanoSynex Amendment, (ii) $560,000 on or before November 30, 2023, against which NanoSynex will issue a promissory note to the Company with upa face value in the amount of such funding, and (iii) $670,000 on or before March 31, 2024, against which NanoSynex will issue a promissory note to the Company with a face value in the amount of such funding. The NanoSynex Amendment further provides that the initial payment of $380,000 will be satisfied by the Company’s surrender of the 281,000 Preferred B Shares of NanoSynex currently held by the Company, resulting in the Company’s ownership in NanoSynex being reduced from approximately 52.8% to approximately 49.97% of the issued and outstanding voting equity of NanoSynex.
In the event we fail to make any future advances, we have agreed to forfeit additional shares in a number that will be equal to a fraction, the numerator of which is the amount of the default (i.e., the amount that we should have, but failed, to advance to NanoSynex pursuant to the terms of the NanoSynex Amendment), and the denominator of which shall be the price per share that we originally paid in consideration for our Preferred A-1 shares of NanoSynex to the previous holder thereof, being $~~10.4~~1.5716 ~~million of future funding based on NanoSynex’s achievement of certain future development milestones and subject to other terms and conditions~~per share.
The Nanosynex Amendment supersedes any payments contemplated by the Original Nanosynex Agreement, such that except as described in the ~~Funding~~Nanosynex Amendment, the Company will have no further payment obligations to NanoSynex under the Original Nanosynex Agreement ~~entered into with NanoSynex (see Note 2 – Liquidity~~or otherwise (including by way of equity investment, loan financing or credit lines), and Nanosynex will have no further payment obligations to the Company for ~~further details regarding~~advances previously received under the ~~terms and conditions of the Funding Agreement).~~Original Nanosynex Agreement.

Litigation and Other Legal Proceedings

On November 9, 2021, the Company was named as a defendant in an action brought by Mediant Communications Inc. (“Mediant”) in the U.S. District Court for the Southern District of New York. The complaint alleged that Qualigen entered into an implied contract with Mediant, whereby Qualigen retained Mediant to distribute proxy materials and subsequently conduct shareholder vote tabulations. The Company filed a Motion to Dismiss with the District Court and on March 14, 2022 a hearing was held during which the presiding judge ruled in favor of the Motion to Dismiss. The Company and Mediant settled the litigation on April 5, 2022 in the amount of $96,558, at which time the amount was paid.
NOTE 13 — RESEARCH AND LICENSE AGREEMENTS

The University of Louisville Research Foundation

Between June 2018 and April 2022, the Company entered into license and sponsored research agreements with the University of Louisville Research Foundation (“ULRF”) for QN-247, a novel aptamer-based compound that has shown promise as an anticancer drug. Under the agreements, the Company ~~will take~~took over development, regulatory approval and commercialization of the compound from ULRF and is responsible for maintenance of the related intellectual property portfolio. In return, ULRF received a $50,000 convertible promissory note in payment of an upfront license fee, which was subsequently converted into the Company’s common stock, and the Company agreed to reimburse ULRF for sponsored research expenses of up to approximately $805,000 and prior patent costs of up to $200,000.In addition, the Company agreed to pay ULRF (i) royalties, on patent-covered net sales associated with the commercialization of anti-nucleolin agent-conjugated nanoparticles, of 4% (on net sales up to a cumulative $250,000,000) or 5% (on net sales above a cumulative $250,000,000), until expiration of the last to expire of the licensed patents, (ii) 30% to 50% of any non-royalty sublicensee income received (50% for sublicenses granted in the first two years of the ULRF license agreement, 40% for sublicenses granted in the third or fourth years of the ULRF license agreement, and 30% for sublicenses granted in the fifth year of the ULRF license agreement or thereafter), (iii) reimbursements for ongoing costs associated with the preparation, filing, prosecution and maintenance of licensed patents, incurred prior to June 2018, and (iv) payments ranging from $100,000 to $5,000,000 upon the achievement of certain regulatory and commercial ~~milestones~~milestones.. Milestone payments for the first therapeutic indication would be $100,000 for first dosing in a Phase 1 clinical trial, $200,000 for first dosing in a Phase 2 clinical trial, $350,000 for first dosing in a Phase 3 clinical trial, $500,000for regulatory marketing approval and $5,000,000 upon achieving a cumulative $500,000,000 of Licensed Product ~~sales; the~~sales. The Company ~~would~~ also agreed to pay another $500,000 milestone payment for any additional regulatory marketing approval for each additional therapeutic (or diagnostic) indication. The Company must also ~~must~~ pay ULRF shortfall payments if the total amounts actually paid with respect to royalties and non-royalty sublicensee income for any year is less than the applicable annual minimum (ranging from $10,000 to $50,000) for such year.

21
Sponsored research expenses related to these agreements for the three months ended June 30, ~~2022~~2023 and ~~2021~~2022 were approximately $~~77,000~~0 and $~~89,000~~77,000, respectively, and for the six months ended June 30, ~~2022~~2023 and ~~2021~~2022 were approximately $~~164,000~~0 and $~~152,000~~164,000, respectively, and these amounts are recorded in research and development expenses in the condensed consolidated statements of operations and other comprehensive loss. License costs were approximately $~~14,000~~1,000 and $~~17,000~~14,000 related to these agreements for the three months ended June 30, ~~2022~~2023 and ~~2021,~~2022, respectively, and approximately $~~69,000~~22,000 and $~~53,000~~69,000 related to these agreements for the six months ended June 30, ~~2022~~2023 and ~~2021,~~2022, respectively, and are included in research and development expenses in the condensed consolidated statements of operations and other comprehensive loss.
22

In March 2019, the Company entered into a sponsored research agreement and an option for a license agreement with ULRF for development of several small-molecule RAS interaction inhibitor drug candidates. Under the terms of this agreement, the Company agreed to reimburse ULRF for sponsored research expenses of up to $693,000 for this program. In February 2021 and March 2022, the Company extended the term of this agreement until January 2023 and increased the amount that the Company will reimburse ULRF for sponsored research expenses to approximately $2.7 million. In July 2020, the Company entered into an exclusive license agreement with ULRF for RAS interaction inhibitor drug candidates. Under the agreement, the Company took over development, regulatory approval and commercialization of the candidates from ULRF and is responsible for maintenance of the related intellectual property portfolio. In return, ULRF received approximately $112,000 for an upfront license fee and reimbursement of prior patent costs. In addition, the Company has agreed to pay ULRF (i) royalties, on patent-covered net sales associated with the commercialization, of 4% (on net sales up to a cumulative $250,000,000) or 5% (on net sales above a cumulative $250,000,000), until expiration of the licensed patent, and 2.5% (on net sales for any sales not covered by Licensed Patents), (ii) 30% to 50% of any non-royalty sublicensee income received (50% for sublicenses granted in the first two years of the ULRF license agreement, 40% for sublicenses granted in the third or fourth years of the ULRF license agreement, and 30% for sublicenses granted in the fifth year of the ULRF license agreement or thereafter), (iii) reimbursements for ongoing costs associated with the preparation, filing, prosecution and maintenance of licensed patents, incurred prior to July 2020, and (iv) payments ranging from $50,000 to $5,000,000 upon the achievement of certain regulatory and commercial ~~milestones~~.milestones. Milestone payments for the first therapeutic indication would be $50,000 for first dosing in a Phase 1 clinical trial, $100,000 for first dosing in a Phase 2 clinical trial, $150,000 for first dosing in a Phase 3 clinical trial, $300,000 for regulatory marketing approval and $5,000,000upon achieving a cumulative $500,000,000 of Licensed Product sales. The Company also must pay ULRF shortfall payments if the total amounts actually paid with respect to royalties and non-royalty sublicensee income for any year is less than the applicable annual minimum (ranging from $20,000 to $100,000) for such year.

Sponsored research expenses related to these agreements for the three months ended June 30, ~~2022~~2023 and ~~2021~~2022 were approximately $~~220,000~~333,000 and $~~99,000~~220,000, respectively, and for the six months ended June 30, ~~2022~~2023 and ~~2021~~2022 were approximately $~~405,000~~556,000 and $~~206,000~~405,000, respectively, and are recorded in research and development expenses in the condensed consolidated statements of operations and other comprehensive loss. License costs related to these agreements for the three months ended June 30, ~~2022~~2023 and ~~2021~~2022 were approximately $~~16,000~~15,000 and $016,000, respectively, and for the six months ended June 30, ~~2022~~2023 and ~~2021~~2022 were approximately $~~18,000~~29,000 and $~~40,000~~18,000, respectively, and are included in research and development expenses in the condensed consolidated statements of operations and other comprehensive loss.

In June 2020, the Company entered into an exclusive license agreement with ULRF for its intellectual property in the use of QN-165 as a treatment for COVID-19. Under the agreement, the Company took over development, regulatory approval and commercialization of the compound (for such use) from ULRF and is responsible for maintenance of the related intellectual property portfolio. In return, ULRF received approximately $24,000 for an upfront license fee and reimbursement of prior patent costs. In addition, the Company was required to enter into a separate sponsored research agreement with ULRF (for QN-165 as a treatment for COVID-19) for at least $250,000. In November 2020, the Company executed a sponsored research agreement with ULRF (for QN-165 as a treatment for COVID-19) supporting up to approximately $430,000 in research which satisfied this requirement. This sponsored research agreement expired in November 2021.

In addition, under the exclusive license agreement the Company ~~has~~ agreed to pay ULRF (i) royalties, on patent-covered net sales associated with the commercialization of QN-165 as a treatment for COVID-19, of 4% (on net sales up to a cumulative $250,000,000) or 5% (on net sales above a cumulative $250,000,000), until expiration of the licensed patents, and 2.5% (on net sales for any sales not covered by Licensed Patents), (ii) 30% to 50% of any non-royalty sublicensee income received (50% for sublicenses granted in the first two years of the ULRF license agreement, 40% for sublicenses granted in the third or fourth years of the ULRF license agreement, and 30% for sublicenses granted in the fifth year of the ULRF license agreement or thereafter), (iii) reimbursements for ongoing costs associated with the preparation, filing, prosecution and maintenance of licensed patents, incurred prior to June 2020, and (iv) payments ranging from $50,000 to $5,000,000 upon the achievement of certain regulatory and commercial ~~milestones~~milestones.. Milestone payments would be $50,000 for first dosing in a Phase 1 clinical trial, $100,000 for first dosing in a Phase 2 clinical trial, $150,000 for first dosing in a Phase 3 clinical trial, $300,000 for regulatory marketing approval and $5,000,000 upon achieving a cumulative $500,000,000 of Licensed Product sales. The Company must also ~~must~~ pay ULRF shortfall payments if the total amounts actually paid with respect to royalties and non-royalty sublicensee income for any year is less than the applicable annual minimum (ranging from $5,000 to $50,000) for such year.

22
~~Sponsored~~There were no sponsored research expenses ~~related to these agreements for the three months ended June 30, 2022 and 2021 were $~~0 ~~and approximately $25,000, respectively, and for the six months ended June 30, 2022 and 2021 were $~~0 ~~and $94,000, respectively, and are recorded in research and development expenses in the condensed consolidated statements of operations and other comprehensive loss. License~~or license costs related to these agreements for the three months ended June 30, 2023 and 2022, ~~and 2021 were $~~0 ~~and $16,000, respectively, and~~or for the six months ended June 30, ~~2022~~2023 and ~~2021 were $~~0 ~~and $16,000, respectively.~~
~~Advanced Cancer Therapeutics~~
In December 2018, the Company entered into a license agreement with Advanced Cancer Therapeutics, LLC (“ACT”), granting the Company exclusive rights to develop and commercialize QN-165, an aptamer-based drug candidate. In return, ACT received a $~~25,000~~ ~~convertible promissory note in payment of an upfront license fee, which was subsequently converted into the Company’s common stock.~~ In addition, the Company agreed to pay ACT (i) royalties, on net sales associated with the commercialization of QN-165, of 2% (only if patent-covered and only on net sales above a cumulative $3,000,000) or 1% (if not patent-covered, but only on net sales above a cumulative $3,000,000), until the 15th anniversary of the ACT license agreement and (ii) milestone payments of $100,000 for the Company raising a cumulative total of $2,000,000 in new equity financing after the date of the ACT license agreement, $100,000 upon any first QN-165-based licensed product receiving the CE Mark or similar FDA status, and $500,000 upon cumulative worldwide QN-165-based licensed product net sales reaching $3,000,000. ~~For the three months ended June 30, 2022 and 2021, there were~~ 0 ~~license costs, and for the six months ended June 30, 2022 and 2021, there were $~~0 ~~and approximately $2,000~~, ~~respectively, related to this agreement which are included in research and development expenses in the condensed consolidated statements of operations and other comprehensive loss.~~
~~Prediction Biosciences~~
In November 2015, the Company entered into a long-term development and supply agreement with Prediction Biosciences SAS to develop and manufacture diagnostic tests for use in the stroke point-of-care market. The Company recognizes development revenue and product sales over the performance period of the contract. For both the three and six months ended June 30, 2022 and 2021, there was 0 ~~collaborative research revenue related to this agreement.~~
~~Sekisui Diagnostics~~
In March 2018, the Company extended a strategic partnership entered into in May 2016 with Sekisui. The Company appointed Sekisui as its diagnostics commercial partner and exclusive worldwide distributor with the exception of certain customer accounts retained by Qualigen. Sekisui’s distribution arrangement expired on March 31, 2022.

~~Under the terms of the arrangement, there were product sales to Sekisui of $~~0 ~~and approximately $701,000, respectively, for the three months ended June 30, 2022 and 2021, and approximately $403,000~~ ~~and $1.72~~ ~~million, respectively, for the six months ended June 30, 2022 and 2021.~~
23

Yi Xin

In October 2020, through its wholly-owned diagnostics subsidiary Qualigen, Inc., the Company entered into a Technology Transfer Agreement with Yi Xin Zhen Duan Jishu (Suzhou) Ltd. (“Yi Xin”), of Suzhou, China, for Yi Xin to develop, manufacture and sell new generations of diagnostic test systems based on the Company’s core FastPack technology. In addition, the Technology Transfer Agreement ~~authorized~~authorizes Yi Xin to manufacture and sell the Company’s current generations of FastPack System diagnostic products (1.0, IP and PRO) in China.

The Company will receive low- to mid-single-digit royalties on any future new-generations and current-generations product sales by Yi Xin. ~~The Company~~Under the Technology Transfer Agreement, during the fiscal year ended December 31, 2021 we recognized $0 ~~and~~revenues of approximately $~~38,000~~670,000. There were no ~~in product sales and $~~0 ~~and approximately $479,000~~ ~~in license revenue included in the statement of operations~~revenues under this agreement for the three months ended June 30, ~~2022~~2023, and ~~2021, respectively.~~the three months ended June 30, 2022. The Company provided technology transfer and patent/know-how license rights to facilitate Yi Xin’s development and commercialization.

The Company gave Yi Xin the exclusive rights for China, – which is a market ~~the Company~~it has not otherwise entered, – both for Yi Xin’s new generations of FastPack-based products and for Yi Xin-manufactured versions of ~~the Company’s~~our existing FastPack product lines. Yi Xin ~~will~~ also ~~have~~has the right to sell its new generations of FastPack-based diagnostic test systems throughout the world (but not to or toward current customers of the Company’s existing generations of FastPack products). After March 31, 2022, Yi Xin has the right to sell Yi Xin-manufactured versions of existing FastPack 1.0, IP and PRO product lines worldwide (other than in the United States and other than to or toward current ~~non-U.S.~~non-US customers of those products), as well as the right to buy ~~Company-manufactured~~Qualigen-manufactured FastPack 1.0, IP and PRO products from ~~the Company~~us at distributor prices for resale in and for the United States (but not to or toward current U.S. customers of those products)~~; the~~. The Company did not license Yi Xin to sell in the ~~United States~~U.S. market any Yi Xin-manufactured versions of those legacy FastPack 1.0, IP and PRO product lines. In the Technology Transfer Agreement the Company also confirmed that ~~it would not,~~ after March 31, 2022 it would not seek new FastPack customers outside the United ~~States.~~
23
~~STA Pharmaceutical~~States, European Union, Canada and Mexico.

~~In November 2020,~~On July 20, 2023, the Company entered into a ~~contract~~Purchase Agreement with ~~STA Pharmaceutical Co.~~Chembio, Biosynex, S.A. (“Biosynex”), ~~Ltd.~~and Qualigen, Inc., a wholly-owned subsidiary of ~~WuXi AppTec, for GMP production~~the Company. Pursuant to the Purchase Agreement, the Company agreed to sell to Chembio all of ~~QN-165, which was~~ the ~~Company’s lead drug candidate for~~issued and outstanding shares of common stock of Qualigen, Inc. The Technology Transfer Agreement with Yi Xin described above transferred to Chembio upon the ~~treatment~~closing of ~~COVID-19~~this transaction. See Note 16 - Subsequent Events: Stock Purchase Agreement with Chembio Diagnostics, Inc. and ~~other viral diseases, for potential clinical trials in 2021.~~
~~Research and development expenses related~~ Biosynex, S.A. to ~~this agreement for the three months ended June 30, 2022 and 2021 were $~~0 ~~and $1.9~~ ~~million, respectively,~~ ~~and for the six months ended June 30, 2022 and 2021 were~~ ~~approximately $9,000~~ ~~and $3.1~~ ~~million, respectively, and are recorded in research and development expenses in the~~our unaudited condensed consolidated financial statements ~~of operations and other comprehensive loss.~~for additional details.
UCL Business Limited

In January 2022, the Company entered into a License Agreement with UCL Business Limited to obtain an exclusive worldwide in-license of a genomic quadruplex (G4)-selective transcription inhibitor drug development program which had been developed at University College London, including lead and back-up compounds, preclinical data and a patent estate. (UCL Business Limited is the commercialization company for University College London.) The program’s lead compound is now being developed at Qualigen under the name QN-302 as a candidate for treatment for pancreatic ductal adenocarcinoma (PDAC), which represents the vast majority of pancreatic cancers. The License Agreement required a $150,000 upfront payment, reimbursement of past patent prosecution expenses (approximately $160,000), and (if and when applicable) tiered royalty payments in the low to mid-single digits, clinical/regulatory/sales milestone payments and a percentage of any non-royalty sublicensing consideration paid to Qualigen.

For both the three months ended June 30, ~~2022~~2023 and ~~2021,~~2022, there were license costs of $0, and forfor the six months ended June 30, ~~2022~~2023 and ~~2021~~2022, there were license costs of approximately $~~310,000~~0 and $0310,000, ~~respectively,~~respectively, related to this agreement which are included in research and development expenses in the condensed consolidated statements of operations and other comprehensive loss.
Prediction Biosciences
In November 2015, the Company entered into a long-term development and supply agreement with Prediction Biosciences SAS to develop and manufacture diagnostic tests for use in the stroke Physician Office Laboratory (POL) market. The Company recognizes development revenue and product sales over the performance period of the contract. Product sales related to this agreement for the three months ended June 30, 2023 and 2022 were $0 for both periods, and for the six months ended June 30, 2023 and 2022 were approximately $86,000 and $0, respectively, and are recorded in net product sales in the condensed consolidated statements of operations and other comprehensive loss.
QN-302 Phase 1 Study
In June 2023, the Company entered into a Master Clinical Research Services Agreement with Translational Drug Development, LLC (“TD2”) where TD2 agreed to perform certain clinical research and development services for the Company including but not limited to trial management, side identification and selection, site monitoring/management, medical monitoring, project management, data collection, statistical programming or analysis, quality assurance auditing, scientific and medical communications, regulatory affairs consulting and submissions, strategic consulting, and/or other related services. From time to time, the Company shall enter into Statements of Work (“SOW”) with TD2 for the performance of specific services under this Master Clinical Research Services Agreement (see Note 16 - Subsequent Events: QN-302 Phase 1 Study).
In June 2023, the Company entered into a Master Laboratory Services Agreement with MLM Medical Labs, LLC (“MLM”) where MLM agreed to perform certain clinical research and development services for the Company including but not limited to laboratory, supply, testing, validation, data management, and storage services. From time to time, the Company shall enter into work orders with MLM for the performance of specific services under this Master Laboratory Services Agreement (see Note 16 - Subsequent Events: QN-302 Phase 1 Study).
In June 2023, the Company entered into a Master Services Agreement with Clinigen Clinical Supplies Management, Inc. (“Clinigen”) where Clinigen agreed to provide certain pharmaceutical products and/or services. From time to time, the Company shall enter into Statements of Work (“SOW”) with Clinigen for the performance of specific services under this Master Services Agreement (see Note 16 - Subsequent Events: QN-302 Phase 1 Study).

NOTE 14 — STOCKHOLDERS’ EQUITY

As of June 30, ~~2022~~2023 and December 31, ~~2021,~~2022, the Company had two classes of authorized capital stock: common stock and ~~Series Alpha convertible~~ preferred stock.

Common Stock

Holders of common stock generally vote as a class with the holders of the preferred stock and are entitled to one vote for each share held. Subject to the rights of the holders of the preferred stock to receive preferential dividends, the holders of common stock are entitled to receive dividends when and if declared by the Board of Directors. Following payment of the liquidation preference of the preferred stock, ~~as of June 30, 2022~~ any remaining assets ~~would~~will be distributed ratably among the holders of the common stock and, on an as-if-converted basis, the holders of ~~Series Alpha convertible~~any preferred stock upon liquidation, dissolution or winding up of the affairs of the Company. The holders of common stock have no preemptive, subscription or conversion rights and there are no redemption or sinking fund provisions.

On December 22, 2022, the Company issued to Alpha Capital, an 8% Senior Convertible Debenture in the aggregate principal amount of $3,300,000 for a purchase price of $3,000,000 pursuant to the terms of a Securities Purchase Agreement, dated December 21, 2022. The Debenture is convertible, at any time, and from time to time, at Alpha Capital’s option, into shares of common stock of the Company, at a price equal to $1.32 per share, and other terms and conditions described in the Debenture (see Note 10 - Convertible Debt - Related Party). As part of this transaction, the Company issued to Alpha Capital a warrant to purchase 2,500,000 shares of the Company’s common stock (see Note 9 - Warrant Liabilities). Between January 9 and 12, 2023, Alpha Capital voluntarily converted $1,111,078 of its outstanding the Debenture principal into 841,726 shares of common stock at a conversion price of $1.32 per share.
At June 30, ~~2022,~~2023, the Company has reserved ~~18,891,214~~4,565,097 shares of authorized but unissued common stock for possible future issuance.
At June 30, ~~2022,~~2023, shares were reserved in connection with the following:

SCHEDULE OF RESERVED SHARES

Exercise of issued and future grants of stock options ~~4,767,834~~445,163
Exercise of stock warrants ~~14,123,380~~4,119,934
Total ~~18,891,214~~4,565,097

~~Series Alpha Convertible~~ Preferred Stock

~~As of~~At June 30, ~~2022,~~2023 and December 31, ~~2021,~~2022, there were 0no shares of ~~Series Alpha convertible~~ preferred stock outstanding.

24
Stock Options and Warrants
Stock Options

The Company recognizes all compensatory share-based payments as compensation expense over the service period, which is generally the vesting period.

In April 2020, the Company adopted the 2020 Stock Incentive Plan (the “2020 Plan”), which provides for the granting of incentive or non-statutory common stock options and other types of awards to qualified employees, officers, directors, consultants and other service providers. At June 30, ~~2022~~2023 and December 31, ~~2021~~2022, there were ~~4,767,834~~445,163 and ~~4,748,000~~608,012 outstanding stock options, respectively, under the 2020 Plan and on such dates there were ~~2,789,323~~310,539 and ~~2,809,157~~147,690 shares reserved under the 2020 Plan, respectively, for future grant. The shares available for future grant reflect a 2020 Plan amendment approved by the Company’s stockholders on August 9, 2021 where the number of shares of common stock available for issuance under the 2020 Plan was increased by ~~3,500,000~~.

The following represents a summary of the options granted (under the 2020 Plan and otherwise) to employees and non-employee service providers that are outstanding at June 30, ~~2022,~~2023, and changes during the six-month period then ended:

SCHEDULE OF STOCK OPTION ACTIVITY
Shares Weighted–
Average
Exercise
Price Range of
Exercise
Price Weighted–
Average
Remaining
Life (Years) Shares Weighted–
Average
Exercise
Price Range of
Exercise
Price Weighted–
Average
Remaining
Life (Years)
Total outstanding – December 31, 2021 4,841,856 $ 6.07 $ 1.24 — $1,465.75 8.52
Total outstanding – December 31, 2022 608,012 $ 35.02 $5.14 - $51.30 8.09
Granted 25,000 1.05 1.05 9.54 — — — —
Expired (93,856 ) 93.59 5.75 - 1,465.75 — — — — —
Forfeited (5,166 ) 3.51 1.24 - 4.97 — (162,849 ) 36.01 5.14 - 51.30 —
Total outstanding – June 30, 2022 4,767,834 $ 4.33 $ 1.05 — $5.13 8.19
Total outstanding – June 30, 2023 445,163 $ 34.68 $5.14 — $51.30 7.59
Exercisable (vested) 2,643,665 $ 4.84 $ 1.24 — $5.13 8.00 323,355 $ 44.79 $5.14 — $51.30 7.13
Non-Exercisable (non-vested) 2,124,169 $ 3.68 $ 1.05 — $5.13 8.48 121,808 $ 7.83 $5.14 - $35.20 8.85

There was approximately $~~2.6~~0.9 and $~~2.5~~2.7 million of compensation cost related to outstanding stock options for the six months ended June 30, ~~2022~~2023 and ~~2021~~2022, respectively. As of June 30, ~~2022,~~2023, there was approximately $~~5.6~~0.5 million of total unrecognized compensation cost related to unvested stock-based compensation arrangements. This cost is expected to be recognized over a weighted average period of ~~1.1~~1.47 years.
The following represents a summary of the options granted (under the 2020 Plan and otherwise) to employees and non-employee service providers that are outstanding at June 30, 2021, and changes during the six-month period then ended:
Shares Weighted–
Average
Exercise
Price Range of
Exercise
Price Weighted–
Average
Remaining
Life (Years)
Total outstanding – December 31, 2021 484,186 $ 60.70 $12.40 — $14,657.50 8.52
Granted 2,500 10.50 10.50 9.54
Expired (9,386 ) 935.90 57.50 - 14,657.50 —
Forfeited (517 ) 35.10 12.40 - 49.70 —
Total outstanding – June 30, 2022 476,783 $ 43.30 $10.50 — $51.30 8.19
Exercisable (vested) 264,366 $ 48.40 $12.40 — $50.13 8.00
Non-Exercisable (non-vested) 212,417 $ 36.80 $10.50 — $51.30 8.48

Shares Weighted–
Average
Exercise
Price Range of
Exercise
Price Weighted–
Average
Remaining
Life (Years)
Total outstanding – December 31, 2020 4,011,356 $ 7.05 $ 3.52 - $1,465.75 9.29
Granted 127,000 2.12 1.80 — 3.29 9.83
Expired — — — —
Forfeited (4,500 ) 3.68 3.52 — 4.97 —
Total outstanding – June 30, 2021 4,133,856 $ 6.90 $ 1.80 - $1,465.75 8.82
Exercisable (vested) 1,296,860 $ 11.50 $ 4.97— $1,465.75 8.36
Non-Exercisable (non-vested) 2,836,996 $ 4.80 $ 1.80 — $5.13 9.04
The exercise price for an option issued under the 2020 Plan is determined by the Board of Directors, but will be (i) in the case of an incentive stock option (A) granted to an employee who, at the time of grant of such option, is a 10% stockholder, no less than 110% of the fair market value per share on the date of grant; or (B) granted to any other employee, no less than 100% of the fair market value per share on the date of grant; and (ii) in the case of a non-statutory stock option, no less than 100% of the fair market value per share on the date of grant. The options awarded under the 2020 Plan will vest as determined by the Board of Directors but will not exceed a ten-year period. ~~The weighted average grant date fair value per share of options granted during the six months ended June 30, 2022 was $0.84~~.

Fair Value of Equity Awards

The Company utilizes the Black-Scholes option pricing model to value awards under its ~~Plans.~~equity plans. Key valuation assumptions include:

● Expected dividend yield. The expected dividend is assumed to be zero, as the Company has never paid dividends and has no current plans to pay any dividends on the Company’s common stock.
25
● Expected stock-price volatility. The Company’s expected volatility is derived from the average historical volatilities of publicly traded companies within the Company’s industry that the Company considers to be comparable to the Company’s business over a period approximately equal to the expected term.
● Risk-free interest rate. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant for zero coupon U.S. Treasury notes with maturities approximately equal to the expected term.
● Expected term. The expected term represents the period that the stock-based awards are expected to be outstanding. The Company’s historical share option exercise experience does not provide a reasonable basis upon which to estimate an expected term because of a lack of sufficient data. Therefore, the Company estimates the expected term by using the simplified method provided by the ~~Securities and Exchange Commission.~~SEC. The simplified method calculates the expected term as the average of the time-to-vesting and the contractual life of the options.
26

The material factors incorporated in the Black-Scholes model in estimating the fair value of the options granted for the periods presented were as follows:

SCHEDULE OF ~~ASSUMPTIONS~~ASSUMPTION USED IN BLACK-SCHOLES OPTION-PRICING METHOD

For the Six Months
Ended
June 30,
For the Six Months Ended
June 30,
2022 2021 2023 2022
Expected dividend yield 0.00 % 0.00 % 0.00 % 0.00 %
Expected stock-price volatility 102 % 102 % — 102 %
Risk-free interest rate 1.58% — 1.67 % 0.84% — 1.81 % — 1.58% — 1.67 %
Expected average term of options (in years) 6.00 6.00 — 6.00
Stock price $ 1.05 $ 2.12 $ — $ 1.05

The Company recorded share-based compensation expense and classified it in the unaudited condensed consolidated statements of operations ~~and other comprehensive loss~~ as follows:

SCHEDULE OF SHARE-BASED COMPENSATION EXPENSE
2022 2021 2023 2022
For the Six Months
Ended
June 30, For the Six Months
Ended
June 30,
2022 2021 2023 2022
General and administrative $ 2,329,418 $ 2,201,499 $ 807,980 $ 2,329,418
Research and development 361,029 347,550 98,165 361,029
Total $ 2,690,447 $ 2,549,049 $ 906,145 $ 2,690,447

Equity Classified Compensatory Warrants

In connection with the $4.0 million equity capital raise as part of the May 2020 reverse recapitalization transaction, the Company issued common stock warrants to an advisor and its designees for the purchase of ~~811,431~~81,143 reverse split adjusted shares of the Company’s common stock at ana reverse split adjusted exercise price of $~~1.11~~11.10 per share. The issuance cost of these warrants was charged to additional paid-in capital, and did not result in expense in the Company’s condensed consolidated statements of operations and ~~other~~ comprehensive loss.

In addition, various service providers hold equity classified compensatory warrants issued in 2017 and earlier for the purchase of 66,802 reverse split adjusted shares of Company common stock (originally exercisable to purchase Series C convertible preferred ~~stock, and now instead exercisable to purchase common~~ stock) ~~for the purchase of~~ ~~668,024~~ ~~shares of Company common stock~~ at a weighted average exercise price of $~~2.34~~23.40 per share. These are to be differentiated from the Series C Warrants described in Note ~~10 –~~9 - Warrant Liabilities.

During the year ended December 31, 2021, the Company issued equity classified compensatory warrants to a service provider for the purchase of~~600,000~~ 60,000 reverse split adjusted shares of Company common stock at ana reverse split adjusted exercise price of $~~1.32~~13.20 per share. The fair value issuance cost of approximately $0.3 million using the Black-Scholes options pricing model for these warrants was charged to general and administrative expenses in the Company’s condensed consolidated statements of operations and ~~other~~ comprehensive loss. On April 25, 2022, ~~600,000~~60,000 warrants were repriced from $~~1.32~~13.20 to a reverse split adjusted exercise price of $~~0.60~~6.00 and extended from June 3, 2023 to September 14, 2023. The increase in fair value of $67,370 using a Monte Carlo pricing model for the modification of these warrants was charged to general and administrative expenses in the Company’s condensed consolidated statements of operations and ~~other~~ comprehensive loss. On April 25, 2022 and May 26, 2022 an additional ~~676,194~~67,619 reverse split adjusted warrants were repriced from a reverse split adjusted exercise price of $~~1.11~~11.10 to $~~0.5136~~5.136. The increase in fair value of $31,010 using a Monte Carlo pricing model for the modification of these warrants was charged to additional paid-in capital and did not result in expense on the Company’s condensed consolidated statements of operations and ~~other~~comprehensive loss. On December 22, 2022, 67,620 warrants were repriced from a reverse split adjusted exercise price of $5.136 to $1.32. The increase in fair value of $8,548 using a Monte Carlo pricing model for the modification of these warrants was charged to additional paid-in capital and did not result in expense on the Company’s condensed consolidated statements of operations and comprehensive loss.
26

No compensatory warrants were issued during the six months ended June 30, ~~2022.~~2023.
27
The following table summarizes the activity in the common stock equity classified compensatory warrants for the six months ended June 30, 2023:
SCHEDULE OF WARRANT ACTIVITY
Common Stock
Shares Weighted– Average
Exercise
Price Range of
Exercise Price Weighted–
Average
Remaining
Life (Years)
Total outstanding – December 31, 2022 179,046 $         9.12 $1.32 — $25.40 1.73
Granted to advisor and its designees — —
Exercised — —
Expired — —
Forfeited — —
Total outstanding – June 30, 2023 179,046 $ 9.12 $1.32 — $25.40 1.24
Exercisable 179,046 $ 9.12 $1.32 — $25.40 1.24
Non-Exercisable — $ — $ — —

The following table summarizes the activity in the common stock equity classified compensatory warrants for the six months ended June 30, 2022:

~~SCHEDULE OF WARRANT ACTIVITY~~
Common Stock
Shares Weighted– Average
Exercise
Price Range of
Exercise Price
Weighted–
Average
Remaining
Life (Years)

Total outstanding – December 31, 2021 1,790,648 $ 1.52 $ 1.11 — $2.54 2.64
Granted to advisor and its designees — —
Exercised — —
Expired — —
Forfeited — —
Total outstanding – June 30, 2022 1,790,648 $ 1.06 $ 0.5136 — 2.54 2.23
Exercisable 1,790,648 $ 1.06 $ 0.5136 — $2.54 2.23
Non-Exercisable — $ — $ — —
~~The following table summarizes the activity in the common stock equity classified compensatory warrants for the six months ended June 30, 2021:~~
Common Stock Common Stock
Shares Weighted– Average
Exercise
Price Range of
Exercise Price Weighted–
Average
Remaining
Life (Years) Shares Weighted– Average
Exercise
Price Range of
Exercise Price Weighted–
Average
Remaining
Life (Years)
Total outstanding – December 31, 2020 1,294,217 $ 1.66
Granted — —
Total outstanding – December 31, 2021 179,065 $ 15.20 $11.10 — $25.40 2.64
Granted to advisor and its designees — —
Exercised (38,390 ) 2.09 — —
Expired — — — —
Forfeited (65,179 ) 2.07 — —
Total outstanding – June 30, 2021 1,190,648 $ 1.62
Total outstanding – June 30, 2022 179,065 $ 10.60 $5.14 — $25.40 2.23
Exercisable 1,187,052 $ 1.62 $ 1.11 — $2.54 3.75 179,065 $ 10.60 $5.14 — $25.40 2.23
Non-Exercisable 3,596 $ 2.54 $ 2.54 5.23 — $ — $ — —

There were $~~67,370~~no in compensation costs related to outstanding equity classified compensatory warrants for the six months ended June 30, ~~2022~~2023 and $067,370 for the six months ended June 30, ~~2021.~~2022.

Noncompensatory Equity Classified Warrants

In May 2020, as a commitment fee, the Company issued noncompensatory equity classified warrants to ~~an investor~~Alpha Capital (a related party) for the purchase of ~~270,478~~27,048 reverse split adjusted shares of Company common stock at ana reverse split adjusted exercise price of $~~1.11~~11.10 per share (of which warrants for ~~200,000~~20,000 shares were subsequently exercised in December 2020). In July 2020, the Company issued noncompensatory equity classified warrants to ~~such investor~~Alpha Capital for the purchase of ~~780,198~~78,019 reverse split adjusted shares of Company common stock at ana reverse split adjusted exercise price of $~~0.001~~0.01 per share (which were subsequently exercised in July 2020), and ~~1,920,678~~192,068 reverse split adjusted shares of Company common stock at ana reverse split adjusted exercise price of $~~5.25~~52.50 per share. In August 2020, the Company issued noncompensatory equity classified warrants to ~~such investor~~Alpha Capital for the purchase of ~~1,287,829~~128,783 reverse split adjusted shares of Company common stock at ana reverse split adjusted exercise price of $~~6.00~~60.00 per share. In December 2020, the Company issued noncompensatory equity classified warrants to ~~such investor~~Alpha Capital for the purchase of ~~1,000,000~~100,000 reverse split adjusted shares of Company common stock at ana reverse split adjusted exercise price of $~~0.01~~0.10 per share (which were exercised in February 2021) and ~~2,191,010~~219,101 reverse split adjusted shares of Company common stock at ana reverse split adjusted exercise price of $~~4.07~~40.70 per share. In May 2022, the Company issued noncompensatory equity classified warrants to ~~such investor~~Alpha Capital for the purchase of ~~3,314,641~~331,464 reverse split adjusted shares of Company common stock at ana reverse split adjusted exercise price of $~~0.001~~0.01 per share.

27
~~During the year ended December 31,~~On November 29, 2021, with the exception of the warrants to purchase ~~270,478~~27,048 reverse split adjusted shares of the Company’s common stock at ana reverse split adjusted exercise price of $~~1.11~~11.10 per share, the exercise prices of all outstanding warrants to purchase a total of ~~5,399,517~~539,951 reverse split adjusted shares of the Company’s common stock were modified to ana reverse split adjusted exercise price of $~~2.00~~20.00 per share ~~on November 29, 2021~~ and each of their remaining terms extended by six months. The fair value of the modification cost of these warrant modifications of approximately $2.3 million was charged to additional paid-in capital and did not result in expense on the Company’s condensed consolidated statements of operations and ~~other~~ comprehensive loss. ~~During the period ended June 30,~~In May 2022, pre-funded warrants to purchase ~~3,314,641~~331,464 reverse split adjusted shares of the Company’s common stock at ana reverse split adjusted exercise price of $~~0.001~~0.01 per share with no expiration date were issued. These warrants were subsequently exercised during the period ended September 30, 2022.
28

In conjunction with the NanoSynex ~~acquisition,~~Acquisition, on April 25, 2022 the exercise price of ~~70,478~~7,048 reverse split adjusted outstanding warrants ~~at $1.11~~ ~~was modified to~~with an exercise price of $~~0.60~~11.10 per share was modified to a reverse split adjusted exercise price of $6.00. The increase in fair value of $2,533, using a Monte Carlo pricing model for the modification of these warrants, was charged to additional paid-in capital and did not result in expense on the Company’s condensed consolidated statements of operations and ~~other~~ comprehensive loss. On May 26, 2022, the reverse split adjusted exercise price of these warrants was modified again to $~~0.5136~~5.136, and the increase in fair value of $696, using a Monte Carlo pricing model for the modification of these warrants, was included in consideration transferred in the NanoSynex ~~acquisition (~~Acquisition. On December 22, 2022, the exercise price of these warrants was modified again to $~~see~~ 1.32~~Note 3 - Acquisitions)~~. The increase in fair value of $891, using a Monte Carlo pricing model for the modification of those warrants, was charged to additional paid-in capital and did not result in expense on the Company’s condensed consolidated statements of operations and comprehensive loss.

~~Weighted average remaining life below was calculated excluding~~No noncompensatory equity classified warrants were issued during the ~~3,314,641~~ ~~pre-funded warrants as they have no expiration date.~~six months ended June 30, 2023.
The following table summarizes the noncompensatory equity classified warrant activity for the six months ended June 30, 2023:
SCHEDULE OF WARRANT ACTIVITY
Common Stock
Shares Weighted–
Average
Exercise
Price Range of
Exercise Price Weighted–
Average
Remaining
Life (Years)
Total outstanding – December 31, 2022 547,003 $ 19.76 $1.32 - $20.00 0.33
Legacy Ritter warrants — —
Granted — —
Exercised — —
Expired (455,685 ) 20.00 20.00
Forfeited — —
Total outstanding – June 30, 2023 91,318 $ 18.56 -
Exercisable 91,318 $ 18.56 $1.32 — $20.00 0.58
Non-Exercisable — $ — $ — —

The following table summarizes the noncompensatory equity classified warrant activity for the six months ended June 30, 2022:

~~SCHEDULE OF WARRANT ACTIVITY~~
Common Stock Common Stock
Shares Weighted–
Average
Exercise
Price Range of
Exercise Price Weighted–
Average
Remaining
Life (Years) Shares Weighted–
Average
Exercise
Price Range of
Exercise Price Weighted–
Average
Remaining
Life (Years)
Total outstanding – December 31, 2021 5,549,137 $ 2.01 554,914 $ 20.10
Legacy Ritter warrants — —
Granted 3,314,641 0.001 0.001 331,464 0.01 0.01
Exercised — — — —
Expired — — — —
Forfeited — — — —
Total outstanding – June 30, 2022 8,863,778 1.26 886,378 $ 12.60
Exercisable 8,863,778 $ 1.26 $ 0.001 — $3.77 0.82 886,378 $ 12.60 $0.01 — $37.70 0.82
Non-Exercisable — $ — $ — — — $ — $ — —
NOTE 15 -— ~~QUARTERLY FINANCIAL DATA (UNAUDITED)~~RELATED PARTY TRANSACTIONS

~~As disclosed~~Convertible Debt
On December 22, 2022, the Company issued to Alpha Capital, an 8% Senior Convertible Debenture in the ~~2021 Annual Report,~~aggregate principal amount of $3,300,000 for a purchase price of $3,000,000 pursuant to the terms of a Securities Purchase Agreement, dated December 21, 2022. The Debenture is convertible, at any time, and from time to time, at Alpha Capital’s option, into shares of common stock of the Company, at a price equal to $1.32 per share, subject to adjustment as described in the Debenture and other terms and conditions described in the Debenture, including the Company’s ~~management identified an error~~receipt of the necessary stockholder approvals (See Note 10 - Convertible Debt - Related Party). Between January 9 and 12, 2023, Alpha Capital voluntarily converted $1,111,078 of the Debenture principal into 841,726 shares of common stock at a conversion price of $1.32 per share.
29
Short-Term Debt
NanoSynex has four separate notes payable outstanding to Alpha Capital, issued between March 26, 2020 and September 2, 2021, aggregating to a total principal outstanding balance of $905,000, and aggregate accrued interest of $60,155 for a total outstanding balance of $965,155 as of June 30, 2023. The Notes all accrue interest at 2.62% per annum, accrued daily, and provide that the full amount of principal and interest under each Note shall be due immediately prior to a Liquidation Event (the Maturity Date) unless due earlier in accordance with the terms of the Notes. “Liquidation Event” means either (i) the merger or consolidation of NanoSynex into any other entity, other than one in control or under control of NanoSynex or NanoSynex’s majority shareholder; (ii) a transaction or series of transactions resulting in the ~~previously~~transfer of all or substantially all of NanoSynex’s assets or issued ~~March 31, 2021, June 30, 2021~~ and ~~September 30, 2021 unaudited interim condensed consolidated financial statements~~outstanding share capital (other than to a company under the control of NanoSynex or NanoSynex’s majority shareholders; or (iii) an underwritten public offering by NanoSynex of its ordinary shares. Notwithstanding the above, if NanoSynex receives subsequent debt, convertible debt, or equity funding with gross proceeds of USD $3,000,000 or more, then the unused portion of these Notes shall be due and payable upon the actual receipt of such funding (See Note 8 - Short-Term Debt - Related Party).
NanoSynex Acquisition
The Company acquired a 52.8% voting equity interest in ~~which~~NanoSynex on May 26, 2022 through: (1) the ~~fair value~~purchase of 2,232,861 shares Preferred A-1 Stock of NanoSynex from Alpha Capital (a related party) for 350,000 reverse split adjusted shares of the Company’s common stock and a prefunded warrant to purchase 331,464 reverse split adjusted shares of the Company’s common stock at a purchase price of $0.001 per share (these warrants were subsequently exercised ~~liability classified warrants had been inadvertently excluded~~on September 13, 2022), and (2) the purchase of 381,786 shares of Series B preferred stock of NanoSynex from ~~reclassification into shareholders’ equity. All financial information contained~~NanoSynex in ~~the accompanying notes to these condensed consolidated financial statements has been revised to reflect the correction of this error as shown in the table below.~~exchange for $600,000.
~~SCHEDULE OF ERROR CORRECTIONS AND PRIOR PERIOD ADJUSTMENTS~~
As reported Corrected As reported Corrected
For the Quarter
Ended
June 30, 2021 For the Six Months
Ended
June 30, 2021
As reported Corrected As reported Corrected
Gain on change in fair value of warrant liabilities $ (2,075,100 ) $ (1,982,256 ) $ (4,198,000 ) $ (2,535,064 )
Net loss $ (5,305,233 ) $ (5,398,077 ) $ (8,977,860 ) $ (10,640,796 )
Net loss per common share $ (0.18 ) $ (0.19 ) $ (0.31 ) $ (0.37 )

NOTE 16 — SUBSEQUENT EVENTS

~~In conjunction~~QN-302 Phase 1 Study
Between July 5-13, 2023, pursuant to the Master Clinical Research Services Agreement with TD2, Master Services Agreement with Clinigen, and Master Laboratory Services Agreement with MLM (see Note 13 - Research and License Agreements), the Company entered into work orders with these vendors to provide clinical trial services for the conduct of the QN-302 Phase 1 study. The estimated project timeline was set to start in July 2023 and continue until July 2026. The total amount to be paid under these work orders is currently expected to be approximately $7.6 million over the term of the QN-302 Phase 1 study.
Stock Purchase Agreement with Chembio Diagnostics, Inc. and Biosynex, S.A.
On July 20, 2023, the Company entered into the Purchase Agreement with Chembio, Biosynex, S.A. (“Biosynex”), and Qualigen, Inc., a wholly-owned subsidiary of the Company. Pursuant to the Purchase Agreement, the Company agreed to sell to Chembio all of the issued and outstanding shares of common stock of Qualigen, Inc., which was the legal entity operating the Company’s FastPack™ diagnostics business. The Transaction closed on July 20, 2023. Following the consummation of the Transaction, Qualigen, Inc. became a wholly-owned subsidiary of Chembio.

The aggregate net purchase price paid to the Company for the Shares was $5.2 million in cash, based on a base purchase price of $5.8 million, subject to certain post-closing adjustments, upward or downward, as applicable, for: (i) cash held by Qualigen, Inc. as of the closing of the Transaction; (ii) net working capital of Qualigen, Inc. as of the closing of the Transaction, (iii) certain indebtedness of Qualigen, Inc. as of the closing of the Transaction, and (iv) certain Transaction expenses as of the closing of the Transaction. Of the $5.2 million in cash, $450,000 is being held in escrow to satisfy certain Company indemnification obligations. Any amounts remaining in the Indemnity Escrow that have not been offset or reserved for claims will be released to the Company within five business days following the date that is 18 months after the closing.

Amendment and Settlement Agreement with NanoSynex Ltd.
On July 20, 2023, the Company entered into the NanoSynex Amendment, which amended the NanoSynex Funding Agreement with NanoSynex, to, among other things, provide for the ~~Company provided $1.5~~ ~~million in~~further funding toof NanoSynex, ~~on July 5, 2022. Repayment terms under~~as contemplated by the NanoSynex Funding ~~Agreement are described in Note 2 - Liquidity.~~Agreement.

~~Management has evaluated subsequent events~~Pursuant to the terms of the NanoSynex Amendment, the Company agreed to advance to NanoSynex an aggregate amount of $1,610,000 as follows: (i) $380,000 within five business days of the execution of the NanoSynex Amendment, (ii) $560,000 on or before November 30, 2023, against which NanoSynex will issue a promissory note to the Company with a face value in the amount of such funding, and (iii) $670,000 on or before March 31, 2024, against which NanoSynex will issue a promissory note to the Company with a face value in the amount of such funding. The NanoSynex Amendment further provides that the initial payment of $380,000 will be satisfied by the Company’s surrender of the 281,000 Preferred B Shares of NanoSynex currently held by the Company, resulting in the Company’s ownership in NanoSynex being reduced from approximately 52.8% to approximately 49.97% of the issued and outstanding voting equity of NanoSynex.
In the event we fail to make any future advances, we have agreed to forfeit additional shares in a number that will be equal to a fraction, the numerator of which is the amount of the default (i.e., the amount that we should have, but failed, to advance to NanoSynex pursuant to the ~~requirements~~terms of ~~ASC Topic 855,~~ ~~Subsequent Events,~~ ~~from~~ the ~~balance sheet date through August 15, 2022~~NanoSynex Amendment), and ~~has determined~~the denominator of which shall be the price per share that ~~there are no material subsequent events that require disclosure~~we originally paid in ~~these financial statements, other than as disclosed above.~~consideration for our Preferred A-1 shares of NanoSynex to the previous holder thereof, being $1.5716 per share.

28
The NanoSynex Amendment supersedes any payments contemplated by the Original NanoSynex Agreement, such that except as described in the NanoSynex Amendment, the Company will have no further payment obligations to NanoSynex under the Original NanoSynex Agreement or otherwise (including by way of equity investment, loan financing or credit lines), and NanoSynex will have no further payment obligations to the Company for advances previously received under the Original NanoSynex Agreement.
Stockholder Approval of Alpha Stock Issuance Proposal
On July 13, 2023, the Company held its 2023 annual meeting of stockholders, at which the issuance to Alpha Capital of common stock pursuant to the terms and conditions of (a) the Debenture and (b) the Alpha Warrant were approved in accordance with Nasdaq Listing Rule 5635(d), which requires stockholder approval prior to the issuance of more than 20% of the Company’s issued and outstanding common stock.
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis should be read in conjunction with our interim unaudited condensed consolidated financial statements and related notes included in this Quarterly Report on Form 10-Q (this “Quarterly Report”) and the audited financial statements and notes thereto as of and for the twelve months ended December 31, ~~2021,~~2022, which are contained in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on ~~March 31, 2022 (as~~May 2, 2023, as amended by Amendment No. 1 filed with the ~~“2021~~SEC on July 7, 2023 ( the “2022 Annual Report.) As used in this Quarterly Report, unless the context suggests otherwise, “we,” “us,” “our,” or “Qualigen” refer to Qualigen Therapeutics, Inc. In addition to historical information, this discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions.

Cautionary Note Regarding Forward Looking Statements
This Quarterly Report contains forward-looking statements by ~~Qualigen Therapeutics, Inc.~~the Company that involve risks and uncertainties and reflect ~~our~~the Company’s judgment as of the date of this ~~Quarterly~~ Report. These statements generally relate to future events or ~~our~~the Company’s future financial or operating performance. In some cases, you can identify forward-looking statements because they contain words such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” or “continue” or the negative of these words or other similar terms or expressions that concern ~~our~~the Company’s expectations, strategy, plans or intentions. Such forward-looking statements may relate to, among other things, potential future development, testing and launch of products and product candidates. Actual events or results may differ from our ~~expectations due to a number of factors.~~expectations.

~~These forward-looking statements include, but are not limited~~Some of the factors that we believe could cause actual results to ~~statements about:~~differ from those anticipated or predicted include:
● ~~our ability to~~there can be no assurance that we will successfully develop any drugs or therapeutic devices;
● there can be no assurance that preclinical or clinical development of our ~~ability to progress our drug candidates~~candidate drugs or therapeutic devices ~~through preclinical and clinical development;~~will be successful;
● ~~our ability to obtain the requisite regulatory approvals for our~~there can be no assurance that clinical trials ~~and~~will be approved to begin ~~and complete such trials according to any projected timeline;~~
● ~~our ability to complete enrollment in our clinical trials~~by or will actually begin by or will proceed as contemplated by any projected timeline;
● ~~the likelihood~~there can be no assurance that clinical trials will complete enrollment as contemplated by any projected timeline;
● there can be no assurance that future clinical trial data will be favorable or that such trials will confirm any improvements over other products or lack negative impacts;
● there can be no assurance that any of our ~~ability to successfully commercialize any~~candidate drugs or therapeutic ~~devices;~~devices will receive the required regulatory approvals or that they will be commercially successful;
● ~~our ability~~there can be no assurance that we will be able to procure or earn sufficient working capital to complete the development, testing and launch of our prospective candidate drugs therapeutic products;
● ~~the likelihood~~there can be no assurance that patents will issue on our owned and in-licensed patent applications;
● there can be no assurance that such patents, if any, and our ~~ability to protect our intellectual property;~~
● ~~our ability to compete;~~
● ~~our ability to maintain or expand market demand and/or market share for our diagnostic products generally, particularly in light of COVID-19-related deferral of patients’ physician-office visits~~current owned and ~~in view of FastPack reimbursement pricing challenges; and~~
● ~~our ability to maintain our diagnostic sales and marketing engine without interruption following the expiration of our distribution agreement with Sekisui Diagnostics, LLC (“Sekisui”).~~in-licensed patents would prevent competition;

By their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive dynamics, and healthcare, regulatory and scientific developments and depend on the economic circumstances that may or may not occur in the future or may occur on longer or shorter timelines than anticipated. These risks and uncertainties include risks related to our financial position and our ability to raise additional capital as needed to fund our operations and product development; risks related to the initiation, cost, timing, progress and results of current and future research and development programs, preclinical studies and clinical trials and our ability to obtain and maintain regulatory approvals; risks related to our reliance on third party suppliers and manufacturers; risks related to market acceptance of our products and competition; risks related to our acquisition of NanoSynex, Ltd.; risks related to the ongoing COVID-19 pandemic and the war in Ukraine, including ~~instability in the global credit markets and supply chain disruptions.~~ ~~In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events.~~ Although we believe that we have a reasonable basis for each forward-looking statement contained in this Quarterly Report, we caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward-looking statements contained in this Quarterly Report. In addition, even if our results of operations, financial condition and liquidity, and the development of the industry in which we operate, are consistent in some future periods with the forward-looking statements contained in this Quarterly Report, they may not be predictive of results or developments in other future periods. Any forward-looking statement that we make in this Quarterly Report speaks only as of the date of this Quarterly Report, and we disclaim any intent or obligation to update these forward-looking statements beyond the date of this Quarterly Report, except as required by law. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

29
Future filings with the SEC, future press releases and future oral or written statements made by us or with our approval, which are not statements of historical fact, may also contain forward-looking statements. Because such statements include risks and uncertainties, many of which are beyond our control, actual results may differ materially from those expressed or implied by such forward-looking statements. The forward-looking statements speak only as of the date on which they are made, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they are made.
32

Overview

We are a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug ~~designation, while also commercializing diagnostics.~~ designation.
Our cancer therapeutics pipeline includes QN-302, ~~QN-247~~RAS and ~~RAS-F.~~ QN-247.
Our ~~investigational~~lead oncology therapeutics program, QN-302, ~~compound~~ is aan investigational small molecule ~~G4 selective~~G4-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells. Such binding could, by stabilizing the G4s against DNA “unwinding,” help inhibit cancer cell proliferation. QN-302 is currently undergoing Good Laboratory Practice (GLP) toxicology studies.
Our Pan-RAS portfolio consists of a family of RAS oncogene protein-protein interaction inhibitor small molecules believed to inhibit or block mutated RAS genes’ proteins from binding to their effector proteins. Preventing this binding could stop tumor growth, especially in RAS-driven tumors such as pancreatic, colorectal and lung cancers.
Our investigational QN-247 compound binds nucleolin, a key multi-functional regulatory phosphoprotein that is ~~a DNA coated gold nanoparticle~~overexpressed in cancer ~~drug candidate that has~~cells. Such binding could inhibit the ~~potential to target various types of cancer; the nanoparticle conjugate technology is similar to the core nanoparticle coating technology used in our blood-testing diagnostic products.~~cancer cells’ proliferation. The foundational aptamer of QN-247 is QN-165 (formerly referred to as AS1411), which the Company has deprioritized as a drug candidate for treating COVID-19 and other viral-based infectious diseases. RAS-F is a family of RAS oncogene protein-protein interaction inhibitor small molecules for preventing mutated RAS genes’ proteins from binding to their effector proteins; preventing this binding could stop tumor growth, especially in RAS-driven tumors such as pancreatic, colorectal and lung cancers. We are also identifying strategic partnering opportunities for STARS, a DNA/RNA-based therapeutic device product concept for removing precisely targeted tumor-produced and viral compounds from circulating blood.

~~Our FastPack System diagnostic instruments and test kits are sold commercially primarily in the United States,~~On November 23, 2022, we effected a 1-for-10, as well as certain European countries. The FastPack System menu includes a rapid, highly accurate immunoassay diagnostic testing system for cancer, men’s health, hormone function, and vitamin D status. We provide analyzers todetermined by our ~~customers (physician offices, clinics and small hospitals) at low cost in order to increase sales volumes~~board of ~~higher-margin test kits. Prior to March 31, 2022, most~~directors, reverse stock split of our ~~FastPack product sales were through~~outstanding shares of common stock (the “Reverse Stock Split”). The Reverse Stock Split reduced our ~~partner Sekisui pursuant~~shares of outstanding common stock, stock options, and warrants to ~~a distribution agreement, but we maintained direct distribution for certain house accounts, including selling~~purchase shares of our total testosterone test kits to Low T Center, Inc. (“Low T”), the largest men’s health group in the United States, with 40 locations. The distribution agreement with Sekisui expired on March 31, 2022, at which time the services previously provided by Sekisui reverted to us and ascommon stock. Fractional shares of ~~April 1, 2022 we recognize 100% of the revenue~~common stock that would have otherwise resulted from the ~~sales~~Reverse Stock Split were rounded down to the nearest whole share and cash in lieu of ~~our FastPack diagnostic instruments~~fractional shares was paid to stockholders. All share and ~~test kits.~~ Weper share data for all periods presented in this section and the accompanying financial statements and related disclosures have ~~licensed~~been adjusted retrospectively to reflect the Reverse Stock Split. The number of authorized shares of common stock and ~~technology-transferred our FastPack System technology to Yi Xin Zhen Duan Jishu (Suzhou) Ltd. for~~ the ~~China diagnostics market and other markets outside of the United States in which the Company does not currently sell.~~par value per share remains unchanged.

On May 26, 2022, ~~the Company~~we acquired 2,232,861 shares of Series A-1 Preferred Stock of NanoSynex ~~Ltd,~~Ltd. (“NanoSynex”) from Alpha Capital Anstalt (“Alpha Capital”) in exchange for ~~3,500,000~~350,000 shares of ~~the Company’s~~our common stock and a prefunded warrant to purchase ~~3,314,641~~331,464 shares of ~~the Company’s~~our common stock at an exercise price of $0.001 per share. These warrants were subsequently exercised on September 13, 2022. Concurrently with this transaction, ~~the Company~~we also purchased 381,786 shares of Series B preferred stock from NanoSynex for a total purchase price of $600,000. The transactions resulted in ~~the Company~~our acquiring a 52.8% interest in ~~NanoSynex. The Company envisions future synergies from the integration of its own proprietary results-proven FastPack diagnostics platform with the innovative~~ NanoSynex ~~technology.~~(the “NanoSynex Acquisition”). NanoSynex is a micro-biologics diagnostics company domiciled in Israel.
We do not expect to be profitable before products from our therapeutics pipeline are commercialized. To experience losses while therapeutic products are still under development is, of course, typical for biotechnology companies.
Recent Developments
FDA Clearance of IND Application for QN-302
On August 1, 2023, the Company announced that the U.S. Food and Drug Administration has cleared the Company’s investigational new drug (IND) application for QN-302, allowing us to commence our Phase 1 clinical trial for QN-302.
Sale of FastPack™ Diagnostics Business
On July 20, 2023, we sold all of the issued and outstanding shares of common stock of our wholly-owned subsidiary, Qualigen, Inc., which was the legal entity operating our FastPack™ diagnostics business, to Chembio Diagnostics, Inc. (“Chembio”), a wholly-owned subsidiary of Biosynex, S.A. (the “Transaction”). The aggregate net purchase price paid to us for the shares was $5.2 million in cash, based on a base purchase price of $5.8 million, subject to certain post-closing adjustments, upward or downward, as applicable. Of the $5.2 million, $450,000 is being held in escrow to satisfy certain indemnification obligations. Any amounts remaining in the Indemnity Escrow that have not been offset or reserved for claims will be released to us within five business days following the date that is 18 months after the closing. Following the consummation of the Transaction, Qualigen, Inc. became a wholly-owned subsidiary of Chembio.
Amendment and Settlement Agreement with NanoSynex Ltd.
On July 20, 2023, we entered into an Amendment and Settlement Agreement with Nanosynex (the “NanoSynex Amendment”), which amended the Master Funding Agreement for the Operational and Technology Funding of NanoSynex Ltd. (the “NanoSynex Funding Agreement”) with NanoSynex and our payment obligations to NanoSynex under such agreement. See “Contractual Obligations and Commitments” below.
33
Critical Accounting Policies and Estimates

Our condensed consolidated financial statements do not separate ~~out~~ our diagnostics-related activities ~~and~~from our therapeutics-related activities. Although to date all of our reported revenue is diagnostics-related, our reported expenses represent the total of our ~~therapeutics-related~~diagnostics-related and ~~diagnostics-related~~therapeutics-related expenses.

~~Distribution~~This discussion and ~~Development Agreement~~analysis is based on our condensed consolidated financial statements, which have been prepared in accordance with ~~Sekisui~~U.S. GAAP. The preparation of these condensed consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in our condensed consolidated financial statements. On an ongoing basis, we evaluate our estimates and judgments, including those related to impairment of goodwill and other intangible assets, fair value of warrant liabilities, stock-based compensation, amortization and depreciation, inventory reserves, allowances for doubtful accounts and returns, and warranty costs. We base our estimates on historical experience, known trends and events and various other factors we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

~~In May 2016, through~~While our ~~wholly-owned diagnostics subsidiary Qualigen, Inc.~~significant accounting policies are more fully described in Note 1 - Organization And Summary Of Significant Accounting Policies And Estimates to our unaudited condensed consolidated financial statements appearing in “Item 1. Condensed Consolidated Financial Statements (Unaudited),” we ~~entered into a Distribution~~believe that the following accounting policies are the most critical to aid you in fully understanding and Development Agreement (the “Sekisui Distribution Agreement”) with Sekisui. Under the Sekisui Distribution Agreement, Sekisui served as the exclusive worldwide distributor for FastPack products (although we retained certain specific accounts for direct transactions). Sekisui’s exclusive distribution arrangements expired on March 31, 2022.evaluating our financial condition and results of operations:

Under the Sekisui Distribution Agreement, we began development of a proposed “FastPack 2.0” product line for a new whole blood vitamin D assay, which if successfully introduced by us would have been distributed by Sekisui. Between May 2016 and January 2018, Sekisui paid us a total of approximately $5.5 million upon the achievement of specified development milestones related to this product line.
30 ● Convertible debt
● Research and development

● Revenue recognition
We conducted a clinical trial of FastPack 2.0 in March 2019, and determined in May 2019 that it was uncertain whether the results of the trial would enable the test to receive FDA approval. As a result, we discontinued our FastPack 2.0 project with Sekisui. Currently, no further FastPack 2.0 analyzer or test development is ongoing, and we have licensed and transferred our FastPack 2.0 technology to Yi Xin Zhen Duan Jishu (Suzhou) Ltd. for them to further develop and commercialize as described below.
● Allowance for doubtful accounts and returns
● Inventory
~~Technology Transfer Agreement with Yi Xin~~
● Impairment of long-lived assets
● Business combination
Through our wholly-owned diagnostics subsidiary Qualigen, Inc., we entered into a Technology Transfer Agreement dated as of October 7, 2020 with Yi Xin Zhen Duan Jishu (Suzhou) Ltd. (“Yi Xin”), of Suzhou, China, for Yi Xin to develop, manufacture and sell new generations of diagnostic test systems based on our core FastPack technology. In addition, the Technology Transfer Agreement authorized Yi Xin to manufacture and sell our current generations of FastPack System diagnostic products (1.0, IP and PRO) in China.
● Goodwill
● In Process R&D
Under the Technology Transfer Agreement, we received aggregate net cash payments of $670,000, of which we recognized approximately $38,000 in product sales and $632,000 in license revenue during 2021. In addition, we will receive low- to mid-single-digit royalties on any future new-generations and current-generations product sales by Yi Xin. We recognized no product sales or license revenue for the three months and six months ended June 30, 2022 .We recognized no product sales or license revenue in the three months ended June 30, 2021 and $38,000 in product sales and $479,000 in license revenue in the condensed consolidated statement of operations and other comprehensive loss for the six months ended June 30, 2021
● Derivative financial instruments and warrant liabilities
● Stock-based compensation
~~We provided technology transfer and patent/know-how license rights to facilitate Yi Xin’s development and commercialization.~~
In the Technology Transfer Agreement (as amended in August 2021), we gave Yi Xin the exclusive rights for China – which is a market we have not otherwise entered – both for Yi Xin’s new generations of FastPack-based products and for Yi Xin-manufactured versions of our existing FastPack product lines. Yi Xin also has the right to sell its new generations of FastPack-based diagnostic test systems throughout the world (but not to or toward current customers of our existing generations of FastPack products). In addition, after March 31, 2022, Yi Xin has the right to sell Yi Xin-manufactured versions of existing FastPack 1.0, IP and PRO product lines worldwide (other than in the United States and other than to or toward current non-US customers of those products). Also, after March 31, 2022, Yi Xin has the right to buy Qualigen-manufactured FastPack 1.0, IP and PRO products from us at distributor prices for resale in and for the United States (but not to or toward current US customers of those products); we did not license Yi Xin to sell in the United States market any Yi Xin-manufactured versions of those legacy FastPack product lines, even after March 31, 2022.
In the Technology Transfer Agreement, we also confirmed that we would not, after the March 31, 2022 expiration of the Sekisui Distribution Agreement, seek new FastPack customers outside the United States.
Yi Xin is a newly-formed company and its operations are subject to many risks. There can be no assurance that Yi Xin will successfully commercialize any products or that we will receive any royalties from Yi Xin.
● Income taxes

Warrant Liabilities

In 2004, Qualigen, Inc. issued ~~a series of~~ Series C preferred stock warrants to investors and brokers in connection with a private placement. These warrants were subsequently extended and survived the May 2020 Ritter reverse recapitalization transaction and are now exercisable for Qualigen Therapeutics common stock. These warrants ~~contained~~contain a provision that if ~~Qualigen, Inc. issues~~we issue shares (except in certain defined scenarios) at a price below the warrants’ exercise price, the exercise price will be re-set to such new price and the number of shares underlying the warrants will be increased in the same proportion as the exercise price decrease. For accounting purposes, ~~this provision gives~~such warrants give rise to ~~“warrant liabilities” (even though there is not any “liability”~~warrant liabilities. The operation of the “double-ratchet” provisions in these warrants in connection with the ~~sense that we would be obligated~~NanoSynex Acquisition and the convertible debenture financing transaction in December 2022 now allow the holders to ~~pay any cash sum to anyone).~~exercise for a significantly higher number of shares than before. Accounting principles generally accepted in the United States of America (“U.S. GAAP”) require us to recognize the fair value of these warrants as warrant liabilities on our condensed consolidated balance sheets and to reflect period-to-period changes in the fair value of the warrant liabilities on our condensed consolidated ~~statements~~Statements of ~~operations~~Operations. The estimated fair value of these warrant liabilities was $0.1 million and ~~other comprehensive loss.~~$0.8 million at June 30, 2023 and December 31, 2022, respectively. There were 1,349,571 of these warrants outstanding at June 30, 2023 and December 31, 2022.

On December 22, 2022, as part of the convertible debenture financing, the Company issued to Alpha Capital a common stock warrant for 2,500,000 shares of common stock of the Company (the “Alpha Warrant”). The exercise price of the Alpha Warrant ~~liabilities were $1.0~~is $1.65. The Alpha Warrant may be exercised by Alpha Capital, in whole or in part, at any time on or after June 22, 2023 and before June 22, 2028. U.S. GAAP requires us to recognize the fair value of this warrant as a warrant liability on our condensed consolidated balance sheets and to reflect period-to-period changes in the fair value of the warrant liability on our condensed consolidated statements of operations. The estimated fair value of this warrant liability was $2.0 million and $2.8 million at June 30, 2023 and December 31, 2022, ~~and~~respectively.
Because the ~~change in~~ fair value ~~was $0.7 million for~~of the ~~six months ended June 30, 2022. Because fair value~~above liability classified warrants will be determined each quarter on a “mark-to-market” basis, ~~this item will usually~~it could result in significant variability in our future quarterly and annual ~~statements~~consolidated statement of operations and ~~condensed~~ consolidated balance sheets based on changes in our public market common stock price. Pursuant to U.S. GAAP, a quarter-to-quarter increase in our stock price would result in aan increase (possibly quite large) ~~increase~~ in the fair value of the warrant liabilities and a quarter-to-quarter decrease in our stock price would result in a decrease (possibly quite large) ~~decrease~~ in the fair value of the warrant liabilities. ~~There were 3,468,958 and 2,481,614 of these warrants outstanding at June 30, 2022 and December 31, 2021, respectively.~~
31
~~COVID-19 Update~~

The COVID-19 pandemic has had a dramatic impact on businesses globally and our business as well. Our sales of diagnostic products fell significantly during 2020 and our net loss increased significantly, as deferral of patients’ non-emergency visits to physician offices, clinics and small hospitals sharply reduced demand for FastPack tests. Since then we have experienced some recovery in demand. The ultimate severity and duration of the pandemic and economic repercussions of the virus and government actions taken in response to the pandemic remain uncertain at this time, and will ultimately depend on many factors, including the speed of global dissemination and effectiveness of the vaccination and containment efforts throughout the world, as well as seasonality, and the emergence of new vaccine-resistant variants or new outbreaks.
In the United States, federal, state, and local government directives and policies have been put in place from time to time during the course of the pandemic to manage public health concerns and address the economic impacts of the pandemic, including reduced business activity and overall uncertainty presented by this new healthcare challenge. Similar actions have been taken by governments around the world. Our facilities could be required to temporarily curtail production levels or temporarily cease operations based on government mandates or as a result of the pandemic. To m~~itigate risks, we continue to evaluate the extent to which COVID-19 may impact our business and operations and adjust risk mitigation planning and business continuity activities as needed.~~
32 34

Results of Operations

Comparison of the Three Months Ended June 30, ~~2022~~2023 and ~~2021~~2022

The following table summarizes our results of operations for the three months ended June 30, ~~2022~~2023 and ~~2021:~~2022:

For the Three Months Ended
June 30, For the Three Months Ended
June 30,
2022 2021 2023 2022
REVENUES
Net product sales $ 1,430,534 $ 1,117,935 $ 1,627,031 $ 1,430,534
License revenue — —
Total revenues 1,430,534 1,117,935 1,627,031 1,430,534

EXPENSES
Cost of product sales 1,099,677 916,624 1,016,542 1,099,677
General and administrative 2,660,857 2,952,100 2,665,849 2,660,857
Research and development 1,506,227 4,508,466 1,326,544 1,506,227
Sales and marketing 305,103 135,543 169,223 305,103
Total expenses 5,571,864 8,512,733 5,178,158 5,571,864

LOSS FROM OPERATIONS (4,141,330 ) (7,394,798 ) (3,551,127 ) (4,141,330 )

OTHER INCOME (EXPENSE), NET
OTHER EXPENSE (INCOME), NET
Gain on change in fair value of warrant liabilities 14,800 1,982,256 (440,294 ) (14,800 )
Interest income, net 4,824 12,718
Other income (expense), net (376 ) 2,352
Total other income, net 19,248 1,997,326
Interest expense (income), net 377,416 (4,823 )
Loss on disposal of equipment held for lease 63,302 —
Other income, net (5,680 ) 376
Total other expense (income), net (5,256 ) (19,247 )

LOSS BEFORE PROVISION FOR INCOME TAXES (4,122,082 ) (5,397,472 )
LOSS BEFORE (BENEFIT) PROVISION FOR INCOME TAXES (3,545,871 ) (4,122,082 )

PROVISION FOR INCOME TAXES 5,438 605
(BENEFIT) PROVISION FOR INCOME TAXES (38,182 ) 5,438

NET LOSS (4,127,520 ) (5,398,077 ) (3,507,689 ) (4,127,520 )

Net loss attributable to noncontrolling interest (4,116 )
—
(43,484 ) (4,116 )

Net loss attributable to Qualigen Therapeutics, Inc. $ (4,123,404 ) $ (5,398,077 ) $ (3,464,205 ) $ (4,123,404 )

Other comprehensive loss, net of tax
Net loss $ (4,127,520 ) $ (5,398,077 ) $ (3,507,689 ) $ (4,127,520 )
Foreign currency translation adjustment 65,540
—
(56,747 ) 65,540
Other comprehensive loss (4,061,980 ) (5,398,077 ) (3,564,436 ) (4,061,980 )
Comprehensive loss attributable to noncontrolling interest (4,116 )
—
(43,484 ) (4,116 )
Comprehensive loss attributable to Qualigen Therapeutics, Inc. stockholders $ (4,057,864 ) $ (5,398,077 )
Comprehensive loss attributable to Qualigen Therapeutics, Inc. $ (3,520,952 ) $ (4,057,864 )

Revenues

Net product sales

Net product sales are primarily generated from sales of diagnostic tests. Net product sales during the three-month periods ended June 30, ~~2022~~2023 and ~~2021~~2022 were approximately ~~$1.4~~$1.6 million and ~~$1.1~~$1.4 million, respectively, representing an increase of approximately ~~$0.3~~$0.2 million, or ~~28%~~14%. This increase was primarily due to ~~the expiration of the Sekisui Distribution Agreement on March 31, 2022, at which time the services previously provided by Sekisui reverted to the Company, which resulted~~growth in ~~the Company recognizing 100% of the revenue from direct~~ sales ~~of our FastPack diagnostic instruments~~volumes and ~~test kits.~~higher average unit selling prices.

33
Expenses

Cost of Product Sales

Cost of product sales ~~increased~~decreased during the three months ended June 30, ~~2022,~~2023, to ~~$1.1~~$1.0 million, or ~~77%~~62% of net product sales, compared to approximately ~~$0.9~~$1.1 million, or ~~82%~~77% of net product sales, during the three months ended June 30, ~~2021.~~2022. This ~~increase~~decrease of ~~$0.2~~$0.1 million, and decrease as a percentage of sales was ~~due~~ primarily ~~to the increase in sales during the three-month period and higher average unit selling prices~~ due to ~~the termination of the Sekisui agreement on March 31, 2022.~~a reduction in force implemented in January 2023.

General and Administrative Expenses

General and administrative expenses ~~decreased 10% from $3.0~~remained the same at $2.7 million, ~~during~~for the three months ended June 30, ~~2021, to $2.7 million during the three months ended June 30, 2022. This decrease was primarily due to a $0.4 million reduction in spending for professional fees related to investor relations, legal, accounting,~~2023 and ~~consulting fees, partially offset by a $0.1 million increase in employee/director stock-based compensation expense.~~2022.

Research and Development Costs

Research and development costs include ~~therapeutics~~therapeutic and ~~diagnostics~~diagnostic research and product development costs. Research and development costs decreased from ~~$4.5 million for the three months ended June 30, 2021 to~~ $1.5 million for the three months ended June 30, ~~2022.~~2022 to $1.3 million for the three months ended June 30, 2023. Of the $1.3 million of research and development costs for the three months ended June 30, 2023, approximately $1.2 million (89%) was attributable to therapeutics and $0.2 million (11%) was attributable to diagnostics. Of the $1.5 million of research and development costs for the three months ended June 30, 2022, $1.1 million (73%) was attributable to therapeutics and $0.4 million (27%) was attributable to diagnostics. Of the $4.5 million of research and development costs for the three months ended June 30, 2021, $4.2 million (93%) was attributable to therapeutics and $0.3 million (7%) was attributable to diagnostics.

The ~~decrease~~$0.1 million increase in therapeutics research and development costs during the three months ended June 30, ~~2022~~2023 compared to the three months ended June 30, ~~2021~~2022 was primarily due to a $3.4 million decrease in pre-clinical research costs related to the potential application of QN-165 for the treatment of COVID-19 (which has since been deprioritized to a non-core program), a $0.2 million decrease in legal and recruiting fees, offset by an increase of ~~$0.1~~$0.5 million in ~~pre-clinical~~preclinical research costs for QN-302, ~~which we acquired in January 2022, an increase~~offset by a decrease of ~~$0.2~~$0.4 million in ~~pre-clinical~~preclinical research costs for ~~QN-247, and an increase of $0.2 million in pre-clinical research costs for our RAS program.~~QN-247.

The ~~increase~~$0.2 million decrease in diagnostics research and development costs during the three months ended June 30, ~~2022~~2023 compared to the three months ended June 30, ~~2021~~2022 was primarily due ~~primarily~~ to a $0.2 million decrease in stock-based compensation expense and a $0.1 million decrease in payroll expenses related to FastPack due to the January 2023 reduction in force, offset by an increase of $0.1 million in ~~supplies expense of approximately $0.1 million.~~research and development expenses for NanoSynex.

For the future, we expect our therapeutic research and development costs to ~~continue to outweigh our diagnostic research and development costs, and to~~ be relatively lower in periods when we are focusing on ~~pre-clinical~~preclinical activities and meaningfully higher in periods when we are provisioning for and conducting clinical trials, if any.

Sales and Marketing Expenses

Sales and marketing expenses were approximately ~~$0.3~~$0.2 million for the three months ended June 30, ~~2022, an increase~~2023, a decrease of ~~$0.2~~$0.1 million or ~~125%~~45%, from the three months ended June 30, ~~2021.~~2022. This ~~increase~~decrease was primarily due to ~~a $0.1 million increase in~~reduced payroll expenses related to the ~~assumption of Sekisui sales personnel~~January 2023 reduction in ~~the current quarter, and also due to increased spending for advertising, conventions and tradeshows of $0.1 million.~~force.

Other Income (Expense), Net

Change in Fair Value of Warrant Liabilities

During ~~the~~ three months ended June 30, ~~2022 and 2021,~~2023 we experienced a ~~gain of approximately $15,000 and $2.0~~$0.4 million ~~respectively,~~gain on change in fair value of warrant liabilities arising from our liability classified warrants described above. The estimated fair value of these warrants decreased to $2.1 million as of June 30, 2023 from $3.6 million as of December 31, 2022, primarily due to ~~declines~~a reduction in our stock price and ~~reduction in the~~shorter remaining ~~terms~~outstanding life of the warrants. ~~Typically,~~
Because the fair value of the warrant liabilities will be determined each quarter on a ~~decline~~“mark-to-market” basis, this item is likely to continue to result in significant variability in our future quarterly and annual consolidated statements of operations based on unpredictable changes in our public market common stock price and the number of warrants outstanding at the end of each quarter.
Interest Expense (Income), Net
Interest expense, net during the three months ended June 30, 2023 was approximately $377,000 due to accrued interest on the convertible debt, as compared to interest income, net of approximately $5,000 during the three months ended June 30, 2022.
36
Loss on Disposal of Equipment Held for Lease
Loss on disposal of equipment held for lease during the three months ended June 30, 2023 was $63,000, compared to $0 during the three months ended June 30, 2022. This increase of $63,000 was due to a write off of discontinued FastPack analyzers that were acquired from Sekisui.
Other Income, Net
Other income was immaterial during the three months ended June 30, 2023 and 2022.
Comparison of the Six Months Ended June 30, 2023 and 2022
The following table summarizes our results of operations for the six months ended June 30, 2023 and 2022:
For the Six Months Ended
June 30,
2023 2022
REVENUES
Net product sales $ 3,234,201 $ 2,152,563
Total revenues 3,234,201 2,152,563

EXPENSES
Cost of product sales 2,281,368 1,928,524
General and administrative 4,380,283 5,559,608
Research and development 3,448,095 3,370,972
Sales and marketing 368,337 443,426
Total expenses 10,478,083 11,302,530

LOSS FROM OPERATIONS (7,243,882 ) (9,149,967 )

OTHER EXPENSE (INCOME), NET
Gain on change in fair value of warrant liabilities (1,478,967 ) (698,042 )
Interest expense (income), net 921,652 (11,132 )
Loss on voluntary conversion of convertible debt 1,077,287 —
Loss on disposal of equipment held for lease 63,302 —
Other income, net (10,559 ) 341
Loss on fixed asset disposal 300 —
Total other expense (income), net 573,015 (708,833 )

LOSS BEFORE (BENEFIT) PROVISION FOR INCOME TAXES (7,816,897 ) (8,441,134 )

(BENEFIT) PROVISION FOR INCOME TAXES (201,959 ) 6,173

NET LOSS (7,614,938 ) (8,447,307 )

Net loss attributable to noncontrolling interest (304,512 ) (4,116 )

Net loss attributable to Qualigen Therapeutics, Inc. $ (7,310,426 ) $ (8,443,191 )

Other comprehensive loss, net of tax
Net loss $ (7,614,938 ) $ (8,447,307 )
Foreign currency translation adjustment 119,473 65,540
Other comprehensive loss (7,495,465 ) (8,381,767 )
Comprehensive loss attributable to noncontrolling interest (304,512 ) (4,116 )
Comprehensive loss attributable to Qualigen Therapeutics, Inc. $ (7,190,953 ) $ (8,377,651 )
Revenues
Net product sales
Net product sales are primarily generated from sales of diagnostic tests. Net product sales during the six-month periods ended June 30, 2023 and 2022 were approximately $3.2 million and $2.2 million, respectively, representing an increase of approximately $1.0 million, or 50%. This increase was primarily due to the expiration of the Sekisui Distribution Agreement on March 31, 2022, at which time the distribution services previously provided by Sekisui reverted to us, which resulted in our recognizing 100% of the revenue from sales of our FastPack diagnostic test kits and instruments beginning in the second quarter of 2022.
Expenses
Cost of Product Sales
Cost of product sales increased during the six months ended June 30, 2023 to $2.3 million, or 71% of net product sales, compared to approximately $1.9 million, or 90% of net product sales, during the six months ended June 30, 2022. This increase of $0.4 million, and decrease as a percentage of sales was relative to the increase in sales volumes and higher average unit selling prices due to the termination of the Sekisui agreement on March 31, 2022 as well as a reduction in force implemented in January 2023.
General and Administrative Expenses
General and administrative expenses decreased from $5.6 million, during the six months ended June 30, 2022 to approximately $4.4 million during the six months ended June 30, 2023, a decrease of $1.2 million or 21%. This decrease was primarily due to a $1.5 million decrease in stock-based compensation expense due to the January 2023 reduction in force, partially offset by an increase in accounting fees of $0.3 million.
Research and Development Costs
Research and development costs include therapeutic and diagnostic research and product development costs. Research and development costs remained approximately the same at $3.4 million for the six months ended June 30, 2023 compared to the six months ended June 30, 2022. Of the $3.4 million of research and development costs for the six months ended June 30, 2023, $2.4 million (71%) was attributable to therapeutics and $1.0 million (29%) was attributable to diagnostics. Of the $3.4 million of research and development costs for the six months ended June 30, 2022, $2.7 million (80%) was attributable to therapeutics and $0.7 million (20%) was attributable to diagnostics.
The $0.3 million decrease in therapeutics research and development costs during the six months ended June 30, 2023 compared to the six months ended June 30, 2022 was primarily due to a decrease of $0.9 million of preclinical research costs for our QN-247 program, a decrease of $0.1 million in RAS preclinical research costs, a $0.2 million decrease in payroll-related expenses, and a $0.1 million decrease in preclinical research costs for QN-165, offset by an increase of $1.0 million in preclinical research costs for QN-302.
The $0.3 million increase in diagnostics research and developments costs during the six months ended June 30, 2023 compared to the six months ended June 30, 2022 was due to an increase of $0.8 million in research and development expenses for NanoSynex, offset by a reduction of offset by a reduction of $0.5 million in FastPack research and development expenses due to the January 2023 reduction in force.
For the future, we expect our therapeutic research and development costs to be relatively lower in periods when we are focusing on preclinical activities and meaningfully higher in periods when we are provisioning for and conducting clinical trials, if any.
Sales and Marketing Expenses
Sales and marketing expenses were approximately $0.4 million for the six months ended June 30, 2023, a decrease of $0.1 million or 17% from the six months ended June 30, 2022. This decrease was primarily due to lower payroll costs as a result of the January 2023 reduction in force.
Other Income (Expense), Net
Change in Fair Value of Warrant Liabilities
During six months ended June 30, 2023 we experienced a $1.5 million gain on change in fair value of warrant liabilities arising from our liability classified warrants described above. The estimated fair value of these warrants decreased to $2.1 million as of June 30, 2023 from $3.6 million as of December 31, 2022, primarily due to a reduction in our stock price ~~would result in a decline in~~and shorter remaining outstanding life of the ~~fair value of our warrant liabilities, generating a gain, while an increase in our stock price would result in an increase in the fair value of our warrant liabilities, generating a loss.~~warrants.
38

Because the fair value of the warrant liabilities will be determined each quarter on a “mark-to-market” basis, this item is likely to continue to result in significant variability in our future quarterly and annual statements of operations based on unpredictable changes in our public market common stock price and the number of liability classified warrants outstanding at the end of each quarter.

Interest ~~Income,~~Expense (Income), Net
~~There was approximately $5,000 and $13,000 in interest income during the three months ended June 30, 2022 and 2021, respectively.~~
34
~~Other Income, Net~~
~~Other income was immaterial during the three months ended June 30, 2022 and 2021.~~
~~Net loss attributable to noncontrolling interest~~
~~Net loss attributable to noncontrolling interest was immaterial during the three months ended June 30, 2022 and 2021.~~
~~Other comprehensive income-foreign currency translation adjustment~~

~~Other comprehensive income-foreign currency translation adjustment was $65,540 for~~Interest expense, net during the ~~three~~six months ended June 30, ~~2022~~2023 was approximately $921,000 due to accrued interest on the convertible debt, as compared to ~~$0 for~~interest income, net of approximately $11,000 during the ~~three~~six months ended June 30, ~~2021. The increase of $65,540 was due to the acquisition of NanoSynex in May 2022 and the translation of their June 30, 2022 financial statements into U.S. dollars from New Israeli Shekels.~~
~~Comparison of the Six Months Ended June 30, 2022 and 2021~~2022.

~~The following table summarizes~~Loss on Voluntary Conversion of Convertible Debt
During the six months ended June 30, 2023, we recognized a $1.1 million loss due to a voluntary conversion by Alpha Capital of approximately $1.1 million of convertible debt into 841,726 shares of common stock (see Note 10 - Convertible Debt - Related Party to our ~~results of operations~~condensed consolidated financial statements). We did not have any outstanding convertible debt for the six months ended June 30, ~~2022 and 2021:~~2022.
For the Six Months Ended
June 30,
2022 2021
REVENUES
Net product sales $ 2,152,563 $ 2,538,776
License revenue — 478,654
Total revenues 2,152,563 3,017,430

EXPENSES
Cost of product sales 1,928,524 2,119,103
General and administrative 5,559,608 5,826,038
Research and development 3,370,972 8,007,840
Sales and marketing 443,426 272,129
Total expenses 11,302,530 16,225,110

LOSS FROM OPERATIONS (9,149,967 ) (13,207,680 )

OTHER INCOME (EXPENSE), NET
Gain on change in fair value of warrant liabilities 698,042 2,535,064
Interest income, net 11,132 30,061
Other income (expense), net (341 ) 2,894
Total other income, net 708,833 2,568,019

LOSS BEFORE PROVISION FOR INCOME TAXES (8,441,134 ) (10,639,661 )

PROVISION FOR INCOME TAXES 6,173 1,135

NET LOSS (8,447,307 ) (10,640,796 )

Net loss attributable to noncontrolling interest (4,116 ) —

Net loss attributable to Qualigen Therapeutics, Inc. $ (8,443,191 ) $ (10,640,796 )

Other comprehensive loss, net of tax
Net loss $ (8,447,307 ) $ (10,640,796 )
Foreign currency translation adjustment 65,540 —
Other comprehensive loss (8,381,767 ) (10,640,796 )
Comprehensive loss attributable to noncontrolling interest (4,116 )
—

Comprehensive loss attributable to Qualigen Therapeutics, Inc. stockholders $ (8,377,651 ) $ (10,640,796 )
35
~~Revenues~~Loss on Disposal of Equipment Held for Lease
~~Net product sales~~
~~Net product sales are primarily generated from sales~~Loss on disposal of ~~diagnostic tests. Net product sales~~equipment held for lease during the ~~six-month periods~~six months ended June 30, ~~2022 and 2021 were approximately $2.2 million and $2.5 million, respectively, representing a decrease of approximately $0.4 million, or 15%. This decrease~~2023, was primarily due to the expiration of the Sekisui Distribution Agreement on March 31, 2022, which caused Sekisui to reduce its purchases from us during the first quarter of 2022, as it sold off its remaining inventory prior to the expiration of the agreement. However this reduction in Sekisui purchases during the first quarter was partially offset by higher direct sales of FastPack diagnostic instruments and test kits during the second quarter of 2022 and the Company recognizing 100% of the revenue from these sales,$63,000, compared to ~~the second quarter of 2021.~~
~~License Revenue~~
~~There was no license revenue for~~$0 during the six months ended June 30, 2022. ~~During the six months ended June 30, 2021 there was approximately $0.5 million, due to the recognition~~This increase of ~~revenue from Yi Xin under the Technology Transfer Agreement.~~
~~Expenses~~
~~Cost of Product Sales~~
Cost of product sales decreased during the six months ended June 30, 2022, to $1.9 million, or 90% of net product sales, compared to approximately $2.1 million, or 83% of net product sales, during the six months ended June 30, 2021. This decrease of $0.2 million, and increase as a percentage of sales$63,000 was due to a ~~reduction in production volumes compared to the prior period due to the expiration~~write off of ~~the Sekisui Distribution Agreement, as Sekisui sold off its remaining inventory during the first quarter.~~
~~General and Administrative Expenses~~
~~General and administrative expenses decreased~~discontinued FastPack analyzers that were acquired from ~~$5.8 million, during the six months ended June 30, 2021, to approximately $5.6 million during the six months ended June 30, 2022, a decrease of $0.3 million or 5%.~~ This decrease was primarily due to a $0.6million decrease in investor relations, legal, accounting and consulting fees, partially offset by increases in stock-based compensation expense of $0.1 million, increases in wages/bonuses and related payroll taxes of $0.2 million
~~Research and Development Costs~~
Research and development costs include therapeutics and diagnostics research and product development costs. Research and development costs decreased from $8.0 million for the six months ended June 30, 2021 to $3.4 million for the six months ended June 30, 2022. Of the $3.4 million of research and development costs for the six months ended June 30, 2022, $2.7 million (80%) was attributable to therapeutics and $0.7 million (20%) was attributable to diagnostics. Of the $8.0 million of research and development costs for the six months ended June 30, 2021, $7.3 million (91%) was attributable to therapeutics and $0.7 million (9%) was attributable to diagnostics.
The decrease in therapeutics research and development costs during the six months ended June 30, 2022 compared to the six months ended June 30, 2021 was primarily due to a $6.0 million decrease in pre-clinical research costs related to the potential application of QN-165 for the treatment of COVID-19 (which has since been deprioritized to a non-core program), offset by an increase of $0.5 million in pre-clinical research costs for QN-302, which we acquired in January 2022, an increase of $0.6 million in pre-clinical research costs for QN-247, and an increase of $0.3 million in pre-clinical research costs for our RAS program.
~~There were no material changes in diagnostics research and development costs during the six months ended June 30, 2022 as compared to the six months ended June 30, 2021~~
For the future, we expect our therapeutic research and development costs to continue to outweigh our diagnostic research and development costs, and to be relatively lower in periods when we are focusing on pre-clinical activities and meaningfully higher in periods when we are provisioning for and conducting clinical trials, if any.
~~Sales and Marketing Expenses~~
Sales and marketing expenses were approximately $0.4 million for the six months ended June 30, 2022 , an increase of $0.2 million or 63% from the six months ended June 30, 2021. This increase was primarily due to a $0.1 million increase in payroll expenses related to the assumption of Sekisui sales personnel in the current period and also due to increased spending for advertising, conventions and tradeshows of $0.1 million.
36
~~Other Income (Expense), Net~~
~~Change in Fair Value of Warrant Liabilities~~
During the six months ended June 30, 2022 and 2021, we experienced a gain of $0.7 million and $2.5 million, respectively, on change in fair value of warrant liabilities, primarily due to declines in our stock price, reductions in the remaining terms of the warrants during both periods, and warrant exercises during the prior period. Typically, a decline in our stock price would result in a decline in the fair value of our warrant liabilities, generating a gain, while an increase in our stock price would result in an increase in the fair value of our warrant liabilities, generating a loss.
Because the fair value of the warrant liabilities will be determined each quarter on a “mark-to-market” basis, this item is likely to continue to result in significant variability in our future quarterly and annual statements of operations based on unpredictable changes in our public market common stock price and the number of liability classified warrants outstanding at the end of each quarter.
~~Interest Income, Net~~
~~There was approximately $11,000 and $30,000 in interest income during the six months ended June 30, 2022 and 2021, respectively.~~Sekisui.

Other Income, Net

Other income was immaterial during the six months ended June 30, ~~2022~~2023 and ~~2021.~~
~~Net loss attributable to noncontrolling interest~~
~~Net loss attributable to noncontrolling interest was immaterial during the six months ended June 30, 2022 and $0 during the six months ended June 30, 2021.~~
~~Other comprehensive income-foreign currency translation adjustment~~
Other comprehensive income-foreign currency translation adjustment was $65,540 for the six months ended June 30, 2022 as compared to $0 for the six months ended June 30, 2021. The increase of $65,540 was due to the acquisition of NanoSynex in May 2022 and the translation of their June 30, 2022 financial statements into U.S. dollars from New Israeli Shekels.2022.

Liquidity and Capital Resources

As of June 30, ~~2022,~~2023, we had approximately ~~$9.7~~$1.3 million in cash. ~~The Company has incurred recurring losses from operations~~ and ~~has~~ an accumulated deficit atof $110.7 million. For the six months ended June 30, ~~2022. The Company expects to continue to incur losses subsequent to~~2023 and the ~~condensed consolidated balance sheet date~~year ended December 31, 2022, we used cash of ~~June 30, 2022. In December 2021, the Company raised $8.82~~$5.6 million ~~through a Securities Purchase Agreement with several institutional investors.~~
~~Based on the Company’s current cash position,~~ and assuming currently planned expenditures and level of operations, the Company believes it has sufficient capital to fund operations for the 12-month period subsequent to the issuance of the accompanying unaudited condensed financial statements. We will need substantial additional funding to continue our operations, particularly for QN-302 clinical trials, to continue preclinical development of QN-247 and RAS-F, and to continue funding the NanoSynex$13.2 million, respectively, in operations.

AsOn July 25, 2023, we received a ~~pre-clinical development-stage therapeutics biotechnology company,~~cash payment of $4.7 million from Chembio for all of the outstanding shares of common stock of Qualigen, Inc., which payment is subject to post-closing adjustments, upward or downward, as applicable, for: (i) cash held by the Subsidiary as of the closing of the Transaction; (ii) net working capital of the Subsidiary as of the closing of the Transaction, (iii) certain indebtedness of the Subsidiary as of the closing of the Transaction, and (iv) certain Transaction expenses as of the closing of the Transaction. An additional $450,000 is being held in an escrow account to satisfy certain indemnification obligations. Any amounts remaining in the Indemnity Escrow that have not been offset or reserved for claims will be released to us within five business days following the date that is 18 months after the closing of the Transaction.
On July 20, 2023, we ~~expect~~entered into the NanoSynex Amendment with NanoSynex, which amended the NanoSynex Funding Agreement. See “Contractual Obligations and Commitments” below.
The Company’s cash balances as of the date that the accompanying financial statements were issued along with the proceeds from the above sale to Chembio, without additional financing, are expected to fund operations into the first quarter of 2024. The Company expects to continue to have net losses and negative cash flow from operations, which over time will challenge ~~our~~its liquidity. These factors raise substantial doubt about the Company’s ability to continue as a going concern for the one-year period following the date that these financial statements were issued.
There is no assurance that profitable operations will ever be achieved, or, if achieved, could be sustained on a continuing basis. In order to fully execute our business plan, we will require significant additional ~~financing~~funding for planned research and development activities, capital expenditures, clinical testing for our QN-302 clinical trials, preclinical development of RAS and ~~pre-clinical testing and~~QN-247, as well as commercialization activities.
Historically, our principal sources of cash have included proceeds from the issuance of common and preferred equity and proceeds from the issuance of debt. In December 2022 we raised $3.0 million from the sale of a convertible debt instrument (see Note 10-Convertible Debt - Related Party to our unaudited condensed consolidated financial statements). There can be no assurance that further financing ~~can~~will be obtained on favorable terms, or at all. If we are unable to obtain funding, we could be required to delay, reduce or eliminate research and development programs, product portfolio expansion or future commercialization efforts, which could adversely affect our business prospects.

~~To the extent~~The accompanying financial statements have been prepared assuming that we ~~raise additional capital through~~will continue as a going concern. The financial statements do not include any adjustments that would be necessary should we be unable to continue as a going concern, and therefore, be required to liquidate our assets and discharge our liabilities in other than the ~~sale~~normal course of ~~equity or convertible debt securities, the ownership interests of our common stockholders will be diluted,~~business and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through government or other third-party funding, commercialization, marketing and distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on termsat amounts that may ~~not be favorable to us.~~differ from those reflected in the accompanying financial statements.

Our condensed consolidated balance sheet at June 30, ~~2022~~2023 includes ~~$1.0~~$2.1 million of warrant liabilities. We do not consider the warrant liabilities to constrain our liquidity, as a practical matter. Our current liabilities at June 30, ~~2022~~2023 include ~~$0.9~~$1.8 million of accounts payable, ~~and $1.4~~$2.0 million of accrued expenses and other current ~~liabilities.~~liabilities, a $0.2 million R&D grant liability, $0.3 million of accrued vacation, $1.8 million in short term debt and convertible debt to a related party.

37
Contractual Obligations and Commitments

We have no material contractual obligations that are not fully recorded on our condensed consolidated balance sheets or fully disclosed in the notes to the unaudited condensed consolidated financial statements.
Lease Agreement with Bond Ranch LP
On December 15, 2021, our wholly-owned subsidiary Qualigen, Inc. entered into a Second Amendment to Lease with Bond Ranch LP. This Amendment extended ~~the Company’s~~our triple-net leasehold on ~~its~~our existing 22,624-square-foot headquarters/manufacturing facility at 2042 Corte del Nogal, Carlsbad, California for the 61-month period of November 1, 2022 to November 30, 2027. Over the 61 months, the base rent payable will total $1,950,710; however, the base rent for the first 12 months of the 61-month period will be only $335,966. Additionally, Qualigen, Inc. iswas entitled to a $339,360 tenant improvement allowance. On July 20, 2023, the Company entered into a Purchase Agreement with Chembio, Biosynex, S.A. (“Biosynex”), and Qualigen, Inc., a wholly-owned subsidiary of the Company. Pursuant to the Purchase Agreement, the Company agreed to sell to Chembio all of the issued and outstanding shares of common stock of Qualigen, Inc. The lease commitments described above transferred to Chembio upon the closing of this transaction. See Note 12 –- Commitments and Contingencies ~~of the~~and Note 16 - Subsequent Events: Stock Purchase Agreement with Chembio Diagnostics, Inc. and Biosynex, S.A. to our unaudited condensed consolidated financial statements for additional details.

~~We have no material contractual obligations that are not fully recorded on our condensed consolidated balance sheets or fully disclosed in the notes to the financial statements.~~License and Sponsored Research Agreements

We have obligations under various license and sponsored research agreements to make future payments to third parties that become due and payable on the achievement of certain development, regulatory and commercial milestones (such as the start of a clinical trial, filing for product approval with the FDA or other regulatory agencies, product approval by the FDA or other regulatory agencies, product launch or product sales) or on the sublicense of our rights to another party. We have not included these commitments on our balance sheet because the achievement and timing of these events is not ~~fixed and~~ determinable. Certain milestones are in advance of receipt of revenue from the sale of products and, therefore, we may require additional debt or equity capital to make such payments.

~~License and Sponsored Research Agreements with ULRF~~
We have multiple license and sponsored research agreements with ~~UofL Research Foundation (“ULRF”).~~ULRF. Under these agreements, we have taken over development, regulatory approval and commercialization of various drug compounds from ULRF and are responsible for maintenance of the related intellectual property portfolio. We agreed to reimburse ULRF for sponsored research expenses of up to $805,000 and prior patent costs of up to $200,000 for QN-247. As of June 30, 2022, there were no remaining unexpensed amounts under this sponsored research agreement for QN-247. We alsoFor example, we agreed to reimburse ULRF for sponsored research expenses of up to $2.7 million and prior patent costs of up to $112,000 for RAS. As of June 30, ~~2022 we had up~~2023, there was approximately $239,000 remaining due to ~~$1.2 million remaining due~~ULRF under this sponsored research agreement for RAS. We also agreed to reimburse ULRF for sponsored research expenses of up to ~~$430,000~~$830,000 and prior patent costs of up to ~~$24,000~~$200,000 for ~~QN-165.~~QN-247. As of June 30, ~~2022 we had~~2023, there were no remaining ~~unexpensed~~un-expensed amounts due to ULRF under this sponsored research agreement for ~~QN-165.~~QN-247 and the agreement was terminated effective August 31, 2022. Under the terms of these agreements, we are required to make patent maintenance payments and payments based upon development, regulatory and commercial milestones for any products covered by the in-licensed intellectual property. The maximum aggregate milestone payments we may be obligated to make per product are $5 million. We will also be required to pay a royalty on net sales of products covered by the in-licensed intellectual property in the low single digits. The royalty is subject to reduction for any third-party payments required to be made, with a minimum floor in the low single digits. We have the right to sublicense our rights under these agreements, and we will be required to pay a percentage of any sublicense income.

On January 13, 2022, we entered into a License Agreement with UCL Business Limited to obtain an exclusive worldwide in-license of a genomic quadruplex (G4)-selective transcription inhibitor drug development program which had been developed at University College London, including lead and back-up compounds, preclinical data and a patent estate. (UCL Business Limited is the commercialization company for University College London.) The program’s lead compound ~~will be further~~is being developed ~~at Qualigen~~by us under the name QN-302 as a candidate for treatment of pancreatic ductal adenocarcinoma (PDAC), which represents the vast majority of pancreatic cancers. The Agreement requires (if and when applicable) tiered royalty payments in the low to mid-single digits, clinical/regulatory/sales milestone payments, and a percentage of any non-royalty sublicensing consideration paid to ~~Qualigen.~~the Company.

~~Termination of Sekisui Distribution~~Technology Transfer Agreement with Yi Xin

~~Following~~Through our wholly-owned diagnostics subsidiary Qualigen, Inc., we entered into a Technology Transfer Agreement, dated as of October 7, 2020, with Yi Xin of Suzhou, China, which authorizes Yi Xin to develop, manufacture and sell new generations of diagnostic test systems based on our core FastPack technology. In addition, the ~~expiration~~Technology Transfer Agreement authorizes Yi Xin to manufacture and sell our current generations of FastPack System diagnostic products (1.0, IP and PRO) in China. We have provided technology transfer and patent/know-how license rights to facilitate Yi Xin’s development and commercialization.
Under the terms of the ~~Sekisui Distribution~~Technology Transfer Agreement, we have provided Yi Xin the exclusive rights for China, which is a market we have not otherwise entered, both for Yi Xin’s new generations of FastPack-based products and for Yi Xin-manufactured versions of our existing FastPack product lines. Yi Xin has the right to sell its new generations of FastPack-based diagnostic test systems throughout the world (but not to or toward current customers of our existing generations of FastPack products); provided that any non-China sales would, until March 31, 2022, need to be through Sekisui. As of April 1, 2022, Yi Xin has right to sell Yi Xin-manufactured versions of existing FastPack 1.0, IP and PRO product lines worldwide (other than in the ~~second quarter~~United States and other than to or toward current non-US customers of those products). Yi Xin also has the right, as of April 1, 2022, to buy Qualigen-manufactured FastPack 1.0, IP and PRO products from us at distributor prices for resale in and for the United States (but not to or toward current U.S. customers of those products). We did not license Yi Xin to sell in the United States market any Yi Xin-manufactured versions of those legacy FastPack product lines, even after March 31, 2022. We agreed in the Technology Transfer Agreement that we would not, after March 31, 2022, seek new FastPack customers outside the United States, European Union, Canada, and Mexico.
Under the Technology Transfer Agreement, during the fiscal year ended December 31, 2021 we recognized revenues of approximately $670,000. There were no revenues under this agreement for the six months ended June 30, 2023, and the six months ended June 30, 2022. We will receive low- to mid-single-digit royalties on any future new-generations and current-generations product sales by Yi Xin.
Yi Xin is a newly-formed company and is subject to many risks. There can be no assurance that Yi Xin will successfully commercialize any products or that we will receive any royalties from Yi Xin.
On July 20, 2023, the Company ~~has~~entered into a ~~commitment~~Purchase Agreement with Chembio, Biosynex, S.A. (“Biosynex”), and Qualigen, Inc., a wholly-owned subsidiary of the Company. Pursuant to ~~purchase leased FastPack rental systems back from Sekisui at Sekisui’s net book value,~~ the ~~amount~~Purchase Agreement, the Company agreed to sell to Chembio all of ~~which has not yet been determined.~~the issued and outstanding shares of common stock of Qualigen, Inc. The Technology Transfer Agreement with Yi Xin described above transferred to Chembio upon the closing of this transaction. See Note 16 - Subsequent Events: Stock Purchase Agreement with Chembio Diagnostics, Inc. and Biosynex, S.A. to our unaudited condensed consolidated financial statements for additional details.

~~Master Agreement for the Operational and Technological Funding of NanoSynex~~Alpha Convertible Debt
On December 22, 2022, we issued an 8% Senior Convertible Debenture in the aggregate principal amount of $3,300,000 (“the Debenture”) to Alpha Capital for a purchase price of $3,000,000 pursuant to the terms of a Securities Purchase Agreement, dated December 21, 2022. The Debenture is convertible, at any time, and from time to time, at Alpha Capital’s option, into shares of our common stock, at a price equal to $1.32 per share, subject to adjustment as described in the Debenture and other terms and conditions described in the Debenture, including the Company’s receipt of the necessary stockholder approvals, which were obtained at our 2023 annual meeting of stockholders.
In January 2023 Alpha Capital converted $1,111,078 of the Debenture principal into 841,726 shares of common stock at a conversion price of $1.32 per share.
Commencing June 1, 2023 and continuing on the first day of each month thereafter until the earlier of (i) December 22, 2025 and (ii) the full redemption of the Debenture (each such date, a “Monthly Redemption Date”), we must redeem $110,000 plus accrued but unpaid interest, liquidated damages and any amounts then owing under the Debenture (the “Monthly Redemption Amount”). The Monthly Redemption Amount must be paid in cash; provided that after the first two monthly redemptions, we may elect to pay all or a portion of a Monthly Redemption Amount in shares of common stock, based on a conversion price equal to the lesser of (i) the then applicable conversion price of the Debenture and (ii) 85% of the average of the VWAPs (as defined in the Debenture) for the five consecutive trading days ending on the trading day that is immediately prior to the applicable Monthly Redemption Date. We may also redeem some or all of the then outstanding principal amount of the Debenture at any time for cash in an amount equal to 105% of the then outstanding principal amount of the Debenture being redeemed plus accrued but unpaid interest, liquidated damages and any amounts then owing under the Debenture. Our election to pay monthly redemptions in shares of common stock or to effect an optional redemption is subject to the satisfaction of the Equity Conditions (as defined in the Debenture), including our receipt of the necessary stockholder approvals, which we obtained at our 2023 annual meeting of stockholders.
The Debenture accrues interest at the rate of 8% per annum, which does not begin accruing until December 1, 2023, and will be payable on a quarterly basis. Interest may be paid in cash or shares of common stock of the Company or a combination thereof at the option of the Company; provided that interest may only be paid in shares if the Equity Conditions have been satisfied, including our receipt of the necessary stockholder approvals, which we obtained at our 2023 annual meeting of stockholders.
During the three and six months ended June 30, 2023, we recognized an extinguishment loss on voluntary conversion of convertible debt of $0 and approximately $1.1 million, respectively, and recorded accrued interest of approximately $383,000 and $945,000, respectively (of which approximately $364,000 and $898,000 was a reduction to the discount, respectively) in other expenses in the condensed consolidated statements of operations. In June 2023 we paid the first Monthly Redemption Amount of $110,000 in cash, and as of June 30, 2023 the remaining Debenture principal balance was approximately $2.1 million, the remaining discount was approximately $1.3 million, the fair value of the Alpha Warrant was approximately $2.0 million, and the fair value of the suite of bifurcated embedded derivative features was $0.
41
NanoSynex Funding Agreement
As a condition to the ~~closing of the~~ NanoSynex ~~transaction on May 26, 2022, the Company~~Acquisition, we entered into ~~a Master~~the Funding Agreement ~~for the Operational and Technological Funding of~~with NanoSynex, ~~(the “Funding Agreement”)~~ pursuant to which we agreed to fund NanoSynex up to an aggregate of approximately $10.4 million over ~~the next~~a three ~~years,~~year period, subject to NanoSynex’s achievement of certain performance milestones specified in the NanoSynex Funding Agreement and the satisfaction of other terms and conditions described in the NanoSynex Funding Agreement. ~~The Company may terminate~~
These funding commitments were to be made in the form of convertible promissory notes to be issued to us with a face value equal to the amount paid by us to NanoSynex upon satisfaction of the applicable performance milestone, bearing interest at the rate of 9% per annum on the principal balance from time to time outstanding under the particular promissory note, convertible at our option into additional shares of NanoSynex in order for us to maintain at least a 50.1% controlling ownership interest in NanoSynex, should NanoSynex issue additional shares. During the year ended December 31, 2022, a total of approximately $2.4 million was funded to NanoSynex, and for the six months ended June 30, 2023 an additional $0.5 million was funded to NanoSynex under the Funding ~~Agreement after October 29, 2022 upon 120 days’ notice.~~Agreement.
On July 20, 2023, we entered into the NanoSynex Amendment with NanoSynex, which amended the NanoSynex Funding Agreement and our payment obligations under such agreement. Pursuant to the terms of the Nanosynex Amendment, we will make an initial payment of $380,000 to NanoSynex by surrendering the Preferred B shares of NanoSynex held by us, resulting in our ownership in NanoSynex being reduced from approximately 52.8% to approximately 49.97% of the issued and outstanding voting equity of NanoSynex. In addition, we also agreed to (i) advance $560,000 to NanoSynex on or before November 30, 2023 (the “First Advance”), against which NanoSynex will issue a promissory note to us with a face value in the amount of such funding, and (ii) advance $670,000 to NanoSynex on or before March 31, 2024 (the “Second Advance,” and, together with the First Advance, the “New Advances”), against which NanoSynex will issue a promissory note to us with a face value in the amount of such funding. In addition, $2,880,000 in promissory notes delivered by NanoSynex to us for advances previously made by us to NanoSynex under the NanoSynex Funding Agreement were canceled.In the event we fail to make the New Advances, we have agreed to forfeit additional shares in a number that will be equal to a fraction, the numerator of which is the amount of the default (i.e., the amount that we should have, but failed, to advance to NanoSynex pursuant to the terms of the NanoSynex Amendment), and the denominator of which shall be the price per share that we originally paid in consideration for our Preferred A-1 shares of NanoSynex to the previous holder thereof, being $1.5716 per share.
The NanoSynex Amendment supersedes any payments contemplated by the NanoSynex Funding Agreement, such that except as described in the NanoSynex Amendment, we will have no further payment obligations to NanoSynex under the NanoSynex Funding Agreement or otherwise (including by way of equity investment, loan financing or credit lines), and NanoSynex will have no further payment obligations to us for advances previously received under the NanoSynex Funding Agreement.
Other Service Agreements
We enter into contracts in the normal course of business, including with clinical sites, contract research organizations, and other professional service providers for the conduct of clinical trials, contract manufacturers for the production of our product candidates, contract research service providers for preclinical research studies, professional consultants for expert advice and vendors for the sourcing of clinical and laboratory supplies and materials. These contracts generally provide for termination on notice, and therefore are cancelable contracts.

38
Cash Flows

The following table sets forth the significant sources and uses of cash for the periods set forth below:

For the Six Months Ended For the Six Months Ended
June 30, June 30,
2022 2021 2023 2022
Net cash (used in) provided by:
Operating activities $ (7,827,798 ) $ (8,785,057 ) $ (5,562,416 ) $ (7,827,798 )
Investing activities 71,871 (114,691 ) (246,418 ) 71,871
Financing activities 3,859 155,580 — 3,859
Net decrease in cash $ (7,752,068 ) $ (8,744,168 )
Effect of exchange rate on cash 115,803 (34,228 )
Net decrease in cash and restricted cash $ (5,693,031 ) $ (7,786,296 )
Net Cash Used in Operating Activities
During the six months ended June 30, 2023, operating activities used $5.6 million of cash, primarily resulting from a net loss of $7.6 million. Cash flows from operating activities (as opposed to net loss) for the six months ended June 30, 2023 were positively impacted by adjustments for a $1.1 million non cash loss on voluntary conversion of convertible debt, accretion of discount of $0.8 million on convertible debt, $0.9 million in stock-based compensation expense, a $0.9 million increase in accounts payable, a $0.4 million increase in accrued expenses and other current liabilities, a $0.4 million decrease in prepaid expenses and other assets, and depreciation and amortization of $0.2 million. Cash flows from operating activities (as opposed to net loss) for the six months ended June 30, 2023 were negatively impacted by adjustments for a $1.5 million decrease in fair value of warrant liabilities, a $0.2 million decrease in accounts receivable and inventory reserves and allowances, a $0.6 million decrease in R&D grant liability, a $0.2 million decrease in deferred tax liability, and a $0.1 million decrease in operating lease liability.

During the six months ended June 30, 2022, operating activities used $7.8 million of cash, primarily resulting from a net loss of $8.4 million. Cash flows from operating activities (as opposed to net loss) for the six months ended June 30, 2022 benefitted from $2.7 million in stock-based compensation expense, a $0.2 million decrease in net accounts receivable, and depreciation and amortization of $0.2 million. Cash flows from operating activities (as opposed to net loss) for the six months ended June 30, 2022 were negatively impacted by a $0.8 million decrease in accrued expenses and other current liabilities, a $0.6 million increase in prepaid expenses and other assets, $0.3 million increase in net inventory, a $0.7 million decrease in fair value of warrant liabilities and a $0.1 million decrease in operating lease liability.

During the six months ended June 30, 2021, operating activities used $8.8 million of cash, primarily resulting from a net loss of $10.6 million. Cash flows from operating activities for the six months ended June 30, 2021 benefitted from the $0.7 million decrease in prepaid expenses and other assets, a $2.5 million increase in stock-based compensation expense, a $1.2 million increase in accrued expenses and other current liabilities and a $0.3 million increase in accounts payable, due to higher costs related to therapeutics research and development. On the other hand, cash flows from operating activities for the six months ended June 30, 2021 were negatively impacted by a $2.5 million decrease in fair value of warrant liabilities, a $0.2 million increase in accounts receivable, and a $0.2 million increase in deferred revenue. The decrease in prepaid expenses was primarily due to the expensing during the period of $1.1 million of previous prepayments to STA Pharmaceutical Co., Ltd., a subsidiary of WuXi AppTec, our manufacturer of QN-165 for our anticipated clinical trials, but was offset in part by an approximately $0.6 million increase of prepaid expenses for director and officer liability insurance.
Net Cash Provided by (Used in) Investing Activities
During the six months ended June 30, 2023, net cash used in investing activities was approximately $0.2 million, due to the purchase of property and equipment.

During the six months ended June 30, 2022, net cash provided by investing activities was approximately $0.1 million, primarily due to $0.7 million in cash acquired in the NanoSynex transaction, offset by the $0.6 million purchase of NanoSynex stock.

~~During~~Net Cash Provided by Financing Activities
Net cash provided by financing activities for the six months ended June 30, ~~2021, net cash used in investing activities~~2023 was ~~approximately $0.1 million, primarily related to the purchase of property and equipment.~~
~~Net Cash Provided by Financing Activities~~$0.

Net cash provided by financing activities for the six months ended June 30, 2022 was approximately $4,000, due to net proceeds from exercise of warrants.
Net cash provided by financing activities for the six months ended June 30, 2021 was approximately $0.2 million, due to approximately $0.3 million of net proceeds from the exercise of warrants, offset by $0.1 million in principal payments on notes payable.
~~Critical Accounting Estimates~~
We believe the estimates, assumptions and judgments involved in the accounting policies described in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Item 7 of our Annual Report on Form 10-K for the year ended December 31, 2021 (the “2021 Annual Report”) are most critical to understanding and evaluating our reported financial results. During the three and six months ended June 30, 2022, other than the business combinations, IPR&D, and goodwill accounting policies described below, there have been no material changes to the critical accounting policies and estimates as described in Item 7 of our 2021 Annual Report.
39
The Company accounts for business combinations using the acquisition method pursuant to FASB ASC Topic 805. This method requires, among other things, that results of operations of acquired companies are included in the Company’s financial results beginning on the respective acquisition dates, and that assets acquired and liabilities assumed are recognized at fair value as of the acquisition date. Intangible assets acquired in a business combination are recorded at fair value using a discounted cash flow model. The discounted cash flow model requires assumptions about the timing and amount of future net cash flows, the cost of capital and terminal values from the perspective of a market participant. Each of these factors can significantly affect the value of the intangible asset. Any excess of the fair value of consideration transferred (the “Purchase Price”) over the fair values of the net assets acquired is recognized as goodwill. The fair value of assets acquired and liabilities assumed in certain cases may be subject to revision based on the final determination of fair value during a period of time not to exceed 12 months from the acquisition date. Legal costs, due diligence costs, business valuation costs and all other acquisition-related costs are expensed when incurred.
IPR&D represents the fair value assigned to the research and development assets that have not reached technological feasibility. The value assigned to IPR&D is determined by estimating the costs to develop the acquired technology into commercially viable products, estimating the resulting revenue from the projects, and discounting the net cash flow to present value. The revenue and cost projections used to value acquired IPR&D are, as applicable, reduced based on the probability of success of developing the new product. Additionally, projections consider relevant market sizes and growth factors, expected trends in technology and the nature and expected timing of new product introductions. The rates utilized to discount the net cash flow to its present value are commensurate with the stage of development of the project and uncertainties in the economic estimates used in the projections. Upon the acquisition of acquired IPR&D, an assessment is completed as to whether the acquisition constitutes an acquisition of the purchase of a single asset or a group of assets. Multiple factors are considered in this assessment, including the nature of the technology acquired, the presence or absence of separate cash flows, the development process and stage of completion, quantitative significance, and the Company’s rationale for entering into the transaction.
If a business is acquired, as defined under the applicable accounting standards, then the acquired IPR&D is capitalized as an intangible asset. If an asset or group of assets is acquired that do not meet the definition under the applicable accounting standards, then the acquired IPR&D is expensed on its acquisition date. Future costs to develop these assets are recorded to research and development expense in the Company’s consolidated statements of income as they are incurred.
IPR&D is evaluated for impairment annually using the same methodology as described above for calculating fair value. If the carrying value of the acquired IPR&D exceeds the fair value, then the intangible asset is written down to its fair value, with the resulting adjustment recorded as a charge to operations. Changes in estimates and assumptions used in determining the fair value of acquired IPR&D could result in an impairment.
Goodwill represents the difference between the purchase price and the fair value of the identifiable tangible and intangible net assets acquired, when accounted for using the purchase method of accounting. Goodwill has an indefinite useful life and is not amortized but is reviewed for impairment annually and whenever events or changes in circumstances indicate that the carrying value of the goodwill may not be recoverable.
In testing for impairment, the fair value of the reporting unit is compared to the carrying value. If the net assets assigned to the reporting unit exceed the fair value of the reporting unit, an impairment loss equal to the difference would be recorded.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

AsWe are a ~~“smaller~~smaller reporting ~~company”~~company as defined by ~~Item 10~~Rule 12b-2 of ~~Regulation S-K, we~~the Exchange Act and are not required to provide the information otherwise required ~~by Item 3.~~under this Item.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures as of June 30, ~~2022,~~2023, the end of the period covered by this Quarterly Report.

Based on this evaluation, our principal executive officer and principal financial officer have concluded that, due to the material weakness described below, our disclosure controls and procedures as of June 30, ~~2022~~2023 were not effective to provide reasonable assurance that the information required to be disclosed by us in reports filed under the Securities Exchange Act of 1934, as amended (the “Exchange Act’), is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. We believe that a disclosure controls system, no matter how well designed and operated, cannot provide absolute assurance that the objectives of the disclosure controls system are met, and no evaluation of disclosure controls can provide absolute assurance that all disclosure control issues, if any, within a company have been detected.

40 43

Changes in Internal Control over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act. Internal control over financial reporting is a process designed under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of ~~condensed~~ consolidated financial statements for external purposes in accordance with U.S. GAAP.
As of December 31, ~~2021,~~2022, our management assessed the effectiveness of our internal control over financial reporting using the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control-Integrated Framework, ~~(the “2013 Framework”).~~or 2013 Framework. Based on this assessment, our management concluded that, as of December 31, ~~2021,~~2022, our internal control over financial reporting was not effective because of a material weakness in our internal control over financial reporting related to the lack of accounting department resources and/or policies and procedures to ensure recording and disclosure of items in compliance with generally accepted accounting ~~principles, as further described in our 2021 Annual Report.~~principles. We have taken and ~~are taking~~continue to take steps to remediate the material weakness, including implementing additional procedures and utilizing external consulting resources with experience and expertise in U.S. GAAP and public company accounting and reporting requirements to assist management with its accounting and reporting of complex and/or non-recurring transactions and related disclosures. ~~Nevertheless,~~
Notwithstanding the identified material weakness, our management believes that the condensed consolidated financial statements included in this Quarterly Report fairly represent in all material respects our financial condition, results of operations and cash flows at and for the periods presented in accordance with U.S. GAAP. Nonetheless, we also believe that an internal control system, no matter how well designed and operated, cannot provide absolute assurance that the objectives of the internal control system are met, and no evaluation of internal control can provide absolute assurance that all internal control issues and instances of fraud, if any, within a company are detected.

Except as described above, there were no changes to the Company’s internal control over financial reporting made during the quarter ended June 30, 2022 that we believe materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. We do expect to implement additional internal controls related to the acquisition of NanoSynex to include internal and external audits related to the international operations of this entity.
Notwithstanding the identified material weakness, our management believes that the condensed consolidated financial statements included in this Quarterly Report fairly represent in all material respects our financial condition, results of operations and cash flows at and for the periods presented in accordance with U.S. GAAP.
41 44

PART II - OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

We are not currently involved in any legal matters. From time to time, we could become involved in disputes and various litigation matters that arise in the normal course of business. These may include disputes and lawsuits related to intellectual property, licensing, contract law and employee relations matters.

ITEM 1A. RISK FACTORS

The Company’s business, reputation, results of operations and financial condition, as well as the price of its stock, can be affected by a number of factors, whether currently known or unknown, including those described in Part I, Item 1A of the Company’s ~~2021~~2022 Annual Report under the heading “Risk Factors.” When any one or more of these risks materialize, the Company’s business, reputation, results of operations and financial condition, as well as the price of its stock, can be materially and adversely affected. Except ~~for the following additional risk factors related to the acquisition of NanoSynex, Ltd.,~~as described below, there have been no material changes to the Company’s risk factors ~~described in~~since the ~~2021~~2022 Annual Report.

~~Risks Related to the Acquisition of NanoSynex, Ltd. (“NanoSynex”)~~
~~The NanoSynex acquisition~~We may ~~not~~ be ~~successful in achieving its intended benefits and may disrupt our current operations.~~
~~In May 2022, we acquired~~classified as a majority interest in NanoSynex, Ltd (“NanoSynex”). This acquisition poses a number of potential integration risks that may result in negative consequences to our business, financial condition, and results of operations. These risks include, but are not limited to:
● ~~failure of the business to perform as planned following the acquisition, and to receive the necessary regulatory approvals for its Antimicrobial Susceptibility Testing (AST) platform;~~
● ~~the assimilation and retention of employees, including key employees;~~
● ~~higher than expected costs and/or a need to allocate resources to manage unexpected operating difficulties;~~
● ~~diversion of the attention and resources of management or other disruptions to current operations;~~
● ~~retaining required regulatory approvals, licenses, and permits;~~
● ~~the assumption of liabilities of the acquired business not identified during due diligence; and~~
● ~~other unanticipated issues, expenses, and liabilities.~~
● ~~establishing appropriate internal controls for the management of overseas financial and other resources.~~
~~In addition, while we are based in Carlsbad, California, NanoSynex’~~s operations are located in Ness Ziona, Israel, which could further stretch our resources and management’s time, and we will need to rely, to a large extent, on the existing executive team of NanoSynex. Failure to adequately integrate our operations and personnel could adversely affect our combined business and our ability to achieve our objectives and strategy. No assurance can be given that we will realize synergies in the areas we currently operate.
~~Our Master Agreement for the Operational and Technological Funding of NanoSynex obligates us to make milestone payments to NanoSynex.~~transient investment company.

As a condition to the closing with NanoSynex, we entered into a Master Agreement for the Operational and Technological Funding of NanoSynex (the “Funding Agreement”) with NanoSynex pursuant to which we have agreed to fund NanoSynex up to an aggregate of approximately $10.4 million over the next three years, subject to NanoSynex’s achievement of certain performance milestones specifiedWe are not engaged in the ~~Funding Agreement~~business of investing, reinvesting, or trading in securities, and we do not hold ourselves out as being engaged in those activities. Under the ~~satisfaction~~Investment Company Act, however, a company may be deemed an investment company under Section 3(a)(1)(C) of ~~other terms~~the Investment Company Act if the value of its investment securities is more than 40% of its total assets (exclusive of government securities and ~~conditions described in the Funding Agreement.~~cash items) on an unconsolidated basis.

~~The requirement~~We have recently divested certain shares of NanoSynex Ltd. (“NanoSynex”) which has resulted in our ownership in NanoSynex being reduced from approximately 52.8% to ~~make any payments under~~approximately 49.97% of the ~~Funding Agreement will reduce~~issued and outstanding voting equity of NanoSynex. Since we no longer hold a controlling interest in NanoSynex, the investment securities we hold, including our ~~liquidity. Furthermore, there can be no assurance~~minority interest in NanoSynex, could exceed 40% of our total assets, exclusive of government securities cash items, on an unconsolidated basis, and, accordingly, we could determine that we ~~will~~ have ~~the funds necessary to make the required payments to NanoSynex, if required, or be able to raise such funds when needed on terms acceptable to us, or at all. As~~become a result, we may be required to delay our product development or future commercialization efforts. In addition, our inability to make any required payments to NanoSynex could negatively impact NanoSynex’s ability to further its development efforts, which will ultimately have a negative impact on our business and results of operations due to our majority interest in NanoSynex. We may terminate this agreement after October 29, 2022, but only after providing 120 days’ notice.transient investment company.

~~Under the terms~~A transient investment company can avoid being classified as an investment company if it can rely on one of the ~~Funding Agreement, we will receive in exchange for any payment made to NanoSynex~~exclusions under the ~~Funding Agreement~~Investment Company Act. One such exclusion, Rule 3a-2 under the Investment Company Act, allows a transient investment company a grace period of one year from the earlier of (a) the date on which an issuer owns securities and/or ~~more promissory notes (which~~cash having a value exceeding 50% of the issuer’s total assets on either a consolidated or unconsolidated basis and (b) the date on which an issuer owns or proposes to acquire investment securities having a value exceeding 40% of the value of such issuer’s total assets (exclusive of government securities and cash items) on an unconsolidated basis. We are in the process of performing a valuation of our minority investment in Nanosynex to determine whether we need to invoke the grace period. We may ~~contain convertible features) with a face value equal~~take actions to cause the ~~amount paid~~investment securities held by us to ~~NanoSynex upon satisfaction~~be less than 40% of the applicable performance milestones. Any promissory notes issued to us by NanoSynex under the Funding Agreement will bear interest at a rate of 9.00% per annum on the principal balance from time to time outstanding under the promissory note. If NanoSynex is unable to make the required payments of principal or interest under any promissory notes that are issued, our ~~liquidity will be negatively impacted,~~total assets, which may ~~require us to delay~~include acquiring assets with our ~~product development~~cash on hand or ~~future commercialization efforts.~~liquidating our investment securities.

As Rule 3a-2 is available to a company no more than once every three years, and assuming no other exclusion were available to us, we would have to keep within the 40% limit for at least three years after we cease being a transient investment company. This may limit our ability to make certain investments or enter into joint ventures that could otherwise have a positive impact on our earnings. In any event, we do not intend to become an investment company engaged in the business of investing and trading securities.
Classification as an investment company under the Investment Company Act requires registration with the SEC. If an investment company fails to register, it would have to stop doing almost all business, and its contracts would become voidable. Registration is time consuming and restrictive and would require a restructuring of our operations, and we would be very constrained in the kind of business we could do as a registered investment company. Further, we would become subject to substantial regulation concerning management, operations, transactions with affiliated persons and portfolio composition, and would need to file reports under the Investment Company Act regime. The cost of such compliance would result in our incurring substantial additional expenses, and the failure to register if required would have a materially adverse impact to conduct our operations.
42 45

~~Because~~ a significant portion of NanoSynex’s total assets are represented by goodwill, indefinite-lived intangible assets, and definite-lived intangible assets, we could be required to write off some or all of this goodwill and other intangibles, which may adversely affect our financial condition and results of operations.
We used the acquisition method of accounting to account for the acquisition of a majority interest in NanoSynex consummated on May 26, 2022. A portion of the purchase price for this business is allocated to identifiable tangible and intangible assets and assumed liabilities based on estimated fair values at the date of acquisition. Goodwill is measured indirectly as the excess of the sum of (1) the consideration transferred (including contingent consideration, if any) and (2) the fair value of any noncontrolling interest in the acquiree over the net assets acquired and liabilities assumed. The purchase price allocation resulted in a goodwill value of $4.9 million and a value of $5.7 million related to other intangible assets. The carrying value of these assets as of June 30, 2022, was $4.9 million and $5.7 million, respectively. When we perform impairment tests, it is possible that the carrying value of goodwill or other intangible assets could exceed their implied fair value and therefore would require adjustment. Such adjustment would result in a charge to operating income in that period. Once adjusted, there can be no assurance that there will not be further adjustments for impairment in future periods.
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Unregistered Sales of Equity Securities

None

Purchases of Equity Securities by the Issuer and Affiliated Purchasers

None

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None

ITEM 4. MINE SAFETY DISCLOSURES

Not Applicable

ITEM 5. OTHER INFORMATION

None
43

ITEM 6. EXHIBITS

Incorporated by Reference Incorporated by Reference
Exhibit No. Description Form File No. Exhibit
Filing Date
Description Form File No. Exhibit
Filing Date

2.1 Agreement and Plan of Merger, among Ritter Pharmaceuticals, Inc., RPG28 Merger Sub, Inc. and Qualigen, Inc., dated January 15, 2020 8-K 001-37428 2.1 January 21, 2020 Contingent Value Rights Agreement, dated May 22, 2020, among the Company, John Beck in the capacity of CVR Holders’ Representative and Andrew J. Ritter in his capacity as a consultant to the Company. 8-K 001-37428 2.4 5/29/2020

2.2 Amendment No. 1 to Agreement and Plan of Merger among Ritter Pharmaceuticals, Inc., RPG28 Merger Sub, Inc. and Qualigen, Inc., dated February 1, 2020 S-4 333-236235 Annex B April 6, 2020 Stock Purchase Agreement, dated July 20, 2023, by and between Qualigen Therapeutics, Inc., Chembio Diagnostics, Inc., Biosynex, S.A., and Qualigen, Inc. 8-K 001-37428 2.1 7/26/2023

2.3 Amendment No. 2 to Agreement and Plan of Merger among Ritter Pharmaceuticals, Inc., RPG28 Merger Sub, Inc. and Qualigen, Inc., dated March 26, 2020 S-4 333-236235 Annex C April 6, 2020

2.4 Contingent Value Rights Agreement, dated May 22, 2020, among the Company, John Beck in the capacity of CVR Holders’ Representative and Andrew J. Ritter in his capacity as a consultant to the Company. 8-K 001-37428 2.4 May 29, 2020

3.1 Amended and Restated Certificate of Incorporation 8-K 001-37428 3.1 July 1, 2015 Amended and Restated Certificate of Incorporation 8-K 001-37428 3.1 7/1/2015

3.2 Certificate of Amendment to the Amended and Restated Certificate of Incorporation 8-K 001-37428 3.1 September 15, 2017 Certificate of Amendment to the Amended and Restated Certificate of Incorporation 8-K 001-37428 3.1 9/15/2017

3.3 Certificate of Amendment to the Amended and Restated Certificate of Incorporation 8-K 001-37428 3.1 March 22, 2018 Certificate of Amendment to the Amended and Restated Certificate of Incorporation 8-K 001-37428 3.1 3/22/2018

3.4 Certificate of Designation of Preferences, Rights and Limitations of Series Alpha Preferred Stock of the Company, filed with the Delaware Secretary of State on May 20, 2020 8-K 001-37428 3.1 May 29, 2020 Certificate of Designation of Preferences, Rights and Limitations of Series Alpha Preferred Stock of the Company, filed with the Delaware Secretary of State on May 20, 2020 8-K 001-37428 3.1 5/29/2020

3.5 Certificate of Amendment to the Certificate of Incorporation of the Company, filed with the Delaware Secretary of State on May 22, 2020 [reverse stock split] 8-K 001-37428 3.2 May 29, 2020 Certificate of Amendment to the Certificate of Incorporation of the Company, filed with the Delaware Secretary of State on May 22, 2020 [reverse stock split] 8-K 001-37428 3.2 5/29/2020

3.6 Certificate of Merger, filed with the Delaware Secretary of State on May 22, 2020 8-K 001-37428 3.3 May 29, 2020 Certificate of Merger, filed with the Delaware Secretary of State on May 22, 2020 8-K 001-37428 3.3 5/29/2020

3.7 Certificate of Amendment to the Certificate of Incorporation of the Company, filed with the Delaware Secretary of State on May 22, 2020 [name change] 8-K 001-37428 3.4 May 29, 2020 Certificate of Amendment to the Certificate of Incorporation of the Company, filed with the Delaware Secretary of State on May 22, 2020 [name change] 8-K 001-37428 3.4 5/29/2020

3.8 Amended and Restated Bylaws of the Company, through August 10, 2021 10-Q 001-37428 3.8 August 16, 2021 Amended and Restated Bylaws of the Company, through August 10, 2021 10-Q 001-37428 3.1 8/13/2021

3.9 Certificate of Amendment to the Amended and Restated Certificate of Incorporation, as amended 8-K 001-37428 3.1 11/22/2022

4.1 Warrant Agency Agreement between Ritter Pharmaceuticals, Inc. and Corporate Stock Transfer, Inc. and Form of Warrant Certificate 8-K 001-37428 4.1
October 4, 2017

Warrant, issued by the Company in favor of Alpha Capital Anstalt, dated May 22, 2020 8-K 001-37428 10.13 5/29/2020

4.2 Form of Warrant, issued by the Company in favor of GreenBlock Capital LLC and its designees, dated May 22, 2020 [post-Merger] 8-K 001-37428 10.10 5/29/2020

4.3 Common Stock Purchase Warrant in favor of Alpha Capital Anstalt, dated July 10, 2020 8-K 001-37428 10.2 7/10/2020

4.4 Common Stock Purchase Warrant in favor of Alpha Capital Anstalt, dated August 4, 2020 8-K 001-37428 10.3 8/4/2020

4.5 “Two-Year” Common Stock Purchase Warrant for 1,348,314 shares in favor of Alpha Capital Anstalt, dated December 18, 2020 8-K 001-37428 10.3 12/18/2020

4.2 First Amendment to Warrant Agency Agreement between Ritter Pharmaceuticals, Inc. and Corporate Stock Transfer, Inc. 8-K 001-37428 4.1 May 7, 2018

4.3 Second Amendment to Warrant Agency Agreement between the Company and Equiniti Group plc, dated November 9, 2020 10-K 001-37428 4.3 March 31, 2021

4.4 Warrant, issued by the Company in favor of Alpha Capital Anstalt, dated May 22, 2020 [post-Merger] 8-K 001-37428 10.13 May 29, 2020

4.5 Form of Warrant, issued by the Company in favor of GreenBlock Capital LLC and its designees, dated May 22, 2020 [post-Merger] 8-K 001-37428 10.10 May 29, 2020

4.6 Common Stock Purchase Warrant for 1,920,768 shares in favor of Alpha Capital Anstalt, dated July 10, 2020 8-K 001-37428 10.2 July 10, 2020

4.7 Pre-Funded Common Stock Purchase Warrant for 1,920,768 shares in favor of Alpha Capital Anstalt, dated July 10, 2020 8-K 001-37428 10.3 July 10, 2020

4.8 Common Stock Purchase Warrant for 1,287,829 shares in favor of Alpha Capital Anstalt, dated August 4, 2020 8-K 001-37428 10.3 August 4, 2020

4.9 “Two-Year” Common Stock Purchase Warrant for 1,348,314 shares in favor of Alpha Capital Anstalt, dated December 18, 2020 8-K 001-37428 10.3 December 18, 2020

4.10 “Deferred” Common Stock Purchase Warrant for 842,696 shares in favor of Alpha Capital Anstalt, dated December 18, 2020 8-K 001-37428 10.4 December 18, 2020

4.11 “Prefunded” Common Stock Purchase Warrant for 1,000,000 shares in favor of Alpha Capital Anstalt, dated December 18, 2020 8-K 001-37428 10.5 December 18, 2020

4.12 Form of liability classified Warrant to Purchase Common Stock (“exploding warrant”) 10-K 001-37428 4.13 March 31, 2021

4.13 Form of “service provider” (non-”exploding”) compensatory equity classified Warrant 10-K 001-37428 4.14 March 31, 2021

4.14 Description of Common Stock 10-K 001-37428 4.7 March 31, 2020
31.1* ~~Certificate of principal executive officer pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002~~
31.2* ~~Certificate of principal financial officer pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002~~
32.1* ~~Certificate of principal executive officer and principal financial officer pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002~~
4.6 “Deferred” Common Stock Purchase Warrant for 842,696 shares in favor of Alpha Capital Anstalt, dated December 18, 2020 8-K 001-37428 10.4 12/18/2020

4.7 Form of liability classified Warrant to Purchase Common Stock 10-K 001-37428 4.13 3/31/2021

4.8 Form of “service provider” compensatory equity classified Warrant 10-K 001-37428 4.14 3/31/2021

4.9 Description of Common Stock 10-K/A 001-37428 4.9 7/7/2023

4.10 Amended and Restated Common Stock Purchase Warrant to GreenBlock Capital LLC, dated April 25, 2022 10-Q 001-37428 4.15 5/13/2022

4.11 Amended and Restated Common Stock Purchase Warrant to Christopher Nelson, dated April 25, 2022 10-Q 001-37428 4.16 5/13/2022

4.12 Common Stock Purchase Warrant for 2,500,000 shares in favor of Alpha Capital Anstalt, dated December 22, 2022 8-K 001-37428 4.1 12/22/2022

10.1* Separation Agreement and General Release, dated June 20, 2023, by and between Qualigen Therapeutics, Inc. and Amy Broidrick

10.2 Amendment and Settlement Agreement, dated July 20, 2023, by and between Qualigen Therapeutics, Inc. and NanoSynex Ltd. 8-K 001-37428 10.1
7/26/2023

31.1 Certificate of principal executive officer pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.2 Certificate of principal financial officer pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32.1 Certificate of principal executive officer and principal financial officer pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101.INS# Inline XBRL Instance Document.

101.SCH# Inline XBRL Taxonomy Extension Schema Document.

101.CAL# Inline XBRL Taxonomy Extension Calculation Linkbase Document.

101.DEF# Inline XBRL Taxonomy Extension Definition Linkbase Document.

101.LAB# Inline XBRL Taxonomy Extension Label Linkbase Document.

101.PRE# Inline XBRL Taxonomy Extension Presentation Linkbase Document.

104 Cover page Interactive Data File (embedded within the Inline XBRL document)

* Filed or furnished herewith.
+ Indicates management contract or compensatory plan or arrangement.
# XBRL (Extensible Business Reporting Language) information is furnished and not filed herewith, is not a part of a registration statement or Prospectus for purposes of sections 11 or 12 of the Securities Act of 1933, is deemed not filed for purposes of section 18 of the Securities Exchange Act of 1934, and otherwise is not subject to liability under these sections.
46

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

August ~~15, 2022~~14, 2023 QUALIGEN THERAPEUTICS, INC.

By: /s/ Michael S. Poirier
Name: Michael S. Poirier
Title: Chief Executive Officer

47 49


													Total
								Accumulated					Qualigen Therapeutics,
		Common Stock				Additional		Other					Inc.						Total
		Shares		Amount $		Paid-In Capital		Comprehensive Income		Accumulated Deficit			Stockholders’ Equity			Noncontrolling Interest			Stockholders’ Equity
Balance at December 31, 2021	-		35,290,178	$	35,290	$	101,274,073	$	—	$	(84,744,629	)	$	16,564,734		$	—		$	16,564,734
Stock issued upon exercise of warrants			5,363		5		4,711		—		—			4,716			—			4,716
Stock-based compensation	-		—		—		1,267,166		—		—			1,267,166			—			1,267,166
Net loss			—		—		—		—		(4,319,787	)		(4,319,787	)		—			(4,319,787	)
Balance at March 31, 2022	-		35,295,541	$	35,295	$	102,545,950	$	—	$	(89,064,416	)	$	13,516,829		$	—		$	13,516,829
Common stock issued for business acquisition			3,500,000		3,500		1,841,000		—		—			1,844,500			—		$	1,844,500
Prefunded warrants issued for business acquisition			—		—		1,746,816		—		—			1,746,816			—			1,746,816
Foreign currency translation adjustment			—		—		—		65,540		—			65,540			—			65,540
Fair value of noncontrolling interest related to business acquisition			—		—		—		—		—			—			4,000,000			4,000,000
Fair value of warrant modification for business acquisition			—		—		696		—		—			696			—			696
Stock-based compensation	-		—		—		1,423,282		—		—			1,423,282			—			1,423,282
Net loss			—		—		—		—		(4,123,404	)		(4,123,404	)		(4,116	)		(4,127,520	)
Balance at June 30, 2022	-		38,795,541	$	38,795	$	107,557,744	$	65,540	$	(93,187,820	)	$	14,474,259		$	3,995,884		$	18,470,143


																	Total
	Series Alpha Convertible											Accumulated					Qualigen Therapeutics,
	Preferred Stock				Common Stock				Additional			Other					Inc.					Total
	Shares		Amount $		Shares		Amount $		Paid-In Capital			Comprehensive Income		Accumulated Deficit			Stockholders’ Equity			Noncontrolling Interest		Stockholders’ Equity
Balance at December 31, 2020	$	180	$	1		27,296,061	$	27,296	$	85,114,755		$	—	$	(66,847,492	)	$	18,294,560		$	—	$	18,294,560
Stock issued upon cash exercise of warrants		—		—		1,319,625		1,320		1,813,353			—		—			1,814,673			—		1,814,673
Stock issued upon net-exercise of warrants		—		—		192,373		192		(192	)		—		—			—			—		—
Stock issued for professional services		—		—		25,000		25		101,725			—		—			101,750			—		101,750
Stock-based compensation		—		—		—		—		1,262,123			—		—			1,262,123			—		1,262,123
Net loss		—		—		—		—		—					(5,242,719	)		(5,242,719	)				(5,242,719	)
Balance at March 31, 2021		180	$	1		28,833,059	$	28,833	$	88,291,764		$	—	$	(72,090,211	)	$	16,230,387		$	—	$	16,230,387
Stock issued upon cash exercise of warrants		—		—		69,129		69		142,513			—		—			142,582			—		142,582
Stock-based compensation		—		—		—		—		1,286,926			—		—			1,286,926			—		1,286,926
Net loss		—		—		—		—		—			—		(5,398,077	)		(5,398,077	)		—		(5,398,077	)
Balance at June 30, 2021		180	$	1		28,902,188	$	28,902	$	89,721,203		$	—	$	(77,488,288	)	$	12,261,818		$	—	$	12,261,818

Consideration transferred, net of cash acquired
Cash paid for NanoSynex preferred stock:	$	600,000

Purchase of NanoSynex common Stock:
Price per share of Qualigen Stock on May 26, 2022	$	0.527

FMV of 3,500,000 shares of Qualigen stock issued to Alpha Capital Anstalt	$	1,844,500
FMV of 3,314,641 shares of Qualigen stock related to prefunded warrant issued to Alpha Capital Anstalt	$	1,746,816
Total consideration paid for NanoSynex common stock	$	3,591,316

FMV of consideration related to related to repricing of 70,478 shares of Alpha Capital/Qualigen warrants ^*	$	696

NanoSynex cash acquired		(735,354	)
Total consideration transferred, net of cash acquired	$	3,456,658

	Purchase Price Allocation
Accounts receivable	$	75,336
Property and equipment		120,942
In process R&D		5,700,000
Accounts payable		(4,588	)
Accrued expenses and other payables		(291,093	)
R&D grant liability		(1,362,264	)
Short term debt		(941,898	)
Deferred tax liability		(736,000	)
Noncontrolling interest assumed		(4,000,000	)
Identifiable net assets acquired		(1,439,565	)
Goodwill		4,896,223
Total consideration transferred, net of cash acquired	$	3,456,658

	Consolidated Pro Forma Financial Results for the Six Months Ending
	June 30, 2022			June 30, 2021
Net revenues	$	2,152,563		$	3,017,430
Net loss	$	(8,722,302	)	$	(10,800,317	)

	June 30, 2022		December 31, 2021		June 30, 2023		December 31, 2022
Raw materials	$	808,815	$	823,315	$	1,027,455	$	949,796
Work in process		327,311		188,135		177,591		200,318
Finished goods		174,087		44,428		358,353		436,183
Total inventory	$	1,310,213	$	1,055,878	$	1,563,399	$	1,586,297

	Common Stock Warrants
	Shares		Weighted– Average Exercise Price		Range of Exercise Price		Weighted– Average Remaining Life (Years)
Total outstanding – December 31, 2022		3,849,571	$	1.53		$1.32 - $1.65		3.9
Exercised		—		—		—		—
Forfeited		—		—		—		—
Expired		—		—		—		—
Granted		—		—		—		—
Total outstanding – June 30, 2023		3,849,571	$	1.53		$1.32 - $1.65		3.41
Exercisable		3,849,571	$	1.53		$1.32 - $1.65		3.41

	Common Stock Warrants (received in exchange for the Series C Warrants)									Common Stock Warrants
	Shares			Weighted– Average Exercise Price		Range of Exercise Price		Weighted– Average Remaining Life (Years)		Shares			Weighted– Average Exercise Price		Range of Exercise Price		Weighted– Average Remaining Life (Years)
Total outstanding – December 31, 2021		2,481,614		$	0.72				2.00
Total outstanding –December 31, 2021											248,161		$	7.20				2.00
Exercised		(5,363	)		0.72						(536	)		7.20
Forfeited		(2,476,251	)		0.72						(247,625	)		7.20
Expired		—			—						—			—
Granted		3,468,958			0.51						346,896			5.10
Total outstanding – June 30, 2022		3,468,958		$	0.51						346,896		$	5.10
Exercisable		3,468,958		$	0.51	$	0.51		1.51		346,896		$	5.10	$	5.10		1.51

	Quoted										Quoted
	Market		Significant								Market		Significant
	Prices for		Other		Significant						Prices for		Other		Significant
	Identical		Observable		Unobservable						Identical		Observable		Unobservable
	Assets		Inputs		Inputs						Assets		Inputs		Inputs
Common Stock Warrant liabilities	(Level 1)		(Level 2)		(Level 3)			Total			(Level 1)		(Level 2)		(Level 3)			Total
Balance as of December 31, 2021	$	—	$	—	$	1,686,200		$	1,686,200
Balance as of December 31, 2022											$	—	$	—	$	3,622,647		$	3,622,647
Exercises		—		—		(858	)		(858	)		—		—		—			—
Gain on change in fair value of warrant liabilities		—		—		(698,042	)		(698,042	)		—		—		(1,478,967	)		(1,478,967	)
Balance as of June 30, 2022	$	—	$	—	$	987,300		$	987,300
Balance as of June 30, 2023											$	—	$	—	$	2,143,680		$	2,143,680

	June 30, 2022						June 30, 2021						June 30, 2023						June 30, 2022
	Range			Weighted Average			Range			Weighted Average			Range			Weighted Average			Range			Weighted Average
Risk-free interest rate		2.80% — 2.87	%		2.82	%		0.34% — 0.46	%		0.103	%	4.05% — 5.31%				4.49	%	2.80% — 2.87%				2.82	%
Expected volatility (peer group)		74% — 96	%		78.6	%		82% — 83	%		82.83	%	66.3% — 134%				110.55	%	74% — 96%				78.6	%
Term of warrants (in years)		1.39 — 1.99			1.51			2.41 — 2.99			2.5		.39 — 4.98			3.41			1.39 — 1.99			1.51
Expected dividend yield		0.00	%		0.00	%		0.00	%		0.00	%		0.00	%		0.00	%		0.00	%		0.00	%

	June 30, 2023			December 31, 2022
Senior secured convertible debenture	$	2,078,922		$	3,300,000
Discount on convertible debenture		(1,266,503	)		(3,239,803	)
Total convertible debt-related party	$	812,419		$	60,197

	As of June 30,		As of June 30,		As of June 30,
	2022		2021		2023		2022
Shares of common stock subject to outstanding options		4,767,834		4,133,856		445,163		476,783
Shares of common stock subject to outstanding warrants		14,123,380		9,540,187		4,119,934		1,412,338
Shares of common stock subject to conversion of Series Alpha Convertible Preferred Stock		—		243,418
Total common stock equivalents		18,891,214		13,917,461		4,565,097		1,889,121

	Operating lease right-of-use assets
Net right-of-use assets at December 31, 2021	$	1,645,568
Less amortization of operating lease right-of-use assets		(109,804	)
Operating lease right-of-use assets at June 30, 2022	$	1,535,764

	Operating lease right-of-use assets
Net right-of-use assets at December 31, 2022	$	1,422,538
Less amortization of operating lease right-of-use assets		(116,568	)
Operating lease right-of-use assets at June 30, 2023	$	1,305,970

	Operating lease liabilities
Lease liabilities at December 31, 2021	$	1,676,655
Less principal payments on operating lease liabilities		(73,408	)
Lease liabilities at June 30, 2022		1,603,247
Less non-current portion		(1,425,808	)
Current portion at June 30, 2022	$	177,439

	Operating lease liabilities
Lease liabilities at December 31, 2022	$	1,542,564
Less principal payments on operating lease liabilities		(116,756	)
Lease liabilities at June 30, 2023		1,425,808
Less non-current portion		(1,168,653	)
Current portion at June 30, 2023	$	257,155

Year Ending December 31,	Amount			Amount
2022 (six months)	$	277,192
2023		368,341
2023 (six months)					184,171
2024		379,392			379,392
2025		390,773			390,773
2026		402,497			402,497
2027		379,165			379,164
Total		2,197,360			1,735,997
Less present value discount		(594,113	)		(310,189	)
Operating lease liabilities	$	1,603,247		$	1,425,808


Exercise of issued and future grants of stock options			~~4,767,834~~445,163
Exercise of stock warrants			~~14,123,380~~4,119,934
Total			~~18,891,214~~4,565,097

	Shares			Weighted– Average Exercise Price		Range of Exercise Price		Weighted– Average Remaining Life (Years)		Shares			Weighted– Average Exercise Price		Range of Exercise Price		Weighted– Average Remaining Life (Years)
Total outstanding – December 31, 2021		4,841,856		$	6.07	$	1.24 — $1,465.75		8.52
Total outstanding – December 31, 2022											608,012		$	35.02		$5.14 - $51.30		8.09
Granted		25,000			1.05		1.05		9.54		—			—		—		—
Expired		(93,856	)		93.59		5.75 - 1,465.75		—		—			—		—		—
Forfeited		(5,166	)		3.51		1.24 - 4.97		—		(162,849	)		36.01		5.14 - 51.30		—
Total outstanding – June 30, 2022		4,767,834		$	4.33	$	1.05 — $5.13		8.19
Total outstanding – June 30, 2023											445,163		$	34.68		$5.14 — $51.30		7.59
Exercisable (vested)		2,643,665		$	4.84	$	1.24 — $5.13		8.00		323,355		$	44.79		$5.14 — $51.30		7.13
Non-Exercisable (non-vested)		2,124,169		$	3.68	$	1.05 — $5.13		8.48		121,808		$	7.83		$5.14 - $35.20		8.85

	For the Six Months Ended June 30,						For the Six Months Ended June 30,
	2022			2021			2023			2022
Expected dividend yield		0.00	%		0.00	%		0.00	%		0.00	%
Expected stock-price volatility		102	%		102	%		—			102	%
Risk-free interest rate		1.58% — 1.67	%		0.84% — 1.81	%		—		1.58% — 1.67		%
Expected average term of options (in years)		6.00			6.00			—			6.00
Stock price	$	1.05		$	2.12		$	—		$	1.05

	Common Stock
	Shares		Weighted– Average Exercise Price		Range of Exercise Price		Weighted– Average Remaining Life (Years)
Total outstanding – December 31, 2022		179,046	$	9.12	$1.32 — $25.40		1.73
Granted to advisor and its designees		—		—
Exercised		—		—
Expired		—		—
Forfeited		—		—
Total outstanding – June 30, 2023		179,046	$	9.12	$1.32 — $25.40		1.24
Exercisable		179,046	$	9.12	$1.32 — $25.40			1.24
Non-Exercisable		—	$	—	$	—		—

	As reported			Corrected			As reported			Corrected
	For the Quarter Ended June 30, 2021						For the Six Months Ended June 30, 2021
	As reported			Corrected			As reported			Corrected
Gain on change in fair value of warrant liabilities	$	(2,075,100	)	$	(1,982,256	)	$	(4,198,000	)	$	(2,535,064	)
Net loss	$	(5,305,233	)	$	(5,398,077	)	$	(8,977,860	)	$	(10,640,796	)
Net loss per common share	$	(0.18	)	$	(0.19	)	$	(0.31	)	$	(0.37	)

	●	~~our ability to~~there can be no assurance that we will successfully develop any drugs or therapeutic devices;

	●	there can be no assurance that preclinical or clinical development of our ~~ability to progress our drug candidates~~candidate drugs or therapeutic devices ~~through preclinical and clinical development;~~will be successful;

	●	~~our ability to obtain the requisite regulatory approvals for our~~there can be no assurance that clinical trials ~~and~~will be approved to begin ~~and complete such trials according to any projected timeline;~~

	●	~~our ability to complete enrollment in our clinical trials~~by or will actually begin by or will proceed as contemplated by any projected timeline;

	●	there can be no assurance that future clinical trial data will be favorable or that such trials will confirm any improvements over other products or lack negative impacts;

	●	there can be no assurance that any of our ~~ability to successfully commercialize any~~candidate drugs or therapeutic ~~devices;~~devices will receive the required regulatory approvals or that they will be commercially successful;

	●	~~our ability~~there can be no assurance that we will be able to procure or earn sufficient working capital to complete the development, testing and launch of our prospective candidate drugs therapeutic products;

	●	~~the likelihood~~there can be no assurance that patents will issue on our owned and in-licensed patent applications;

	●	there can be no assurance that such patents, if any, and our ~~ability to protect our intellectual property;~~

	●	~~our ability to compete;~~

	●	~~our ability to maintain or expand market demand and/or market share for our diagnostic products generally, particularly in light of COVID-19-related deferral of patients’ physician-office visits~~current owned and ~~in view of FastPack reimbursement pricing challenges; and~~

	●	~~our ability to maintain our diagnostic sales and marketing engine without interruption following the expiration of our distribution agreement with Sekisui Diagnostics, LLC (“Sekisui”).~~in-licensed patents would prevent competition;